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Technology
Abstract
The pre-treatment of patients with clopidogrel before primary percutaneous coronary intervention (PCI) has
been shown to lower the risk of complications that could lead to heart attack or stroke during the procedure.
However, the proper administration of clopidogrel requires the measurement of the patient’s drug resistance
due to its inherent variation across the population. Approximately 1.1 million PCIs were performed in the US
alone in 2008. As the patient population is becoming increasingly aware of the benefits of clopidogrel
treatment prior to PCI, there is an ever-expanding market potential for clopidogrel resistance screening
devices. As most of the existing devices utilize traditional test-tube-scale bench-top technology that usually
sets limitations on the throughput and applicability of the test itself, the market demands a device that not
only minimizes the cost per test but also produces consistent and comprehensive results. In this report, guided
by the innovation map, we are able to link soft lithography in combination with micro-patterning technology
to the customer’s requirements, and come up with a higher-throughput system that meets the market demand.
Our system consists of two parts: the chip and the device. We focus our design effort primarily on the chip, in
which micro-channel layout, dry reagent dissolution, reagent mixing and reservoir volume design are carefully
worked out. On the other hand, the design of the device is discussed briefly, but production is assumed to be
outsourced. With the cost estimates from suppliers and the assumed expected market share to be 50%, the net
present value is computed to be about 45 million, indicating a lucrative return to investors.
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Part 1  Introduction 
1.1 Abstract 
The pre-treatment of patients with clopidogrel before primary percutaneous coronary 
intervention (PCI) has been shown to lower the risk of complications that could lead to heart 
attack or stroke during the procedure.  However, the proper administration of clopidogrel 
requires the measurement of the patient’s drug resistance due to its inherent variation across the 
population.  Approximately 1.1 million PCIs were performed in the US alone in 2008.  As the 
patient population is becoming increasingly aware of the benefits of clopidogrel treatment prior 
to PCI, there is an ever-expanding market potential for clopidogrel resistance screening devices.  
As most of the existing devices utilize traditional test-tube-scale bench-top technology that 
usually sets limitations on the throughput and applicability of the test itself, the market demands 
a device that not only minimizes the cost per test but also produces consistent and 
comprehensive results.  In this report, guided by the innovation map, we are able to link soft 
lithography in combination with micro-patterning technology to the customer’s requirements, 
and come up with a higher-throughput system that meets the market demand.   Our system 
consists of two parts: the chip and the device.  We focus our design effort primarily on the chip, 
in which micro-channel layout, dry reagent dissolution, reagent mixing and reservoir volume 
design are carefully worked out.  On the other hand, the design of the device is discussed briefly, 
but production is assumed to be outsourced.  With the cost estimates from suppliers and the 
assumed expected market share to be 50%, the net present value is computed to be about 45 
million, indicating a lucrative return to investors. 
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1.2 Introduction 
1.2.1 Motivation 
In 2008, 1.1 million Americans with circulatory complications underwent Percutaneous 
Coronary Intervention (PCI) procedures.  Often, the success rate of PCI is limited by the risk of 
adverse clotting events.  Research supported by angiographic evaluation evidence has shown that 
clopidogrel (Plavix)1
Since its discovery and development by Bristol-Myers Squibb, clopidogrel has been 
marketed as Plavix worldwide to 110 different countries with annual sales of $5.9 billion and 
exhibiting growth rate of 20%. (1)
 can reduce these events during the procedure and chances of developing 
further complication if administered prior to the procedure.  However, some patients exhibit poor 
response to the drug and require a higher dose to achieve a therapeutic level of the active drug 
metabolite in circulation.  The current evaluation of Plavix resistance requires laboratory scale 
manual mixing of the drug with the patient’s blood and the subsequent observation of platelet 
function.  Progress has been made to increase the throughput and the cost-effectiveness of this 
test, yet none of the existing technologies satisfies the customer’s desires of small blood volume, 
high throughput and automated operation.   
 
  The market potential for Plavix resistance screening devices is 
becoming apparent.  The goal of this design project is to come up with an automated machine 
that uses disposable microfluidic chips to quantify the patient’s resistance to Plavix based on a 
blood volume of less than 1 milliliter. 
                                                 
 
1 “clopidogrel” is the generic name for Plavix and both terms will be used interchangeably 
throughout this report. 
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1.2.2 Project Charter and Scope 
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1.2.3 Technology-Readiness Assessment 
An innovation map (See Figure 1-1) is used to address the need for new technologies 
when preparing a new product.  As discussed by Seider et al., an innovation map has six levels.  
Listing these levels from top to bottom, they are:  customer-value proposition, products, product 
technology, technical differentiation, process/manufacturing technology, and materials 
technology.  The map connects these levels by stating which new technological features will be 
used in the development of the product. (2) 
The innovation map shows the manufacturing of the Multi-Channel Coagulation 
Resistance Assay (MCCRA) System which consists of a microfluidic chip and a device to run 
the physical test and display the results to the practitioner.  The technologies used to fabricate 
these items include soft lithography and replicate molding for the chip and outsourcing for the 
device.  The technical differentials are the features that set the MCCRA System apart from other 
competing products.  The ability to test for varying resistances in patients on a single chip is a 
new concept that makes this new product very valuable.  The device feature for a quick 
turnaround test time is important for hospitals as well as patients.  All of these specifics will be 
discussed in more detail later on.  The market and innovative features of the system make these 
new technologies justifiable.   
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1.2.4 Report Contents Summary 
Our design report can be broken down into four major parts.  Part 1 addresses the motivation 
behind this project, presents a project charter, and briefs on the innovation map that guides us 
through the development of our product.  Part 2 reviews the physiology of blood clots, the 
molecular pathways of clopidogrel, chip manufacture, and market potential analysis.  Part 3 deals 
in depth with chip design, including chip design and manufacture, financial analysis, and a 
summary of the box components in succinct terms since the focus of this project is on the chip.  
Part 4 describes the post-design considerations, which include FDA approval and areas of future 
research and development.  
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Part 2  Concept Stage 
2.1 Physiology of Blood Clotting 
2.1.1 The Basics of Blood 
The blood flowing through the human body, known as whole blood, has four main 
components:  plasma, red blood cells (erythrocytes), white blood cells (leukocytes), and platelets 
(thrombocytes).  The plasma comprises about 55% of the whole blood, while the other 45% 
consists of the three blood cells.  
Plasma is about 90% water, with the other 10% consisting of substances such as proteins, 
electrolytes, hormones, vitamins and cholesterol.  This liquid is responsible for transport of blood 
components through the body. 
Red blood cells are the second most prevalent component of whole blood, accounting for 
about 40-45% of its make-up.  These cells are primarily responsible for the transport of carbon 
dioxide and oxygen to and from the lungs, respectively, through the protein hemoglobin found 
inside the cells. 
White bloods cells compose only about 1% of the total volume of whole blood, and are 
responsible for protecting the body against infection. 
Platelets are anuclear blood cells that gather at the location of an injury to allow 
coagulation to occur at the site.  Deviations in the platelet count from normal values (300,000 to 
600,000 per μL) can be very dangerous to the body.  Too many platelets can lead to unwanted 
clotting, which can in turn cause heart attack or stroke.  Too few platelets, however, can lead to 
the inability to clot normally and thus cause excessive bleeding. (3) 
- 8 - 
 
2.1.2 Hemostasis 
Hemostasis refers to the complex network of steps leading to the formation of a clot at 
the site of a damaged blood vessel.  Its purpose is to stop and prevent further loss of blood at the 
damaged location. (4)  The process involves three major components which are platelets, 
endothelial cells, and blood clotting proteins.  Under normal conditions (i.e. no damage to the 
blood vessel), endothelial cells line the interior of the blood vessel and prevent clots from 
forming on the walls by acting as a physical barrier to the formation as well as by releasing nitric 
oxide, prostacyclin and other molecules that inhibit platelet aggregation, while platelets and 
blood-clotting proteins are found in the blood plasma in an “inactive form” until activated by 
injury. (5) (6)
 Primary hemostasis refers to the 
formation of the platelet plug.  When 
injury occurs, the layer of endothelial 
cells within the vessel is broken and 
subendothelial surfaces are exposed.  
Without the inhibition of the endothelial 
cells, platelets begin to adhere to the wall 
  Hemostasis can be broken down into three categories, known as primary hemostasis, 
secondary hemostasis and tertiary hemostasis.  It is important to note that all three categories in 
fact occur simultaneously.  They are 
only divided in this way for easier 
understanding of mechanisms, not to 
delineate three sequential steps in the 
process. (7) 
Figure 2-1  Coagulation Cascade   
The solid black lines represent activating factors and the complexes 
that they activate. 
- 9 - 
 
of the vessel at the damaged location.  The rate of platelet adhesion at this site is increased by the 
local vasoconstriction that is triggered upon breakage of the blood vessel. (6) 
 In the high shear rate conditions that exist at the site of an injury, von Willebrand factor 
(vWf) is responsible for platelet adhesion to the subendothelium by binding with glycoprotein 
Ib-IX which is found in the membrane of the platelets.  (In areas such as the veins where low 
sheer rate conditions exist, the same process is controlled by collagen exposed during injury, not 
vWf.  Instead, the fibrinogen binds to a platelet receptor known as glycoprotein Ia/IIa, or integrin 
α
Vasoconstriction 
slows down blood flow and reduces the rate of blood lost by narrowing the blood vessel in the 
injured area.  Simultaneously, another area of the vessel is subjected to vasodilation, or 
expansion, so as to balance the narrowing effect. (8) 
2β1).  Upon adhesion to the wall of the blood vessel, the platelets are activated, causing them to 
morph.  The change in shape triggers the activation of glycoprotein IIb/IIIa (or integrin αIIbβ3a 
fibrinogen receptor located on the platelet’s surface).  In addition to shape change, the activated 
platelets release dense granules (which contain serotonin and ADP), thromboxane A2 (TXA2) 
and plated activating factor (PAF).  The latter two secretions are vasoconstriction triggers as well 
as agonists for platelet aggregation.  The platelet agonists TXA2, PAF, ADP, and serotonin 
activate additional platelets, causing them to attach to those that have already adhered to the 
vessel wall.  Thrombin, which is created via the coagulation cascade (which will be explained 
later), also acts as a platelet agonist.  Fibrinogen serves as the primary mediator of platelet 
aggregation by binding to αIIbβ3on two adjacent platelets, thus forming the primary platelet plug. 
(6) 
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 Secondary hemostasis refers to the production of fibrin via the coagulation cascade (See 
Figure 2-1). (9)
 The extrinsic pathway is responsible for the initiation of the coagulation cascade in vivo.  
First, tissue factor is released from monocytes, endothelial cells, and subendothelial cells (the 
amount released is amplified by cytokines).  Then, tissue factor binds to factor VII, which in turn 
activates factor X to Xa.  Factor Xa, small levels of constitutively active factor Va, platelet 
phospholipids, and calcium activate the conversion of prothrombin to thrombin.  Although tissue 
factor pathway inhibitor quickly inhibits this conversion, only the small amount of thrombin that 
is created is needed in order to activate the common pathway. (10)
  The cascade is commonly broken down into the extrinsic pathway, the intrinsic 
pathway, and the common pathway. (10) 
 While the purpose of the extrinsic pathway is to initiate the coagulation cascade, the 
common pathway is responsible for amplifying the cascade.  This amplification is triggered by 
the thrombin that is produced by the extrinsic pathway.  The thrombin activates factor IX and 
factor VIII to XIa and VIIIa.  Then,  VIIa and IXa, phospholipids, and calcium all act to amplify 
the activation of factor X.  By amplifying factor Xa and Va production, large amounts of the 
prothrombinase complex (XaVa) are formed and large amounts of thrombin are generated.  The 
thrombin then cleaves fibrinogen into soluble fibrin monomers, which polymerize into fibrin 
protofibrils which then will polymerize into fibrin fibers which add mechanical stability to the 
forming platelet plug.  Factor XIII, which is also activated by thrombin, then works with calcium 
to stabilize the fibrin polymer by cross-linking the fibrin fibers.  The stabilized polymer is 
insoluble cross-linked fibrin. (10) 
  The intrinsic pathway is not 
believed to have a function in vivo¸ but is responsible for initiation from negatively charged 
synthetic surfaces, such as glass or plastic.  
- 11 - 
 
 Tertiary hemostasis refers to the formation of the enzyme plasmin, which is responsible 
for breaking down the blood clot (known as fibrinolysis).  When the coagulation cascade is 
activated, endothelial cells release tissue plasminogen activator, or tPA.  The tPA converts the 
plasminogen found in the clot into plasmin.  The plasmin then creates fibrin and fibrinogen 
degradation products by proteolytically cleaving the fibrin and fibrinogen that are in the clot.  
However, in order for tPA to activate the plasminogen, fibrin must be present.  This restricts 
activation to only where thrombus is formed, keeping the tPA from undesirably destroying 
fibrinogen, factor V or factor VIII.  In addition to tPA, plasminogen can be activated by 
urokinase, kallikrein or factor XIIa. (11) 
2.2 Clopidogrel (Plavix) 
2.2.1 Mechanism of Action 
Adenosine diphosphate (ADP) 
binds to platelet G-protein linked surface 
receptors P2Y1 and P2Y12 Figure 2-2 ( ). 
Upon binding, the Gq linked P2Y1 
receptor activates phospholipase C and 
causes the cytosolic surge of Ca++, which 
is responsible for the immediate 
conformational change.  The activated Gi 
linked receptor P2Y12 detaches its α subunit from the β subunit, which lead to two independent 
signaling pathways.  The α subunit inhibits adenylyl cyclase (AC), which catalyzes the formation 
of cyclic adenosine monophosphate (cAMP).  The reduced level of cAMP causes a decreased 
Figure 2-2: ADP mediated activation of platelet aggregation (14) 
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level of the specific protein kinases that phosphorylate the vasodilator-stimulated phosphoprotein  
(VASP).  The phosphorylated form of VASP inhibits GP IIb/IIIa receptor, which is responsible 
for platelet aggregation.  In contrast, the β subunit activates the phosphatidylinositol 3-kinase 
(PI3K) which is an important intermediate signaling molecule for dense and α-granule secretion.  
All told, P2Y12 signaling both induces inside-out signaling, activating the αIIbβ3
Clopidogrel requires oxidation by the hepatic cytochrome P450 to result in the opening 
of the thiophene ring and the forming of a carboxyl and thiol group.  However, only a small 
proportion of the clopidogrel undergoes oxidation by CYP450 in vivo. (12)
 integrins, and 
induces granule release. 
  The thiol group 
irreversibly binds to the platelet Gi-protein linked ADP surface receptor, P2Y12, through a 
covalent disulfide bridge, thus reducing the number of inducible P2Y12 receptors on the platelet 
surface that indirectly disable αIIbβ3 activation.  Without the activated αIIbβ3 
2.2.2 Variability of Clopidogel Resistance 
integrins, fibrin and 
fibrinogen cannot bind platelets together. 
Five to ten percent of the patients treated with clopidogrel exhibit resistance.  Of that five 
to ten percent, 25% of these patients are reported to be partially responsive in standard platelet 
assays. (13)  The causes of clopidogrel resistance cannot yet be elucidated and are still areas of 
active research.  Yet many studies seem to agree that there are certain areas of research that seem 
most relevant to clopidogrel resistance:  1) genetic variation of the P2Y12 and P-450 CYP3A; 2) 
extent of P2Y1-dependent platelet aggregation; 3) accelerated platelet turnover; 4) interaction 
with medication that involves cytochrome P-450 CYP3A4.   
- 13 - 
 
2.2.2.1 Polymorphisms of P2Y12 
There are 2 haplotypes, designated H1 and H2, associated with P2Y
and P-450 CYP3A 
12 that have been 
identified.  The H2 haplotype is associated with increased maximal platelet aggregation in 
response to ADP. (14)  Variations of the promoter region of P2Y12 have been observed to increase 
transcriptional efficiency in the H2 haplotype; this partially explains why H2 carriers exhibit 
higher number of P2Y12
Likewise, the variation of CYP3A expression in different individuals has been identified.  
The genetic basis for this difference has not yet been identified, but it is possible to use the 
erythromycin breath test to determine an individual’s CYP3A activity. (15)
 receptors on the platelet surface than non-carriers.   
2.2.2.2 Extent of P2Y
  Lau et al. has shown 
that the positive correlation between CYP3A activity and clopidogrel’s effectiveness. 
1
Studies have found that activation via the P2Y
-Dependent Platelet Aggregation 
1 receptor alone can induce transient 
platelet aggregation. (14)  The expression level of P2Y1
2.2.2.3 Different Platelet Turnover Rates 
 receptor on the platelet surface is different 
across the patient population.   
In times of stress, the bone marrow has accelerated platelet production.  The replenished 
platelets carry P2Y12 receptors that are unexposed to clopidogrel. (13)
2.2.2.4 Interaction with Other Medications Involving P450 
  This dramatically 
decreases the duration of clopidogrel’s anti-clotting effectiveness. 
Drugs that involve cytochrome P450 have been postulated to reduce the effectiveness of 
clopidogrel.  For example, studies have shown that atorvastatin (Lipitor), used to treat 
hypercholesteremia, also requires P-450 CYP3A4 metabolism to become active. (16)  Patients with 
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atherosclerotic disease are often treated for hypercholesteremia with both atorvastatin and 
clopidogrel.  The former is shown to competitively inhibit the latter’s anti-platelet activities. 
2.2.3 Time Dependent Plavix Resistance 
The percentage of platelet aggregation at a certain time post clopidogrel treatment varies 
across patient population and resistance to the drug diminishes given more time.  For example, 
Gurbel et al. correlates the frequency of patients and absolute change in platelet aggregation after 
the drug treatment at 2 hr, 24 hr, 5 days and 30 days; the percentage of patients who are resistant 
to clopidogrel is found to be 63%, 31%, 31% and 15% respectively, where resistance is defined 
empirically by the study. (17)
2.3 Chip Manufacture with PDMS 
  One possible explanation is that each patient’s hepatic cytochrome 
P450 CYP3A rate of metabolism is different. 
 The microfluidic chip that will be at the heart of the POC device will be constructed of an 
elastomer known as polydimethylsiloxane.  Abbreviated as PDMS, it possesses an array of 
qualities that make it an ideal choice for use in fabrication.  First, features with sub 0.1 micron 
fidelity can be formed, meaning that many channels of small width are able to be fabricated on a 
single chip.  Second, it is thermally and electrically insulating.  Third, polydimethylsiloxane is 
mostly non-reactive towards reactants used.  Also, PDMS possesses good bio-compatibility and 
can easily be surface-modified to make it biologically inert, which is an especially important 
characteristic in our system.  In addition, the Young’s Modulus is tunable, allowing one to adjust 
the elastomeric properties of PDMS to that required for the system. Finally, and most important, 
a layer of PDMS is optically transparent for a wide range of light wavelengths, down to 240 
nanometers.  The usefulness of this last characteristic of PDMS is useful because a detection 
system involving visible light will be used for monitoring the blood clotting. 
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 Polydimethlysiloxane will be purchased from any number of chemical suppliers, and, 
once large-scale manufacturing commences, will be purchased in massive bulk installments.  
PDMS is supplied in a two parts: a base and curing agent.  When the two are mixed, the silicon 
hydride groups present in the curing agent react with vinyl groups present in the base, 
polymerizing and forming an elastomeric solid.  The base to curing agent proportions are 
adjustable values, which lead to different degrees of elastomeric solids and thus forms the basis 
for the tunable Young’s Modulus of PDMS. 
 The manufacture of PDMS begins by the creation of a mask, or master.  This mask has a 
reverse image of the intended pattern and is usually created via photolithography.  Once the 
PDMS is mixed using the desired amounts of base and curing agents, it is poured onto the mask 
and allowed to harden.  The device is peeled off the mask and attached to another substrate for 
further patterning.    
 An important manufacturing advantage of PDMS is its ability to be sealed to other 
homogenous or heterogeneous layers of PDMS, which might be necessary in the construction of 
a multilayer device.  In addition this sealing can be done either reversibly or irreversibly, making 
the possibility of peeling the layers apart to inspect the device after use possible. 
 By using PDMS, the ability to mold a number of components becomes possible.  Upon 
fabrication, valves, pumps, mixers, switches and a number of other miniaturized components can 
be fabricated.  Moving up a level of complexity, the potential exists for the combination of these 
in sequence to form microfluidic unit operations. (18) 
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2.4 Lap-On-a-Chip Microfluidic Platform 
Lab-on-a-chip technology involving microfluidics is continuously growing in popularity, 
especially in the biotechnological, medical, and pharmaceutical industries.  By definition, 
microfluidics deals with the behavior, flow, and precise control of fluids that move through 
channels and areas that are of a micro-, nano-, or pico- scale.  Features of a microfluidic setup 
include small volumes and sizes as well as low energy consumption. 
Microfluidic platforms have many appealing features, such as a simple and well defined set 
of fluidic unit operations and a low cost for fabrication.  Some examples of fluidic unit 
operations are fluid transport, fluid mixing, and separation or concentration of molecules.  
“Ideally, the set of unit operations will be connected in a monolithically integrated way so the 
platform allows for a seamless and simple integration of different fluids, which will give the 
platform a significant advantage over more complicated models” (19)
2.5 Customer Requirements 
.   
Considering the needs and features required by potential customers is crucial to designing 
a new product and will most likely determine whether the product succeeds or fails.  Customer 
requirements are determined by analyzing data from the market survey and researching 
competing products.  Once a list of customer requirements is compiled, each requirement is 
given a weighting factor to designate its degree of importance and is also classified as either 
fitness-to-standard (FTS) or new-unique-difficult (NUD). (2)  Table 2-1 shows the desired 
customer requirements. 
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2.6 Critical-to-Quality Variables—Product Requirements 
2.6.1 Critical-to-Quality (CTQ) Variables 
The customer requirements from the previous section must be translated into technical 
requirements that can be manufactured and used in the design of the device.  These technical 
requirements are also called critical-to-quality variables (CTQ) and relate to specific target 
values.  The target values have been determined by researching competing products such as 
Accumetrics VerifyNow P2Y12 Assay, Siemens PFA-100 System, and Helena AggRAM Module 
and by reviewing market survey data.  The technical requirements and target values are shown 
below in Table 2-2.  
Table 2-1  Customer Requirements 
The table above lists the customer requirements compiled from market research.  Each requirement 
corresponds to product requirements, a type, and a weighting factor. 
Customer 
Requirement Product Requirements Type
Weighting 
Factor (%)
Multiple tests simultaneously
Small Sample
Fast turnaround time
Instrument/measurement quality
Reagent quality
Sample quality
Sensitivity Detection limit FTS 15
Low Cost Small reaction amounts NUD 10
40High Throughput NUD
Accuracy FTS 35
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Table 2-2  Critical-to-Quality Variables 
The product requirements are translated into technical requirements and given a target to reach. 
 
2.6.2 House of Quality  
The House of Quality (HOQ) relates the customer requirements to the overall product 
requirements and consists of six sections.  The first section is a list of the customer requirements 
and the second section lists the technical requirements associated with the customer requirements.  
The third section consists of a matrix that shows the relationships between the customer and 
technical requirements, showing whether or not the technical requirement exists for a certain 
customer requirement.  The fourth section, or the top of the house, shows the synergies and 
conflicts among the technical requirements.  In this section, a plus sign is used to designate that 
both variables are increasing or decreasing while a minus sign is used to show if one variable 
increases while the other one decreases or vice versa.  If no relationship exists between the 
variables, the space is left blank.  For the House of Quality in Figure 2-3, the technical 
requirements do not directly relate to each other so the top of the house is blank.  The final 
section displays the weighting factors for the customer requirements which were already 
determined in the customer requirements table. (2)
Customer/Product Requirement Technical Requirement (CTQ) Target (per chip)
Multiple Tests Simultaneously Multiple Concentrations of MRS 2395 4 concentrations of MRS 2395
Small Sample Whole Blood Samples 360 μL
Fast Turnaround Time Total Assay Time ~ 5 minutes + 10 minute incubation
Multiple Tests/[MRS]
2 channels/MRS concentration
Reagent Quality Chemical Purity > 95% pure
Sample Quality Directly From Patient Anti-coagulated blood
Detection Limit Visible Light Detection 380-750 nm
ADP Volume 160 nL
MRS 2395 Mass 0.06327 mg
Collagen Volume 32 nL
Instrument/Measurement Quality
Small Reaction Amounts
Advanced Error Verification System
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Reference Concept 
(Helena's AggRAM Module and Analyzer)
Multiple Tests 
Simultaneously Up to 4 tests simultaneously 0
Small Sample 900 µL +
Fast Turnaround Time 5 minutes plus 45 minute preparation/incubation time +
Advanced Error Detection 
System Baseline channel for 100% aggregation +
$7,995 for device and $14,995 for analyzer
$70 for reagents and cuvettes 
Low Cost +
Requirement MCCRA System
2.7 Product Concepts 
“The Pugh Matrix is used to compare how well the NUD requirements are satisfied by 
the device concept versus its leading competitor” (2)
 
.  Based on data accumulated from 
researching the market, it was determined that Helena’s AggRAM Module and Analyzer is the 
main rival of the MCCRA System.  The requirements are listed and the current solutions to those 
requirements used by the AggRAM Module are presented in Table 2-3.  Our system’s alternative 
for each requirement is ranked as inferior, superior, or equal to our competitor’s solution.  As 
shown in Table 2-3, the MCCRA System has many superior concepts when compared to the 
competition such as a better error detection system, faster turnaround time, lower cost, and 
smaller sample. 
Table 2-3  Pugh Matrix 
The Pugh Matrix compares our product against its competitor in regards to fulfilling requirements. 
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2.8 Market and Competitive Analysis 
2.8.1 Accumetrics—VerifyNow P2Y12
The Accumetrics VerifyNow System uses an optical detection system and a single 
channel assay to measure platelet aggregation.  The P2Y
 Assay  
12 Assay, one form of a test that can be 
performed by the system, is designed to measure how well clopidogrel blocks the P2Y12
The P2Y
 
receptors on the platelets by using light transmittance.  This test is performed using the whole 
blood of a patient who is already being medicated with clopidogrel. 
12 Assay uses 2 mL of whole blood and has a 3 minute runtime, not including an 
incubation period of about 10 minutes.  During the test, the adenosine diphosphate (ADP) is used 
as an agonist to induce the activation of platelets which are present in whole blood.  The 
activated platelets attach to the fibrinogen coated beads and aggregation occurs.  While this 
reaction is occurring in one channel, a baseline channel containing thrombin and fibrinogen 
coated beads is being run simultaneously.  Thrombin receptors are strong platelet activators that 
work independently from the P2Y12
Light transmittance is the method of 
detection used for this system.  The change in 
optical signal in the assay channel is measured 
and reported in P2Y
 receptor so 
this baseline channel is used as the control. 
12 Reaction Units (PRU).  
The change in transmittance is also measured in 
the baseline channel.  The percent inhibition is 
calculated by the percentage difference between 
the PRU and baseline channel results.   
Figure 2-4  Accumetrics VerifyNow System (20) 
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The list price for the VerifyNow System is $8,000 and the Assay Kit costs $1,250 for 25 
tests.  The system is also beneficial because it can be used with assay kits involving aspirin as 
well as αIIbβ3 
2.8.2 Siemens—PFA-100 System 
inhibitors. (20) 
The Siemens PFA-100 System detects platelet dysfunction and is the first commercially 
available in vitro test to incorporate the high-shear flow as well as platelet adhesion and 
aggregation that would occur after a vascular injury.  This test is designed to decipher the 
amount of time in which the platelets will coagulate and close a hole which represents a vascular 
injury.  It is assumed the patient is already taking clopidogrel in order for this test to give usable 
results. 
This test uses 800 µL of citrated whole blood and has a runtime of 5 minutes, not 
including a 15 minute incubation period.  The 
system uses a membrane of collagen and ADP 
to monitor platelet interaction.  The whole 
blood flows through a 150 µm port through 
the collagen/ADP membrane at a shear rate of 
4,000-5,000/s.  The time required for the 
platelets to close the aperture shows the 
platelet hemostatic capacity. (21) 
The list price for the PFA-100 System is $15,000 and the ADP/Collagen Test Cartridges 
as well as the ADP/Epinephrine Test Cartridges are sold in pack of 20 that cost $300 each.   
Figure 2-5  Siemens PFA-100 System (21) 
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2.8.3 Helena—AggRAM Module and Analyzer 
 The Helena AggRAM device uses light transmittance to analyze platelet aggregation in 
four channels at once and specialized software to graph the results.  The four channels can run 
tests for various dilutions of one patient’s blood or run 4 separate patient samples at the same 
time.  The device links to the software and automatically calculates the slope, max % 
aggregation, and time to reach max % aggregation.  The lag phase is displayed on the computer 
along with graphs and curves which can be printed out or saved for documentation.  A database 
exists for the storage of results and graphs for quality control purposes.  This device assumes that 
the patient is already taking clopidogrel but could potentially be modified by adding different 
concentrations of the anticoagulant to the various cuvette samples. (22) 
The run time for the AggRAM Module is about 3 minutes with a 45 minute incubation 
time.  450 µL of whole blood is needed for each cuvette, but generally at least 900 µL is used 
because one of the cuvettes will be used as a baseline with 100% coagulation.  The procedure 
begins forming the test sample by mixing the whole blood and the anticoagulant, sodium citrate.  
This mixture is centrifuged for 10-15 minutes and then sits for 30 minutes before the test can be 
performed.  The baseline sample does not contain anticoagulant but was also centrifuged for 10-
15 minutes.  During this time period a platelet count is performed so the platelets in each sample 
can be standardized, usually to 250,000/mm3
A laser diode is used to conduct light transmittance detection.  The change in absorbance 
along with the increased light transmittance is measured as platelet aggregation occurs.  The 
percent of aggregation is calculated using the following equation: 
.  To begin the test, ADP, collagen, and epinephrine 
are added to all samples except the baseline sample along with a stir bar and then incubated for 
1-3 minutes.  The cuvettes are placed in the module and the light transmittance begins. (23) 
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 % 𝒂𝒂𝒂𝒂𝒂𝒂𝒂𝒂𝒂𝒂𝒂𝒂𝒂𝒂𝒂𝒂𝒂𝒂𝒂𝒂𝒂𝒂 = 𝑶𝑶.𝑫𝑫.𝒂𝒂𝒂𝒂𝒂𝒂𝒂𝒂𝒂𝒂𝒂𝒂𝒊𝒊−𝑶𝑶.𝑫𝑫.𝒎𝒎𝒂𝒂𝒎𝒎𝒂𝒂𝒎𝒎𝒎𝒎𝒎𝒎
𝑶𝑶.𝑫𝑫.𝒂𝒂𝒂𝒂𝒂𝒂𝒂𝒂𝒂𝒂𝒂𝒂𝒊𝒊 ∗ 𝟏𝟏𝟏𝟏𝟏𝟏     (2-1) 
where O.D. is the optical density.  The sample’s results can then be compared to the baseline 
sample and stored graphs of patients that had normal 
platelet aggregation.  
 The price of the device is listed as $7,995 and the 
analyzer software costs $14,995.  The reagent kit 
containing ADP, collagen, and epinephrine costs $116 and 
accounts for 2 full tests. An additional cost must be 
factored in for buying the silicon coated cuvettes and a 
one-time cost for the magnetic stir bars.  
2.8.4 Conclusions 
After comparing the MCCRA System to its three main competitors, the analysis proves 
that the system is a better product.  Table 2-4 compares major features and prices of our device 
against its three main competitors:  Accumetrics’ VerifyNow System, Siemens’ PFA-100 System, 
and Helena Laboratories’ AggRAM Module and Analyzer. 
 While all of the products have an error detection system, our device’s is more advanced 
since each channel has a twin channel running a test on the same concentration.  This feature is 
very beneficial because it will allow errors to be easily displayed in the graphs that show the 
results for the twin channels.  If there is a discrepancy between the graphs, the discrepancy could 
be accounted for by either a diode being broken or a channel being clogged or blocked.  This 
error detection will verify if the test has to be rerun. 
Figure 2-6  Helena Laboratories AggRAM 
Module and Analyzer (22) 
- 25 - 
 
 With a runtime of 5 minutes and an incubation period of 5 minutes, the MCCRA system 
also has a faster or comparable turnaround than the other products.  The system that has the next 
fastest turnaround is Accumetrics’ VerifyNow System which completes its test in 3 minutes and 
has an incubation period of 10 minutes.  The product that has the longest turnaround time is 
Helena Laboratories’ AggRAM Module, which is also the product that is used as our reference 
concept in the Pugh Matrix seen in the Product Concepts section of this report.  While the 
device’s runtime is only 3 minutes, its incubation time is 45 minutes because the whole blood 
sample needs to be centrifuged for 15 minutes and required to sit for 30 minutes before testing. 
 The testing procedure is very efficient.  The MCCRA device uses the least amount of 
whole blood, 550 µL.  Our microfluidic chip has eight assay channels that test four inhibitor 
concentrations so the patient’s resistance to clopidogrel can be assessed in one test rather than 
two or three like other competing products.  The procedure requires very little clean-up because 
all of the reagents and sample are kept on the chip.  This is similar to the test cartridges for the 
PFA-100 System since all of the reagents are in this cartridge along with the blood once it is 
added.  The VerifyNow and AggRAM Systems differ.  The VerifyNow uses a test tube to mix all 
reagents with the blood before it is inserted into the machine and the AggRAM uses cuvettes 
containing the reagents and blood that are placed in the device. 
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 Finally, our product is cheaper than its competition.  The box and software, which are 
sold together as a package, have a list price of only $6,000 while the next cheapest device is 
$8,000.  Helena Laboratories’ AggRAM Module sells at a list price of $7,995 and its software 
costs $14,995 which means our device and software is roughly $17,000 cheaper.  Our 
microfluidic chip is sold for $100 while rival companies have chips or kits that range from $30 to 
$70.  We can justify that our chip is $100 because of the accuracy of the test.  It is unlikely for 
the test to be run more than once while tests for the VerifyNow and the PFA-100 Systems will 
most likely have to be run more than once because the patient’s dosage will need to be adjusted 
and re-tested.  
2.9 Superior Product Concept 
The MCCRA System has two main features that make it better than other competing 
products:  advanced error detection and testing multiple concentrations on one chip. 
The error detection system in the device consists of two channels for each inhibitor 
concentration.  The duplicate channel will be located in a separate part of the channel bifurcation 
system in order to show multiple potential problems.  The potential errors these channels check 
for are deformed channels from manufacturing complications and blockages in blood flow.  
Table 2-4  Competitive Analysis 
Feature MCCRA VerifyNow PFA-100 AggRAM
Runtime 5 minutes 3 minutes 5 minutes 3 minutes
Incubation Time 5 minutes 10 minutes < 15 minutes 45 minutes
Sample Size 550 μL 2 mL 800 μL 900 μL
8 assay channels 1 assay channel 1 assay channel 4 assay channels
4 different assays 1 baseline channel Up to 4 different assays
System Cost $6,000 $8,000 $15,000 $22,990
Cartridge/Test Cost $100 $50 $30 $70
Testing procedure
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Another reason to have multiple channels is to verify that the visible light diodes are working 
properly.  If the graphs from different channels for the same concentration vary, the diode could 
be malfunctioning, indicating a technical problem as supposed to a real result with incorrect 
clinical implications. 
Testing multiple inhibitor concentrations at once on one chip is a very important 
advantage.  This saves the hospitals time and money by measuring the patient’s response to a 
range of concentrations and determining an ‘effective dose’ regime rather than a one-time 
parameter value.  If a patient is in the hospital for only one test versus multiple, their hospital bed 
will most likely be open in a shorter amount of time which keeps the influx of patients for 
hospitals high and the hospital can make more money.  Insurance companies and patients will 
also save money because they will not have to pay for multiple tests.  The MCCRA System is 
creating a phenotype for the patient by testing various ranges of inhibition over a five minute 
time interval.  It is superior to the competing systems because it does not just measure the 
patient’s response at a single point.  The MCCRA System eliminates the need for any guess and 
check procedures and allows for one single test, instead of two to three trials like its leading 
competitors.   
The price of the system is also very comparable or lower than other competing products’ 
prices.   
2.10 Other Important Considerations 
Safety is always an important consideration when running a company and producing a 
product.  It is important for the product to meet the standards of the industry while also keeping 
the manufacturing floor safe for employees. 
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Material Safety Data Sheets (MSDS) for PDMS, collagen, MRS 2395, ADP, acetone, and 
isopropanol have been attached in the Appendix since all of these materials and reagents are used 
daily in our facility.  Among the advantages of our process is the fact that there are no harsh or 
particularly corrosive or reactive chemical in use, both minimizing the risk to employees and the 
environmental impact of an accident. 
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Part 3  Feasibility Stage 
3.1 Process Overview 
3.1.1 Chip Diagram 
 
 
Figure 3-1 is a CAD drawing of our microfluidic chip design.  Point A is the location at 
which the patient’s blood sample is injected onto the chip before testing.  Point B is the 
bifurcation pattern used to create 8 channels that are equal in all dimensions, and arranged so that 
the flow through each of the eight channels is equivalent.  At Point C, immediately following the 
bifurcation, the channels straighten out and this is where MRS 2395 is deposited.  Point D is 
where the mixing section for the blood/MRS 2395 combination, including 10 turns and a series 
of grooves in the channels in order to make sure complete mixing occurs before reaching the 
next reagent.  Point E is another straight area in the channels where ADP is deposited.  At Point 
F, mixing is achieved for the blood/MRS 2395/ADP combination, again implementing 10 turns 
Figure 3-1  To-scale representation of the microfluidic chip (draw in CAD).   
This image is what was used to pattern the photoresist mask used to create the PDMS chip. 
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and a series of grooves in the channel.  The final straight section of the channels where collagen 
is deposited occurs at Point G.  This is where clot formation will occur and light transmittance 
readings through the channel will be taken.  Point H starts the reverse bifurcation of the eight 
channels back down to one to exit into the waste reservoir.  This design is used in order for the 
blood to be pulled through the channels by the vacuum at identical flow rates, since no channel 
will have increased force applied due to its proximity to the vacuum.  The waste reservoir is 
placed at Point I.  The volume of this reservoir is approximately 1500 mL, which is more than 3 
times the amount of space required to hold the blood sample.  By providing sufficient volume in 
the reservoir to hold the entire sample, the blood will never leave the chip and enter into the 
device.  Also, this should allow for enough space between the vacuum and the exit channel to 
make sure that none of the blood is sucked into the vacuum.  This figure is the representation of 
the chip as it was fabricated to be used in lab tests (with the vacuum puncturing at the back 
center location of the reservoir).  The scaled up manufacturing design, however, has the waste 
reservoir wrapping around one side of the chip and the vacuum puncturing the PDMS at the end 
of this section in order to further prevent the splattering of blood onto the vacuum. 
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3.1.2 Process Flowsheet 
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3.1.3 Flow through the Microfluidic Chip 
3.1.3.1 Bifurcation 
The patient’s blood sample is injected into the chip at a 
designated location (See Figure 3-2).  From this point, a single 
channel is branched into two equally sized channels.  Each of 
these channels is then also divided in half.  This is repeated so 
that there is a total of eight channels that are equivalent both in 
dimension and spacing (See Figure 3-2).  For a more detailed 
description see Section 3.2.3. 
3.1.3.2 Addition of MRS 2395 
Once the blood has been equally divided into eight 
separate channels, it is flowed over dry MRS 2395.  Each pair of channels has a different amount 
of MRS 2395.  The four amounts of MRS 2395 used are 0 µg, 0.395 µg, 3.95 µg, and 39.5 µg. 
Having varying amounts of the compound allows for four sets of data, each corresponding to a 
different level of MRS 2395.  Also, by having two streams contain each concentration, there is 
an automatic error detection system since the two values 
for each concentration can be compared for accuracy. 
3.1.3.3 Mixing 
After the blood has passed over the MRS 2395, it 
passes through a mixing section.  In this part of the 
channel, the pathway turns 180° twenty different times 
(after each 0.05 cm length of channel) for a total of 20 
Figure 3-2  Bifurcation 
 Depiction of the bifurcation of channels at 
the beginning of the chip in order to evenly 
divide the entry stream into eight streams.  
The point at which the blood is inserted in 
relation to the bifurcation is indicated. 
Figure 3-3 Three dimensional depiction of a 
section of one of the mixing portions of a 
channel.  In this figure, there are three 180° 
channel bends.  In each of the actual mixing 
sections on the chip there are 10 bends.  The red 
arrows indicate the direction of blood flow. 
 
BLOOD 
INSERTION 
POINT 
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full turns in order to aid in the mixing of the blood and the MRS 2395 (See Figure 3-3).  In order 
to ensure total mixing, there are also grooves built into the top of the channels (See Figure 3-4).  
 
3.1.3.4 Addition of ADP 
After mixing with the MRS 2395, the blood flows over a region containing an ADP 
deposit.  The amount of ADP in each channel is 3.95 µg (equal amount in all eight channels).  
Following the same mixing mechanism as before, the blood containing MRS 2395 is mixed fully 
with the ADP. 
3.1.3.5 Collagen and Light Transmittance 
The blood containing MRS 2395 and ADP then flows over a surface coated with a 
collagen deposit of 4 nL (equal amount in all eight channels).  As it passes over this region, the 
collagen activates the formation of a blood clot (See Section 2.1).  Once the blood starts passing 
over the collagen, the MCCRA device will begin taking light transmittance readings (See Section 
Figure 3-4 Three-dimensional depiction a section of mixing channel with grooves. (Not drawn to scale) 
Note: this is a picture of the PDMS channel when fabricated, however, when joined with the glass surface, the PDMS is flipped 
upside down, and the grooves will be above the flow of the blood.   
 
90° 
90° 
36 µm 
90 µm 
235 µm 
45° 
250 µm 
45° 
60 µm 
235 µm 
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3.3).  The amount of clotting that 
occurs will depend on the resistance 
level of the patient, as well as the 
amount of MRS 2395 that was 
added to each channel.  (See Figure 
3-5) 
3.1.3.6 Waste Disposal 
Once the blood has passed 
over the collagen, it proceeds 
through a reverse bifurcation setup and 
into the waste reservoir.  The second 
bifurcation assures that the blood will 
be pulled at the same flow rate in each of the eight channels by eliminating a variance due to 
proximity to the vacuum.  The waste reservoir is designed so that there is enough space to hold 
1.5 mL of blood (approximately three times the 550 µL of sample that is used).  By making the 
reservoir sufficiently large, all of the blood will be contained on the chip at all times, i.e. at no 
point in the testing process will blood reach the vacuum or any other component of the box.  
After the test is completed, the chip can be removed and disposed of without needed excessive 
cleaning of the box.  Also, the vacuum is connected by a puncture into the top of the chip 
(through the PDMS layer) into the waste reservoir.  By having the vacuum pulling from above 
the waste reservoir, the blood that settles into the bottom of the reservoir will be far enough from 
the vacuum that it will not be pulled up into it.  (See Figure 3-6) 
Figure 3-5 3-D depiction of the collagen section of one of the channels.  
The red arrows indicate the flow of blood through the channel.  A blood 
clot forms on the collagen and a white LED located in the MCCRA device 
above this section of the channel shines on the clot.  The magnitude of 
the transmission through the clot is measured by a light sensor located in 
the device, below the chip. 
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3.1.4 Process Conditions and Reagent Volume  
This section explains the unapparent process embedded between the blood entering the 
machine and read-out from the display.  Shortly after 550 µL of blood enters the micro-channels 
of the chip, which is controlled at 37oC by a temperature reservoir within the box (See Box 
Design), it splits into 8 identical streams through graduated bifurcation.  Each stream first 
encounters the MRS 2395 matrix and undergoes dissolution and mixing.  Downstream to MRS 
2395, the blood flow undergoes ADP-carbohydrate dissolution and mixing processes before 
flowing though collagen, where platelet aggregation is detected.  The 8 streams are grouped into 
2 identical sets of 4 streams.  In either set, each steam dissolves a different amount of MRS 2395 
to achieve 0X, 0.1X, 1X, and 10X the IC50 of 3.6µM. (24)
 
Waste Reservoir 
PDMS 
vacuum 
       Channels 
vacuum 
 
  
Channels 
vacuum 
TOP VIEW 
SIDE VIEW 
  Although the targeted concentrations 
of MRS 2395 are set and ready, the calculation that is needed to determine the amount of MRS 
2395 deposition on the micro-channel to achieve such concentrations is rather involved.  Table 
Figure 3-6 Depiction of the waste reservoir with respect to 
the channels and vacuum location on the chip.   
The light blue lines represent the outline of the waste 
reservoir, the black lines represent the outline of PDMS, the 
gray area represents the area of the chip where the channels 
are located, the black arrows show the direction that the 
vacuum is pulling, and the red arrow shows the direction of 
blood flow out of the channels and into the waste reservoir. 
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3-1 gives a summary of the amount of depositions and detailed computation can be found in 
Appendix 7.2. 
 
 
 
 
 
 
 
 
 
3.2 Detailed Chip Design 
3.2.1 Chip Fabrication 
3.2.1.1 Manufacturing Considerations 
 The microfluidic chip for use in our point-of-care device will be manufactured in our own 
facilities. It was initially proposed that an outside company could be contracted to fabricate the 
chips, partly due to the large cost associated with constructing a fabrication facility. However, it 
was agreed that the intellectual property inherent in our device should not be put at risk by 
outsourcing the process. 
 As mentioned in an earlier chapter, the chip will be constructed of two layers: a bottom 
glass layer and a top PDMS layer. This patterned design must be present on the PDMS layer, 
whereas the deposition of the various reagents must occur on the glass layer. To pattern the 
PDMS, photolithography and soft lithography were both found as options. Advantages and 
Reagent Amt. in stream Amt. deposit on chip 
Whole Blood 550 µL  
MRS 2395 (0xIC50, 2 streams) 0 0 
MRS 2395 (0.1xIC50, 2 streams) 0.36uM 0.00057 mg 
MRS 2395 (1xIC50) 3.6uM 0.0057 mg 
MRS 2395 (10xIC50) 36uM 0.057 mg 
ADP (all 8 streams) 3.6uM 0.0057 mg 
Table 3-1  Reagent target concentration in 8 flowing streams and amount (mg) for deposition on 
micro-channels. 
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disadvantages were associated with both ways, and in the end a soft lithography technique 
known as replica molding was decided upon for use. Another issue that needed to be addressed 
was the method of deposition of the MRS 2395, ADP and bovine collagen. Use of a robotic pin 
tool was considered, as well as an inkjet dispenser for delivery. Since three reagents need to be 
deposited per channel and eight channels are present on one chip, 24 depositions must occur per 
chip. Therefore, the speed of delivery in each system was contrasted to insure that the goal of 
4,000 chips manufactured per day could be attained. After considering a number of attributes, 
including price, a robotic pin tool was found to be suitable for our purposes. Finally, equipment 
including a curing oven, plasma oxidizer, and UV light emitter were needed for curing of the 
PDMS top layer, sealing of the two layers and sterilization of the device, respectively. 
3.2.1.2 Patterning of PDMS Layer 
The top layer of the microfluidic chip will be constructed with the elastomer known 
polydimethylsiloxane, or simply PDMS. This material was decided upon to form the foundation 
of the device because of its advantageous molding capabilities. Initially present in the form of a 
base and curing agent, a mixture of the two parts can be patterned with a certain design using one 
of any number of different methods: microcontact printing (µCP), replica molding (REM), 
microtransfer molding (µTM), micromolding in capillaries (MIMIC), solvent-assisted 
micromolding (SAMIM), and photolithographic patterning of photosensitive PDMS. All of these 
methods have advantages and disadvantages in their application to fabrication of our device. 
 Photolithography methods for fabrication of our device were first explored. 
Microfabrication in the electronics industry almost exclusively uses some form of 
photolithography due to its ability to use a single photomask for the mass-production of thin film 
patterned devices. Because of the rather large goal of one million chips to be produced per year, 
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a parallel process that could yield a high net output of devices per day while maintaining a high 
fidelity of the product was a desirable trait. Since photolithography has been used to great 
success in the electronics industry, a process that incorporated such was sought. The search 
resulted in the finding of a technique for making the PDMS layer of the device photosensitive, 
thus making it susceptible to patterning by ultraviolet light. The method called for the inclusion 
of benzophenone in the initial mixture of PDMS base and curing agent. Amounts of 
benzophenone to be included could range from 0.1%-15% (v:v). The addition of this compound 
led to the formation of a benzophenone radical when irradiated with UV light (λ < 365 nm), 
which abstracts a hydrogen atom from any suitable hydrogen donor. These radicals react with the 
silicon hydride groups present in the PDMS crosslinkers and prevent them from undergoing the 
traditional crosslinking reaction with the PDMS monomer. (25) Therefore, regions of the chip 
irradiated with UV light will be prevented from curing when heated, and the PDMS in these 
areas can be washed away with an organic developer (solution). In this case, the photoinitiator is 
termed a positive resist. The positive acting nature of benzophenone makes for a simplified 
fabrication process for the microfluidic chips. In addition, features on the order of a few microns 
can be easily fabricated using this method. Although the use of photoPDMS seemed like a viable 
option, a number of concerns were brought to our attention. First, the process was not entirely 
proven. The idea for the use of benzophenone as a photoinitiator and subsequent experimentation 
was carried out by a research group at the University of Cincinnati. While the results appeared 
promising and a number of papers have been published regarding photoPDMS, there is no 
industrial documentation showing the successful implementation of this idea into the fabrication 
of any elastomeric (PDMS) device. Furthermore, a number of the steps involved in treating the 
soluble portion of the surface might not be advisable. In the description given, the exposed 
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region was developed by dipping in a toluene solvent for about 5 seconds. The use of this 
organic solvent or any comparable solvent used as developer was advised against due to safety 
issues and FDA approval issues. (26) 
 The field of soft lithography evolved from the need to produce desired patterns utilizing 
elastomers as a mold or stamp, as well as the requirements for a fabrication process that was low 
in cost, easy to learn, and easy to adapt to given set of circumstances. It possesses several 
advantages over conventional photolithography: soft lithography can utilize not just photoresists 
as a patterning surface but many different kinds of polymers, biological macromolecules and 
beads, it can pattern both planar and nonplanar surfaces in all three dimensions, and it can pattern 
features at about an order of magnitude smaller than photolithography.
Consequently, another way to pattern the PDMS into our 
given design was required. 
 (27) A major key to soft 
lithography is the use of a single master to create multiple molds that can then be used to 
fabricate a large amount of devices. The master is normally made using conventional 
photolithography: resist is spun onto a silicon wafer, the image is imprinted on via irradiation 
with UV light or using e-beam lithography, the wafer developed and the pattern made. A PDMS 
mold is then made from this master, which in turn serves as the cast for the further fabrication of 
patterned PDMS layers that are used for any number of microfluidic chip devices. Elastomers are 
used as the material to make molds due to their ability to make conformal contact with surfaces 
over relatively large areas and the ease with which patterned layers can be released from the 
surface of such a mold. In addition to the advantageous qualities of PDMS such as low 
interfacial free energy, good thermal and chemical stability, and optical transparency to 
wavelengths as low as 300 nm, one of the most beneficial qualities it possesses is its durability. 
According to literature, PDMS molds were used up to fifty times without a noticeable decline in 
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performance. (27) For all of its positives, a number of potential issues exist that might become 
problematic in the future. First, the PDMS has been shown to shrink slightly upon curing. This 
would lead to a distorted patterned layer. (28) 
 The first type of soft lithography method analyzed is termed microcontact printing (µCP). 
It is based on a fundamentally basic concept: the design on the surface of a PDMS stamp is 
exploited to form patterns of self-assembled monolayers on the surface of a substrate through 
physical contact. (27) Self assembly, which describes the change from a disordered state of 
material to an ordered state due to local, noncovalent interactions and not under any external 
pressures, is unique to microcontact printing.
Also, due to the elasticity and thermal expansion of 
PDMS, fabrication of multiple layers or layers with nanoscale features might be difficult because 
of the trouble in accurate patterning across large swaths of area. Finally, the suppleness of the 
PDMS restricts the patterning of extreme aspect ratio features (very high or very low 
height/length) because of the risk of deformation. Despite some of these concerns, the usefulness 
and applicability of soft lithography to the fabrication of our microfluidic chip seemed too 
beneficial to ignore. Compared to traditional photolithography processes explored, soft 
lithography allowed for the production of many chips in parallel while retaining a simplistic 
design process. However, a number of different soft lithography fabrication methods exist. Each 
methodology differs in its fabrication of the mold that forms the template for the patterned layer. 
Thus, a detailed analysis of each was required to decide which fit the manufacturing of our 
device appropriately. 
 (29) In brief, the molecules of the system will keep 
changing states until the state with the lowest energy is found (chemical equilibrium). 
Furthermore the system will be at thermal equilibrium, which means that the system will 
spontaneously recover from any defects that might occur. Fabrication of a layer entails the 
- 41 - 
 
coating of a PDMS mold with a ligand (in the form Y(CH 2)nX, where the X head group is 
commonly a methyl group and the Y anchoring group is sulfur, phosphate, etc.), which then 
comes in physical contact with the substrate. (27) 
 The next method explored was microtransfer molding (µTM). In this method, a slim layer 
of liquid prepolymer (base plus curing agent) is applied to the patterned surface of a PDMS mold 
and the excess liquid is removed through any number of means. The combination of the 
prepolymer and curing agent within the mold is then put in contact with the desired substrate, 
when upon curing of the elastomer commences. After curing with UV light or heat, the result is a 
patterned layer of polymer that is left on top of the substrate. These patterned microstructures 
then may be used as masks to control the deposition or etching of the exposed substrate, or more 
simply as a mold for creation of other patterned layers.
Afterwards, etching or further deposition may 
occur to finish patterning the layer. This technique has the possibility of assisting us in creating 
the herringbone structure needed for proper mixing. However, the process appears too tedious 
and not amendable to a manufacturing process that demands high rates of production. Therefore, 
this idea was not investigated further. 
 (30) The method can use a wide array of 
polymers as the mold materials, and fabrication of large structures (about 3 cm2) can be 
completed in a small amount of time. These attributes seem to fit the requirements we are 
seeking in a fabrication scheme. However, two problems become apparent upon inspection. The 
first is relatively straightforward: our chip currently has dimensions of 4 cm by 6 cm and an area 
of 24 cm2, whereas the maximum area of a device found in literature was only about 3 cm2. 
Second, a layering problem exists if this fabrication mode is used. Our plans call for the bottom 
layer of our device to be a glass substrate, onto which the patterned layer of PDMS will make 
contact with. The channels and other patterned features must be present in this interface. 
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However, the product of microtransfer molding leads to a patterned surface not at the interface, 
but at the opposite side of the polymer layer. Although sealing of this side to a glass substrate 
coupled with subsequent removal of the initial substrate is possible, it seems like an unnecessary 
step. The use of a physical mold, though, seems to be a viable alternative to photolithography 
because of the ability to produce identical molds in high volume and combine them on one 
surface to fabricate many PDMS layers in parallel. 
 Micromolding in capillaries (MIMIC) is another soft lithography technique that was 
considered. In MIMIC, a mold composed of an elastomeric material is placed against a desired 
substrate. Channels intentionally formed between the mold and the substrate are filled with a low 
viscosity prepolymer by capillary action. The polymer is cured and the mold is separated from 
the device to yield a substrate layer with microstructures on its surface. (31) Again the range of 
material compatible with this technique is very broad, spanning UV- and thermal prepolymers to 
biological macromolecules. Additionally, the minimum feature size extends down to as low as 
hundreds of nanometers, far exceeding the spatial requirements of our device. However, the 
amount of time to diffuse through the channels by capillary action inhibits this technique by not 
allowing patterned layers to be fabricated fast enough to comply with the desired throughput. 
Also, relying on capillary action to fill the mold’s channels might introduce significant error into 
fabrication and might lead to channel-to-channel variability between chips, and even between 
different channels on a chip. Finally, the amount of PDMS used would have to be large because 
the mold must have the channel features protruding from its surfaces, meaning capillary action 
would have to account for the deposition of most of the elastomer on the chip. Besides 
introducing further potential error and variability in fabrication due to the amount of fluid needed 
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to be moved, the patterned side would again be on the opposite side of the initial substrate-
PDMS interface, leading to more unnecessary processing steps. 
 A fourth technique abiding by the tenets of soft lithography is solvent-assisted 
micromolding (SAMIM). SAMIM generates a pattern in the surface of a material using a good 
solvent that perturbs the material enough so as to make it pliable, but not to the extent of 
affecting the composition or stability of the mold. SAMIM proceeds by taking a PDMS mold and 
wetting its surface with the chosen solvent. (32) 
 The last soft lithography method explored was termed replica molding (REM). The most 
basic of the subset of micromolding techniques, it allows the transfer of the information present 
in a mold to a layer of polymer by simple conformation to the template’s shape.
The mold is then placed onto the surface of the 
substrate. A thin layer of the substrate material is dissolved by the solvent, and this layer 
conforms to the shape of the mold. When the PDMS mold is released from the surface, the 
solvent evaporates and substrate solidifies. The surface of the substrate is now complementary to 
that of the surface of the mold. Solvent-assisted micromolding has been shown to work with a 
wide variety of materials, including organic polymers such as PDMS. Observations of submicron 
features patterned by this method showed very little defects. In the context of our device, a solid 
layer of PDMS would have to be made and then the PDMS mold plus solvent applied to pattern 
the surface. This patterning method fulfilled requirements relating to compatibility with PDMS, 
feature size and adaptability to a large-scale manufacturing scheme. 
 (33) Compared to 
other methods, large amounts of polymer are used in REM. The accuracy of information transfer 
from the mold to the surface depends on noncovalent interactions occurring within the polymer, 
the nature of the mold surface, and the speed at which the mold is filled with the polymer. 
However, the beauty of the process lies in its ability to create a patterned structure 
- 44 - 
 
complementary to that of the mold in just one step. The benefits this imparts to our 
manufacturing process are tremendous: since multiple molds can potentially be grouped together 
on one surface, many PDMS layers can be constructed in parallel. Furthermore, one master with 
the desired image translates into many molds, and the molds are made in simple and cost-
effective way. Feature sizes with a resolution smaller than 10 nanometers were observed in 
laboratory experiments, which far exceed that needed on our microfluidic chip. (34) In addition, it 
has been shown that replication from a single master can proceed more than ten times without 
significant degradation in the quality of the patterned layer or mold. (27) 
 After an exhaustive study of all options, it was agreed that our manufacturing scheme 
would take from the principles underlying replica molding. This micromolding technique 
satisfied our requirements of low cost, ease of production and ability to produce in high volume. 
However, the process would have to be custom fit to our needs. To achieve a chip production  
between one thousand to four thousand chips produced per day (depending on which production 
year considered), many hundred molds needed to be present on each manifold. It was decided 
that a few masters would be created, which would serve as the templates for the molds. The 
masters would be created from normal lithography means. Our design called for channels of 
several different lengths, with heights of 60 micrometers and widths between 250 micrometers 
and 1000 micrometers. The other major feature on the chip is the waste reservoir, which has 
dimensions of 1 centimeter by 2 centimeter by 0.5 centimeter. All of these features are far above 
the feature size limit of photolithography, and can therefore be fabricated with high accuracy. 
Combined with the 
benefits of simple, straightforward micromolding, the durability of the PDMS molds makes 
replica molding the easiest soft lithography technique to transfer from benchtop to large-scale 
manufacturing. 
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With a silicon wafer as a substrate, master creation would 
begin by applying positive photoresist onto the substrate to 
give a resist thickness of approximately 250 micrometers. 
After exposure to UV light under the direction of a chrome 
mask that only permits passage of light in the areas that 
correspond to the channels and reservoir, the master is baked 
to cure the unexposed resist while the exposed resist is washed 
with an organic solvent (developer). The result is a substrate 
with 250 micrometer deep channels and reservoirs in positions 
corresponding to those on our chip. However, all of the 
channels need to be 60 micrometers in depth and have a 
herringbone structure that is recessed 36 micrometers into the 
channel floor. Therefore, a second deposition of approximately 
190 micrometers of positive photoresist is needed. The master 
is then exposed to UV light according to the layout of another 
mask, which will have openings for the herringbone structure 
in the proper channels. After curing and developing 
the master, channels of 60 microns and the mixing 
features of 36 microns are patterned. Finally, the 
master is silanized to give the patterned surface a 
hydrophobic nature, which reduces any adverse 
Figure 3-7 The accompanying diagram shows the 
processing of the master that will be used to 
construct the PDMS molds.  
A silicon wafer (grey) with oxide (green) 
deposited on it is spin-coated with a positive 
resist [1]. The resist is patterned to give 250 
micron deep wells [2]. Another layer of positive 
resist is spin-coated onto the wafer [3]. Finally, 
the resist is again exposed to UV light to fabricate 
the herringbone structure at the bottom of the 
channels. 
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reactions or absorption. An outside microfabrication facility would be contracted to for master 
creation because of the large cost associated with buying the necessary photolithography 
machinery that would only be operated sparingly. 
 When the master was finished, PDMS molds complementary to the surface pattern of the 
master could be made. As mentioned prior, parallel production of the PDMS layer of the 
microfluidic chip called for large manifolds containing hundreds of molds. PDMS was chosen as 
the mold material because of several reasons. First, PDMS is durable enough to withstand 
repeated use as a stamp and not become structurally compromised. Studies showed highly 
accurate pattern transfer by PDMS stamps after more than ten uses. (34) Since our molds will only 
be used once or twice per day, their lifetime could be on the order of a month or two. Also, 
polymers patterned against the PDMS mold won’t adhere or chemically react to the mold’s 
surface. The only concern is that the aspect ratios of the channel features (the features would 
extrude from the mold since its pattern is complementary to that of the master and final PDMS 
layer) fit into the range allowed for PDMS molding. Specifically, the channels all have aspect 
ratios (a ratio of height/width) that fall somewhere between 0.06 and 0.24, while the reservoir 
has an aspect ratio of about 0.125. One study found that aspect ratios of features should fall 
between 0.2 and 2 to obtain defect-free molds. (35) Since our features fall on the low end of that 
scale, the integrity of the pattern of our PDMS molds could be in question. However, small 
changes to our chip design could be undertaken during the initial startup of our manufacturing to 
correct any problems with information transfer by our mold. It was decided that production of 
the molds and manifolds would be outsourced because of the cost of excess equipment necessary 
for their construction, as well as the only occasional need for a new manifold (about once every 
month or two, depending on the actual durability of the PDMS mold). The manifolds will be 
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filled with PDMS and thermally cured, giving the desired PDMS block with channels and 
reservoir ready to be sealed with the bottom layer. With a successful way to fabricate the PDMS 
layer within our manufacturing scheme found, the deposition of reagents is considered. 
 
Figure 3-8 The accompanying diagram shows the 
fabrication of the PDMS layer from its respective mold. 
The mixture of PDMS base and curing agent is applied to 
the PDMS mold at a volume consistent with the desired 
chip features [1]. The mold is then cured for 2 hours at 
80°C [2]. Due to low interfacial energy, the PDMS layer is 
easily plied away from the mold [3]. The PDMS mold is 
now free to be used again, while the PDMS layer and 
glass substrate are surface treated and subsequently 
bonded together [4]. 
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3.2.1.3  Deposition of Reagents on Glass Substrate 
 To successfully carry out an assay of the degree of clopidogrel resistance expressed by 
the patient’s blood, three reagents must be present on the chip. The first is collagen, which acts 
as a substrate for the deposition of platelets and as a secondary activator. ADP, which acts to 
stimulate platelet aggregation, also needs to be deposited. Finally, the platelet aggregation 
inhibitor MRS 2395 is deposited on chip in different concentrations. Since the volumes to 
deposit will be in the tens to hundreds of nanoliters range, normal liquid delivery systems will 
not suffice. Technologies that have evolved from drug discovery allow the addition of nanoliter 
to picoliter amounts of reagent in order to test large libraries for compounds that inhibit a 
biological target. Two fluid delivery systems seem to be candidates for use in the manufacturing 
of the microfluidic chip: inkjet fluid handling and robotic pin tool delivery. The mechanics 
behind each system and the ability to fit our requirements were explored. 
3.2.1.4  Inkjet Fluid Handling System 
 A ubiquitous technology vital to the operation of the personal computer printer, inkjet 
fluid handling is a valuable technology because of its ability to deliver very small volumes of 
reagent. Fluid is delivered in two distinct modes: continuous and demand. In continuous mode, 
fluid flows through a small opening while an electrochemical device creates pressure oscillations 
that cause the fluid to break into droplets of roughly equal size. Once past this opening, 
electrostatic charge is induced in the drops by the action of an electric field. Another electric 
field is then used to direct the drops toward a surface. Using this mode, droplets ranging from 10 
ficoliters to 0.5 microliters are delivered between 80-100 times per second. (36) If the machine is 
run in demand mode, a potential across a layer of piezoelectric material leads to the formation of 
- 49 - 
 
a pressure change in the fluid. The result is the discharge of a single droplet to the desired 
substrate. Therefore, this mode is much more deliberate in its application. 
 Our process required deposition volumes somewhere in low nanoliter range, which is 
easily achieved by this device. Additionally, our goal of 4,000 chips manufactured per day meant 
that the time to deposit the reagent per channel should be as fast as possible. The most optimistic 
estimate of deposition time was found to be about one site every 1-2 seconds. To accomplish our 
manufacturing goals, though, much more than that was needed. Not only are there 8 sites per 
chip, but three different reagents needed to be deposited in eight places, adding up to a total of 
twenty-four spots. Using the optimistic deposition rate of five to ten sites per second, it would 
take about two seconds to deposit one reagent on a chip. The total time to complete deposition on 
one chip would probably be between six to eight seconds. While this is not exactly detrimental to 
the manufacturing process, there is an obvious need for multiple printheads to realize our daily 
manufacturing goal. Initial pricing of an inkjet fluid handling system approached almost 
$200,000. Assuming the prior rate of deposition, we would need three separate systems to 
complete fabrication of 4,000 chips per day. To pay almost half of one million dollars just on the 
fluid delivery system seemed like an exorbitant cost. Therefore, analysis of inkjet fluid handling 
systems was halted and the potential of using a robotic pin tool for liquid transfer was 
investigated. 
3.2.1.5  Robotic Pin Tool 
Known for its use in the screening of compound libraries in drug discovery, robotic pin 
tools are commonly used in the transfer of small reagent volumes between a stock solution and a 
substrate. Fluid is transferred by simply adhering onto the pin tool by surface tension and then 
coming in contact with the substrate surface. The pins that actually transfer the liquid are arrayed 
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in a head that contains a certain amount of pins. For our deposition, a standard 384 pin tool head 
could be used. This gives about a 4.5 millimeter space between pins, which should insure that we 
can deposit the reagent accurately. The pins that will be used are hydrophobic/lipophobic coated, 
which discourages reagent adsorption. 4 nanoliter, 10 nanoliter and 20 nanoliter pins would be 
used for the deposition of collagen, MRS 2395 and ADP, respectively. 
 When a robotic pin tool system with these specifications was priced, the cost to 
implement one was found to be less than half that of the inkjet fluid delivery system. Specifically, 
a mounting plate for the device cost $375, the pin tool head cost $2,521, the pin tools themselves 
cost either $9 or $11 per pin depending on the delivery volume, and the robotic station cost 
$20,000 (all prices were of Beckman equipment). The total here comes to about $30,000, 
assuming a large amount of pin tools are bought. Although the price may not be 100% accurate, 
the money invested in such a system is considerably less than inkjet system and allows us to 
invest in multiple robotic pin tool systems to increase parallel production and throughput of the 
microfluidic devices. No concrete evidence was found regarding deposition rates, but a value of 
3 seconds per transfer was used. The robotic pin tool system from Beckman comes customizable, 
which is useful because of the need for adaption to a manufacturing line. 
3.2.1.6  Reagent Loading Scheme 
Contrasted against each other, the decision to use the robotic pin tool for deposition of the 
reagents was a straightforward one. First, the robotic pin tool could deliver all eight deliveries of 
the same reagent in one deposition. Although some calibration of the system and alteration of the 
chip design might have to occur, the spacing should allow for 8 pins to be present on a pin head 
and deliver the reagent to the desired position. The other main difference was the estimated cost 
of the systems. With purchase costs differing by almost $400,000,  the much lower cost 
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investment possible with the robotic pin tool system lends itself to the purchase of multiple 
systems. This benefit helps us realize our goal of 4,000 chips fabricated per day, and allows for a 
smaller expenditure on equipment if production was to increase in the future. 
 One of the only concerns with the deposition of our reagent is exactly how much will 
evaporate. With such small volumes and large surface area to volume ratios, evaporation occurs 
quite quickly after the droplets are applied to a substrate. In literature, an estimate of 1 nanoliter 
of aqueous solution will evaporate in approximately thirty seconds. (37) 
3.2.1.7  Curing Oven 
Therefore, the amount of 
time it takes to deposit the reagents and then seal the PDMS and glass substrate is crucial to the 
extent of evaporation that will occur. Additional steps can be taken to reduce evaporation of the 
reagents. Including viscous substances, such as glycerol, in the reagent mixture is shown to 
reduce evaporation while not reacting with the deposited compounds. The temperature can also 
be maintained low enough such that the vapor pressures of the compounds are decreased, leading 
to less spontaneous evaporation. Finally, the manifolds can be temporarily sealed following 
deposition to further reduce any loss of reagent. It will probably take a combination of the 
following precautions to combat evaporation and maintain the reagent’s concentration on chip. 
The problem will have to be addressed with appropriate design changes during the first year of 
design. 
 Once the PDMS is deposited into its mold, the prepolymer and curing agent need to be 
allowed to set. This process crosslinks the polymer and forms the basis for its solid support. Our 
recipe calls for the PDMS to be cured for two hours at 80°C. Initial plans required two batches of 
2,000 PDMS molds each. Using a rough estimate of actually area of 2,000 PDMS molds plus 
more area in between the molds and on the edges, the size of the manifold was determined to be 
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about 55 ft2. After contacting a number of companies, two ovens were found. The first oven 
found was from Engineering Production Systems. For an inside chamber area of approximately 
75 ft2, and with outside dimensions of 6 ft x 5.5 ft x 7 ft, one Composite Curing Oven from EPS 
would cost us about $50,000. The oven is fairly high technology, especially considering our very 
basic needs and high tolerance. Another oven, from Wisconsin Oven Corporation, was priced at 
$22,400. The inside area of this oven was about 60 ft2, which is slightly smaller than the EPS 
oven but should accommodate our needed size. Since both are equivalents in the eyes of our 
process, the SWN 610-6 oven from Wisconsin Oven Corporation was chosen for its significantly 
lower price.
3.2.1.8 Plasma Oxidizer 
 (38) 
  To irreversibility bond the two layers together, the adjoining surfaces need to be treated 
by plasma oxidation. This is accomplished by a plasma oxidizer, which is a machine that 
converts gas into ions and directs them at a substrate. PDMS is a repeating polymer consisting of 
–O–Si(CH3)–  subunits. However, introducing the surface of PDMS to air plasma leads to the 
replacement of the silane moiety with a silanol group. When this polar surface comes in contact 
with another substrate, the hydroxyl groups of the silanol condense with hydroxyl, carboxylic or 
ketone groups from the substrate to form a seal. (39) The bonding between the glass substrate and 
PDMS layer in our device yields an inorganic ester bond (Si–O–Si) concomitant on the loss of 
water. The covalent relationship between the surfaces is manifested by the irreversible bond that 
forms between both surfaces. A surface treatment machine from Electric-Technic Products 
accomplishes this task. The BD-80 Corona Treater, priced at about $5,000 per unit, is capable of 
treating one surface with air plasma within the desired 1 minute window. An adaptor kit made it 
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possible for the machine to be hooked up to a conveyor belt for repeated surface treatment of 
many layers. Thus, it was decided that the BD-80 Corona Treater would be purchased. 
3.2.1.9 UV Sterilization 
 As a precaution, it was advised by a number of consultants to sterilize the microfluidic 
chip before storing it to insure no contamination issues arose. Therefore, after packaging into 
vacuum-sealed plastic bags, it was decided the device would pass under an array UV lamps to 
insure a sterilized environment in the chip. A lamp from Cole-Parmer, the UV Germicidal Lamp 
EW-97505-05, was chosen for the task. An array of 5 lamps would be put on the end of each 
production line, and the packages would simply pass under them on their way to refrigerator 
storage. 
3.2.2 Chip Manufacture 
3.2.2.1 Microfluidic Chip Recipe 
 Thirty minutes prior to the beginning of each day, PDMS prepolymer will be mixed with 
viscous curing agent in a large tank. Needing 17.49 millilters of total PDMS in each chip, 
assuming less than 1% shrinkage, and abiding by the 10:1 (v:v) ratio of base to curing agent, the 
tank will contain about 70 L of PDMS. It will be mixed with an impellor at low RPMs for 
approximately 10 minutes. 
 Two manifolds containing 2,000 molds each will be used for the curing stage. Each 
manifold will have two sets of valves with ten spouts each. These will deposit 17.49 mL into 
each mold, taking approximately 20 minutes. Both manifolds will then be placed in the curing 
oven. Currently, the curing time is estimated to be about two hours. 
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 As the PDMS layers are being cured, reagent stocks for each robotic pin tool system will 
be prepared. 10 microliters of bovine collagen will be added to the refrigerated reagent store of 
each robotic pin tool system. 30 microliters of 200 mM ADP will then be added to the reagent 
storage of each robotic pin tool system. In vitro testing needs to be done to ascertain the amount 
of MRS 2395 needed per chip, but an estimation of 20 microliters for the reagent store will be 
used until then. 
Deposition of collagen, ADP, and MRS on the glass substrate, which will be carried out 
by three separate 384 well pin heads, should take 3 seconds each for alignment and actual 
deposition of the liquid. This leads to a total deposition time of about nine seconds. Also, the 
depositing of the reagents will all take place in a slightly cold environment to protect against 
rapid evaporation. 
When the curing bake of the PDMS is complete, the PDMS layer will be placed into 
smaller manifolds containing 100 each. Robotic arms that have suction devices on their tips will 
carry out transfer from a large manifold to a smaller one. The smaller manifolds will then 
progress down the conveyor belt to meet with the finished glass substrate for surface treatment. 
With two surface treatment devices working in parallel, the surface of the PDMS layer is 
oxidized in one minute and then brought into contact with the glass substrate for another 30 
seconds. With the microfluidic chips now in one manifold, the resulting 20-chip manifold is 
placed onto the conveyor belt. 
 The devices are taken from the manifold via a robotic arm and placed in a packaging 
machine that seals the chips in a plastic pouch. As the chips are transported to our freezer, they 
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pass through a UV light array, which effectively sterilizes them for their lifetime in the 
packaging. 
As mentioned prior, the goal will be to fabricate approximately 4,000 chips per day, 
which leads to a yearly manufacturing goal of one million microfluidic chips per year. In the first 
two years of production though, the production goal will only need to be about 200 chips per day. 
It is during this time that many chips will be needed for late-stage concept testing, quality 
assurance and manufacturing process testing, and, most importantly, clinical trial testing for 
FDA approval. Therefore, the majority of the chips produced during this time will not be for sale 
but for testing (See Section 4.1). 
3.2.2.2 Manufacturing Schedule  
The full U.S. market is assumed to be 1.1 million chips per year, which is equal to the 
number of Percutaneous Coronary Intervention (PCI) procedures performed in the United States 
every year.   This number was used to determine the total market since the main use of the 
MCCRA system is going to be before PCI procedures, when administration of clopidogrel is 
required.  Since there are other similar products already on the market, 100% market capture is 
unrealistic (See Section 2.8).  For the basis of calculations, it is assumed that the total market 
captured by this product is 50%, or 550,000 chips per year.   
 Several factors are considered and several assumptions are made in the determination of 
the number of chips that must be manufactured per day in order to meet this market capture goal.  
The first assumption is that the manufacturing facility will operate 8 hours per day, 5 days per 
week, and 50 weeks out of the year (250 days total).  The number of chips needed for sale is 
determined by Equation 3-1. 
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0 :15 :30 :45 1 :15 :30 :45 2 :15 :30 :45 3 :15 :30 :45 4 :15 :30 :45 5 :15 :30 :45 6 :15 :30 :45 7 :15 :30 :45
mix/dep oven*
Deposition on glass substrate
Plasma/Join Layers
UV/Packaging
Deposition on glass substrate
Plasma/Join Layers
UV/Packaging
 𝟓𝟓𝟓𝟓𝟏𝟏,𝟏𝟏𝟏𝟏𝟏𝟏 𝒄𝒄𝒄𝒄𝒂𝒂𝒄𝒄𝒄𝒄 𝒄𝒄𝒂𝒂𝒂𝒂 𝒚𝒚𝒂𝒂𝒂𝒂𝒂𝒂
𝟐𝟐𝟓𝟓𝟏𝟏 𝒅𝒅𝒂𝒂𝒚𝒚𝒄𝒄 𝒂𝒂𝒐𝒐 𝒂𝒂𝒄𝒄𝒂𝒂𝒂𝒂𝒂𝒂𝒂𝒂𝒂𝒂𝒂𝒂𝒂𝒂 𝒄𝒄𝒂𝒂𝒂𝒂 𝒚𝒚𝒂𝒂𝒂𝒂𝒂𝒂 = 𝟐𝟐𝟐𝟐𝟏𝟏𝟏𝟏 𝒄𝒄𝒄𝒄𝒂𝒂𝒄𝒄𝒄𝒄 𝒄𝒄𝒂𝒂𝒂𝒂𝒅𝒅𝒎𝒎𝒄𝒄𝒂𝒂𝒅𝒅 𝒄𝒄𝒂𝒂𝒂𝒂 𝒅𝒅𝒂𝒂𝒚𝒚   (3-1) 
 The next assumption that is made is that approximately 25% of the chips that are made 
during a manufacturing day will be used for quality assurance testing and cannot be counted 
towards the chips to be sold.  Therefore, in order to produce 2200 chips to be sold, 2934 chips 
must actually be manufactured per day (See Equation 3-2). 
𝒄𝒄𝒎𝒎𝒄𝒄𝒄𝒄𝒂𝒂𝒄𝒄𝒄𝒄𝒐𝒐𝒎𝒎𝒊𝒊 𝒄𝒄𝒄𝒄𝒂𝒂𝒄𝒄𝒄𝒄 𝒎𝒎𝒂𝒂𝒅𝒅𝒂𝒂 𝒄𝒄𝒂𝒂𝒂𝒂 𝒅𝒅𝒂𝒂𝒚𝒚 ∗ 𝟕𝟕𝟓𝟓% = 𝟐𝟐𝟐𝟐𝟏𝟏𝟏𝟏 𝒄𝒄𝒄𝒄𝒂𝒂𝒄𝒄𝒄𝒄 𝒄𝒄𝒂𝒂𝒂𝒂𝒅𝒅𝒎𝒎𝒄𝒄𝒂𝒂𝒅𝒅 𝒐𝒐𝒂𝒂𝒂𝒂 𝒄𝒄𝒂𝒂𝒊𝒊𝒂𝒂 (3-2) 
 The final assumption that is made is that 25% of the chips that are manufactured will fail 
due to defect.  Therefore, in order to create 2934 successful chips, 3912 chips must be produced 
(See Equation 3-3). 
𝒂𝒂𝒂𝒂𝒂𝒂𝒂𝒂𝒊𝒊 𝒄𝒄𝒄𝒄𝒂𝒂𝒄𝒄𝒄𝒄 𝒄𝒄𝒂𝒂𝒂𝒂𝒅𝒅𝒎𝒎𝒄𝒄𝒂𝒂𝒅𝒅 𝒄𝒄𝒂𝒂𝒂𝒂 𝒅𝒅𝒂𝒂𝒚𝒚 ∗ 𝟕𝟕𝟓𝟓% = 𝟐𝟐𝟐𝟐𝟐𝟐𝟐𝟐 𝒄𝒄𝒎𝒎𝒄𝒄𝒄𝒄𝒂𝒂𝒄𝒄𝒄𝒄𝒐𝒐𝒎𝒎𝒊𝒊 𝒄𝒄𝒄𝒄𝒂𝒂𝒄𝒄𝒄𝒄 𝒄𝒄𝒂𝒂𝒂𝒂𝒅𝒅𝒎𝒎𝒄𝒄𝒂𝒂𝒅𝒅  (3-3) 
(Note:  for ease of calculations for manufacturing and financial analysis, this number was 
rounded to 4,000 chips manufactured per day). 
 Based on the procedure for creating the chips, a manufacturing schedule was created (See 
Figure 3-9). 
 
  
 
Figure 3-9  Schedule of a single day of operation for manufacture of the MCCRA chip.  The numbers across the top 
represent the hour of operation (in bold) and the breakdown of each hour into 15 minute increments.  Assume that 
hour 0 = the beginning of the day.  Each colored band represents the length of time required for a specific step.  Bands 
separated by a space represent steps that occur simultaneously, but independent of each other (i.e. what is done in 
one band does not have any effect on the other).  Bands that are layered on top of each other also represent steps that 
are occurring simultaneously, however the products of each step are used in the next, and therefore the completion of 
one is dependent on the step represented by the band directly above it. 
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This schedule is based on an eight hour day of manufacturing (time 0 =9:00 AM), assuming 30 
minutes of time prior to operation for opening/setup of the facility and 45 minutes after 
completion of manufacturing for cleanup/shutdown.  The red box labeled “mix/dep” represents 
the time required for the mixing and deposition of the PDMS onto the molds.  Mixing takes 
approximately ten minutes, and each deposition is estimated to take 3 seconds. Since the 
deposition device has the capability of depositing 10 chips at once, the time for this step is 
determined by Equation 3-4. 
  𝟐𝟐,𝟏𝟏𝟏𝟏𝟏𝟏 𝒄𝒄𝒄𝒄𝒂𝒂𝒄𝒄𝒄𝒄∗𝟐𝟐 𝒄𝒄𝒂𝒂𝒄𝒄𝒂𝒂𝒂𝒂𝒅𝒅𝒄𝒄 𝒄𝒄𝒂𝒂𝒂𝒂 𝒅𝒅𝒂𝒂𝒄𝒄𝒂𝒂𝒄𝒄𝒂𝒂𝒂𝒂𝒂𝒂𝒂𝒂
𝟏𝟏𝟏𝟏 𝒄𝒄𝒄𝒄𝒂𝒂𝒄𝒄𝒄𝒄 𝒄𝒄𝒂𝒂𝒂𝒂 𝒅𝒅𝒂𝒂𝒄𝒄𝒂𝒂𝒄𝒄𝒂𝒂𝒂𝒂𝒂𝒂𝒂𝒂𝒂𝒂 = 𝟐𝟐𝟏𝟏 𝒎𝒎𝒂𝒂𝒂𝒂𝒎𝒎𝒂𝒂𝒂𝒂𝒄𝒄    (3-4) 
 Once the PDMS has been deposited, all 4,000 chips are put into the oven, for a total 
curing time of 2 hours.  Before going into the oven, the chips are placed onto 20-chip manifolds 
(See Figure 3-10) for 
easier movement of 
chips between steps.  
The oven (Wisconsin 
Oven Corporation, 
Model:  SWN-610-6) 
has internal dimensions 
of 6’x10’x6’. (40) The 
dimensions of the base 
allow space for 3 manifolds by 4 manifolds (12 total manifolds).  In order to fit all 200 manifolds, 
17 shelves will be required for inside the oven, with the shelves situated approximately 10 cm 
apart. 
Figure 3-10  Manifold for chip manufacturing.  The image to the left shows the manifold 
layout, consisting of 20 total chips.  The image to the right is an enlarged depiction of the 
section of the manifold that is circled in red on the upper picture with dimensions labeled.  
The white area represents the tray holding the chips and the blue rectangles represent the 
chips themselves. 
 35 cm 
35 cm 
9.5 cm 
8.5 cm 
2.5 cm 
1 cm 
1 cm 
1  
cm 
1  
cm 
1.5 cm 
4 cm 
6 cm 
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 While the PDMS molds are in the oven, deposition of the reagents onto the glass 
substrates will be taking place.  It is estimated that deposition will take 3 seconds per site.  Since 
there are 3 reagents in each of 8 channels, there is a total of 24 sites that need to be deposited on 
each chip.  This would results in a total of 80 hours of deposition if each site was deposited one 
at a time.  In order to cut down on this time, the deposition device will be equipped to deposit 
each reagent in all eight channels at once.  This will instead take 9 seconds per chip, for a total of 
10 hours (see equation 3-5).   
  𝟐𝟐 𝒄𝒄𝒂𝒂𝒄𝒄𝒂𝒂𝒂𝒂𝒅𝒅𝒄𝒄
𝒂𝒂𝒂𝒂𝒂𝒂𝒂𝒂𝒂𝒂𝒂𝒂𝒂𝒂
∗
𝟐𝟐 𝒂𝒂𝒂𝒂𝒂𝒂𝒂𝒂𝒂𝒂𝒂𝒂𝒂𝒂𝒄𝒄
𝒄𝒄𝒄𝒄𝒂𝒂𝒄𝒄
∗
𝟐𝟐,𝟏𝟏𝟏𝟏𝟏𝟏 𝒄𝒄𝒄𝒄𝒂𝒂𝒄𝒄𝒄𝒄
𝒅𝒅𝒂𝒂𝒚𝒚
= 𝟏𝟏𝟏𝟏 𝒄𝒄𝒂𝒂𝒎𝒎𝒂𝒂𝒄𝒄     (3-5) 
 Although this reduces the time required for deposition, 10 hours is still too long to fit into 
a normal manufacturing day.  Therefore, two deposition machines will run in parallel, reducing 
the time required for deposition in half to 5 hours. 
 Once the PDMS layers have been removed from the oven, plasma oxidation and sealing 
to the glass substrate can begin, using those substrates that have already been deposited.  The 
plasma oxidation/joining to glass substrate step for each manifold is estimated to take 
approximately 2 minutes, then an additional 30 minutes to sit and finish the binding process.  
Since each manifold can be oxidized while the previous begins the 30 minute resting step, the 
total time required for this part of the process is estimated at 8 hours.  Again, this step will be 
divided in half and run simultaneously, reducing required time to 4 hours.  Once the PDMS and 
glass layers have been joined and have rested for 30 minutes, the UV sterilization and packaging 
step can begin.  The total estimated time for this part of the process is 3.5 hours (for half of the 
chips, again run simultaneously).   
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Once the packaging is complete, the chips are placed in a large refrigerator for storage 
until needed for shipment or quality assurance testing.  As shown in Figure 3-9, many of the 
manufacturing steps can overlap, saving time, allowing for the manufacturing of 4,000 chips to 
be completed during the 8 hour work day.   
3.2.2.3 Manufacturing Facility Floor Plan 
 Taking into account the order of manufacturing as well as the general dimensions of the 
required equipment, a basic floor plan was laid out (see figure 3-11). 
 
 
 
 
 
 
 
 
 
Figure 3-11  Basic Floor plan schematic for the chip manufacturing facility.   
It is based on the order of the steps in the process and the dimensions of the equipment to be use.  Note:  Size conversion 
scale is located below the diagram to the left. 
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3.2.3 Channel Dimensions 
To ensure complete mixing and fully developed flow, bifurcation is used to split the inlet 
stream into eight equal streams.  Murray’s Law is followed to calculate the effective diameter 
(𝑑𝑑𝑒𝑒𝑒𝑒𝑒𝑒 )  of the parent channel (𝑟𝑟𝑝𝑝) , or the channel that splits into two channels to form the 
daughter channels (𝑟𝑟𝑑𝑑).  Murray’s equation is shown below in Equation 3-6.   
   𝑟𝑟𝑝𝑝3 = 𝑟𝑟𝑑𝑑13 + 𝑟𝑟𝑑𝑑23 + ⋯+ 𝑟𝑟𝑑𝑑𝑛𝑛3 = 2 ∗ 𝑟𝑟𝑑𝑑3    (3-6) 
The path-length (𝑙𝑙)  of each branch before the next separation should five to six times the 
effective diameter of the micro-channel.  
     𝒊𝒊 = 𝟓𝟓 ∗ 𝒅𝒅𝒂𝒂𝒐𝒐𝒐𝒐     (3-7) 
The inlet channel has a width of 1 mm and after bifurcation our eight channels have the 
width of 250 µm.  All channels have a height of 60 µm with the exception of the waste reservoir 
well which is .25 cm high. The final lengths and diameters of the channels are shown in Table 3-
2.  To see all of the calculations for the channel widths and length, please refer to Appendix 7.3.   
 
Table 3-2  Channel Dimensions 
3.2.4 Flow Characteristic 
It has been shown that shear rate at the vessel wall is an essential factor in blood clot 
formation both in vivo and in vitro.  Flow velocity is positively correlated with shear rate given 
Channel Width (µm)
Height 
(µm)
Effective 
Diameter (µm)
Entry Length 
(µm)
Entry Length 
(mm)
Final 8 Channels 250 60 138 691 => 0.691
4 Channels After 2nd Split 397 60 174 871 => 0.871
2 Channels After 1st Split 630 60 219 1097 => 1.097
1st Channel 1000 60 276 1382 => 1.382
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the dimensions of the micro-channel.  In our chip design, the fluid flow rate is controlled such 
that average shear rate at the channel wall is comparable to the in vivo shear rate, which is about 
1000 s-1 in human arteries.  With the channel dimension specification (w=250µm, h=60µm) and 
the assumed physical properties of water for whole blood2
     ?̇?𝜸 = 𝒗𝒗
𝒄𝒄
       (3-8) 
where v(x, y) is a function of position of the cross-sectional plane and h is the distance from the 
channel wall. 
From the velocity profile, the fluid velocity required to achieve an average shear rate of 
1000 s
, the 3D velocity profile can be solved. 
(See Appendix 7-11) The shear rate is defined by the following mathematical relation: 
-1
   𝑹𝑹𝒂𝒂 = 𝒎𝒎𝑫𝑫
𝝂𝝂
= �𝟏𝟏×𝟏𝟏𝟏𝟏−𝟐𝟐𝒎𝒎𝒄𝒄 �×𝟐𝟐.𝟔𝟔𝟔𝟔×𝟏𝟏𝟏𝟏−𝟓𝟓𝒎𝒎
𝟔𝟔.𝟔𝟔𝟐𝟐×𝟏𝟏𝟏𝟏−𝟕𝟕 𝒎𝒎𝟐𝟐/𝒄𝒄 = 𝟏𝟏.𝟐𝟐𝟏𝟏𝟓𝟓    (3-9) 
 is then computed to be 0.01 m/s or 1 cm/s. 
Fluid flow is generally characterized by the Reynolds number (Re), which is a ratio of 
inertia to viscosity.  The dimensions of the microfluidic platform constrain the fluid flow to the 
laminar regime, typically, with Reynolds number close to 1.   
where D is the characteristic length (in this case the hydraulic diameter of the channel cross-
section) and 𝝂𝝂 is kinematic viscosity, assuming the physical properties of water.    
The small Reynolds number implies that the flowing stream in the microchannel lacks 
turbulence that is normally required for rapid mixing; this is one of the key limitations 
confronting our chip design.  To overcome the sluggish nature of this type of flow and accelerate 
                                                 
 
2 Blood plasma is 90% water.  Therefore this is a reasonable approximation 
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mixing, a special structure has to be incorporated to the channel.  Discussion on this issue will be 
continued in the following sections. 
3.2.5 Controlled Dissolution of the Embedded Anhydrous ADP and Clopidogrel 
One of the major concerns of this design is the introduction of key reagents, namely ADP 
and MRS 2395 (a P2Y12
Incorporation of dry reagents onto the channel often entails the addition of stabilizing 
preservatives.  For example, some proteins are preserved by drying in tetrahalose, which 
stabilizes proteins by substitution of the water molecular of the hydrated proteins by the sugar 
 inhibitor), into the micro-channel.  There are two options that achieve 
this goal: 1) ADP and MRS 2395 in solution phase are injected into the microchannel by 
mechanical penetration of the chip; or 2) They are deposited on the channel floor as dry reagents 
readily dissolvable by the blood stream.  However, it is almost apparent that the former requires 
additional mechanical technology on the box design that not only necessitates micro-scale 
precision to carry out fluid injection but also undoubtedly increases the cost of our project.  
Furthermore, this mechanical addition adds extra burden on box-side cleaning.  From the point of 
care perspective, this looks appallingly unattractive.   The second option is a relatively simple 
alternative that solves the aforementioned problems.  
The incorporation of preserved reagents into a lab-
on-chip device simplifies operation and increases 
portability.   Additionally, this design translates into 
a classic well-defined mass transport problem that 
helps the design team to further explore the 
application of mass transport theories.  Figure 3-12: Fluorescence image of the anhydrous 
reagent dissolution in a flow stream (41) 
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molecules, thereby maintaining the native 
form of the proteins. (41)
However, preserving ADP and MRS 
2395 directly on the surface of the channel 
without some “anchoring” agents will certainly 
result in washout of ADP and MRS 2395 at the first few seconds of operation.  By drying ADP 
and MRS 2395 in a heavy carbohydrate (usually Dextran), we essentially create a carbohydrate 
matrix that encapsulates the dry reagents.  This mesh sugar structure not only helps secure the 
dry reagents in place but also establishes a relatively constant concentration gradient that in turn 
gives us spatial and temporal control of the ADP & MRS 2395 concentration in the bulk fluid. 
The reagents with carbohydrate in a well-mixed solution form are deposited onto the 
floor of the channel by robotic pin tools.  The solution is allowed to dry.  Since the original 
solution is well-mixed, the patterning of ADP & MRS 2395 can be assumed to be uniform.  The 
patch of dry reagents spans across the 250µm-wide channel and the length is yet to be 
determined. 
  Fortunately, ADP 
and MRS 2395 are relatively stable as dry 
reagents.  No stabilizing reagents are required.  
The release of ADP and MRS 2395 from the carbohydrate matrix and their subsequent 
transport downstream may be controlled by parameters such as channel and patch dimensions, 
patch shapes, fluid flow rate, and the chemical composition of the matrices. Under the pre-
specified flow rate and channel dimension, the only manipulative parameters are length of the 
patch and the composition of the matrix, the latter of which will not be explored further here; it 
Figure 3-13: Time dependence of the dissolved reagent 
concentration in stream (41).  
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will be experimentally determined by trial and error.  For the following discussion, the length of 
the patch is computed by invoking the film theory model.  Our problem is can be formulated as 
laminar forced convection over a flat plate. 
The problem can be translated into the following statement: Whole blood flows through a 
patch with a constant ADP concentration CADP,s
Under this modeling assumption, the Reynolds number, which is the ratio of inertial 
forces to viscous forces, is defined mathematically as the following (42)
.  The dimension of the channel is specified; the 
width, in the y direction, is 250 µm while the height, in the z direction, is 60 µm; the edge effects 
in the y direction are assumed to be negligible.  A theoretical boundary is drawn in Figure 3-14 
to elucidate the focus of the problem.  Now, it is clear that the release of ADP from point B must 
equal to the amount of ADP leaving point C, which is the product of the volumetric flow rate V̇ 
and the well-mixed ADP concentrationCADP .  The length of the ADP strip, x, must be designed 
such that the flux of ADP at point B satisfies the material balance. 
    𝑹𝑹𝒂𝒂𝒎𝒎 = 𝝆𝝆𝒎𝒎∞𝒎𝒎𝝁𝝁 = 𝒎𝒎∞𝒎𝒎𝒗𝒗       (3-10) 
: 
where 𝑢𝑢∞  is the bulk fluid velocity; v is the kinematic viscosity (unit of m
2/s); and x is the 
position measured from the starting point of the patch.  Therefore, Rex is a not constant value 
across the length of the patch; it is a linear function of x. 
Figure 3-14: Blood flow past a ADP concentration patch 
V 
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B 
Bulk fluid 
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The Schmidt number, defined as the ratio of momentum diffusivity to mass diffusivity, is 
used to characterize fluid flow that involves mass transfer. (42) 
     𝑺𝑺𝒄𝒄 = 𝝁𝝁
𝝆𝝆 𝑫𝑫𝑨𝑨𝑨𝑨 = 𝒗𝒗𝑫𝑫𝑨𝑨𝑨𝑨      (3-11) 
in which 𝜌𝜌 is the density of the fluid (kg/m3); DAB is diffusion coefficient (m2
  The Sherwood number, which is dimensionless ratio of convective to diffusive mass 
transport, is defined as (42) 
/s). 
     𝑺𝑺𝒄𝒄𝒎𝒎����� = 𝒄𝒄𝒎𝒎���� 𝒎𝒎𝑫𝑫𝑨𝑨𝑨𝑨     (3-12) 
, denoted by variables with a superscript bar: 
where ℎ𝑚𝑚  is the mass transfer coefficient.  This definition is also valid in terms of average 
quantities.  From now on, the bar notation denotes average quantities. 
The semi-empirical mass transfer correlation corresponding to forced convection over a 
flat plate is taken from. (42) 
    𝑺𝑺𝒄𝒄𝒎𝒎����� = 𝟏𝟏.𝟔𝟔𝟔𝟔𝟐𝟐 𝑹𝑹𝒂𝒂𝒎𝒎𝟏𝟏/𝟐𝟐 𝑺𝑺𝒄𝒄𝟏𝟏/𝟐𝟐    (3-13) 
Equation 3-12 is substituted into Equation 3-13 and ℎ𝑚𝑚���� is solved in terms of 𝑥𝑥: 
    𝒄𝒄𝒎𝒎���� = 𝟏𝟏.𝟔𝟔𝟔𝟔𝟐𝟐�𝒎𝒎𝒎𝒎𝒗𝒗 � 𝝁𝝁𝝆𝝆𝑫𝑫𝑨𝑨𝑨𝑨�𝟏𝟏/𝟐𝟐𝑫𝑫𝑨𝑨𝑨𝑨𝒎𝒎       (3-14) 
The number of ADP molecules released from the plate is proportional to the 
concentration gradient and the proportionality constant is ℎ𝑚𝑚����𝐴𝐴𝐵𝐵.
 (42) 
   𝒂𝒂𝑨𝑨𝑫𝑫𝑨𝑨,𝑨𝑨 = 𝒄𝒄𝒎𝒎����𝑨𝑨𝑨𝑨�𝑪𝑪𝑨𝑨𝑫𝑫𝑨𝑨,𝒄𝒄 − 𝑪𝑪𝑨𝑨𝑫𝑫𝑨𝑨,∞�     (3-15) 
in which AB or the product of the width of the channel (W) and 𝑥𝑥 (𝑊𝑊𝑥𝑥) is the area of the 
rectangular ADP patch; 𝐶𝐶𝐴𝐴𝐴𝐴𝐴𝐴 ,𝑠𝑠 is the concentration of ADP at the surface, which is manipulated 
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experimentally; 𝐶𝐶𝐴𝐴𝐴𝐴𝐴𝐴 ,∞  is the concentration of ADP initially in the bulk fluid (assumed to be 0 
for now). 
As discussed above, this number has be the same as the number of ADP molecules 
leaving at point C by material balance: 
     𝒂𝒂𝑨𝑨𝑫𝑫𝑨𝑨,𝑪𝑪 = ?̇?𝑽𝑪𝑪𝑨𝑨𝑫𝑫𝑨𝑨      (3-16) 
     𝒂𝒂𝑨𝑨𝑫𝑫𝑨𝑨,𝑨𝑨 = 𝒂𝒂𝑨𝑨𝑫𝑫𝑨𝑨,𝑪𝑪      (3-17) 
    𝒄𝒄𝒎𝒎����(𝒎𝒎)𝑨𝑨𝑨𝑨�𝑪𝑪𝑨𝑨𝑫𝑫𝑨𝑨,𝒄𝒄 − 𝑪𝑪𝑨𝑨𝑫𝑫𝑨𝑨,∞� = ?̇?𝑽𝑪𝑪𝑨𝑨𝑫𝑫𝑨𝑨  (3-18) 
Substituting the expression for ℎ𝑚𝑚���� and 𝐴𝐴𝐵𝐵, the above equation is solved for x in terms of 𝐶𝐶𝐴𝐴𝐴𝐴𝐴𝐴 ,𝑠𝑠 
and we have: 
    𝒎𝒎 = 𝟐𝟐.𝟐𝟐𝟔𝟔𝟔𝟔 ?̇?𝒄𝟐𝟐𝑪𝑪𝑨𝑨𝑫𝑫𝑨𝑨𝟐𝟐𝒗𝒗
𝒎𝒎�
𝝁𝝁
𝝆𝝆𝑫𝑫𝑨𝑨𝑨𝑨
�
𝟐𝟐/𝟐𝟐
𝑫𝑫𝑨𝑨𝑨𝑨
𝟐𝟐𝑪𝑪𝑨𝑨𝑫𝑫𝑨𝑨,𝒄𝒄𝟐𝟐𝑾𝑾𝟐𝟐      (3-19) 
Four different values of 𝐶𝐶𝐴𝐴𝐴𝐴𝐴𝐴  are desired in our design.  In increasing order, they are 0.1, 
1, 10, 100 times the IC50 (which is 2mM) of ADP, or 0.2mM, 2mM, 20mM and 200mM 
respectively.  From the above relation, it is clear that the required length of the patch is 
proportional to 𝐶𝐶𝐴𝐴𝐴𝐴𝐴𝐴2.  If 𝐶𝐶𝐴𝐴𝐴𝐴𝐴𝐴 ,𝑠𝑠(the surface concentration of ADP) is set constant, 𝑥𝑥 could range 
from 100um for 0.2mM to 100m for 200mM.  This range is not physically feasible in a chip with 
a length of 6cm.  On the other hand, 𝑥𝑥 can be set constant, 150um for the sake of consistent 
dimensional design, and 𝐶𝐶𝐴𝐴𝐴𝐴𝐴𝐴 ,𝑠𝑠 is varied to achieve the 4 specified concentration of ADP.  The 
above relation is arranged to solve for 𝐶𝐶𝐴𝐴𝐴𝐴𝐴𝐴 ,𝑠𝑠 in terms of 𝐶𝐶𝐴𝐴𝐴𝐴𝐴𝐴 . 
    𝑪𝑪𝑨𝑨𝑫𝑫𝑨𝑨,𝒄𝒄 = � 𝟏𝟏.𝟓𝟓𝟏𝟏𝟔𝟔?̇?𝑽
�
𝒎𝒎𝒎𝒎
𝒗𝒗
�
𝝁𝝁
𝝆𝝆𝑫𝑫𝑨𝑨𝑨𝑨
�
𝟏𝟏
𝟐𝟐
𝑫𝑫𝑨𝑨𝑨𝑨𝑾𝑾
�𝑪𝑪𝑨𝑨𝑫𝑫𝑨𝑨     (3-20) 
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Previously, we make the assumption that 𝐶𝐶𝐴𝐴𝐴𝐴𝐴𝐴 ,∞  is approxomaely 0.  To validate this claim, we 
have to ensure that the boundary layer near the end of the patch does exceed the channel height 
of 60 µm (42)
    𝜹𝜹𝒄𝒄 ≈
𝟓𝟓𝒎𝒎
𝑺𝑺𝒄𝒄𝟏𝟏/𝟐𝟐�𝑹𝑹𝒂𝒂𝒎𝒎 < 60 µ𝒎𝒎      (3-21) 
Detailed calculation is performed in the Appendix 7.4.  The results are tabulated: 
: 
CADP,s IC (uM) C50 MRS2395 x (um)  (uM) Re Sc x Sh δC
0 
 (um) 
0x 0 149    2.18    705.5       8.7            57  
24.8 0.1x 0.36 149    2.18    705.5       8.7            57  
248 1x 3.6 149    2.18    705.5       8.7            57  
2480 10x 36 149    2.18    705.5       8.7            57  
Table 3-3: The required surface ADP concentration corresponding to in-stream ADP concentration (in red)  
In conclusion, these values are only approximations.  For further development of our 
design, experiments are necessary to extract better estimates of these quantities.  However, the 
numbers and equations here serve as initial guesses for future trial and error experiments and 
provide insight into the relationship between critical to quality variables. 
3.2.5.1 Laminar Forced Convection over a Flat Plate 
Peclet number, defined as the dimensionless ratio of convective motion to diffusive 
motion, is another insightful indictor of fluid mixing behavior.  On micro-scale, this diffusive 
solute motion is slow relative to the convection of the solution along the channel, or Pe is large.  
With our channel dimension specification, the Peclet number is computed as the following: 
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  𝑨𝑨𝒂𝒂 = 𝒎𝒎𝒊𝒊
𝑫𝑫
= �𝟏𝟏×𝟏𝟏𝟏𝟏−𝟐𝟐𝒎𝒎/𝒄𝒄�(𝟐𝟐.𝟔𝟔𝟔𝟔×𝟏𝟏𝟏𝟏−𝟓𝟓𝒎𝒎)
𝟏𝟏𝟏𝟏−𝟏𝟏𝟏𝟏𝒎𝒎𝟐𝟐/𝒄𝒄 = 𝟐𝟐𝟔𝟔𝟔𝟔𝟏𝟏 ≫ 𝟏𝟏𝟏𝟏𝟏𝟏    (3-22) 
where D is the molecular diffusivity, u is the velocity, l is the effective diameter of the 
rectangular channel. 
The small Re, implying the absence of turbulence, and the large Pe, meaning slow 
diffusive solute motion, suggest the length required for mixing is unreasonably long.  For such 
unperturbed flows, the approximate distance along the channel required for mixing to occur is 
suggested by (43) 
  𝜟𝜟𝒚𝒚𝒎𝒎 ≈ 𝒎𝒎 × �𝒊𝒊𝟐𝟐𝑫𝑫� = 𝑨𝑨𝒂𝒂 × 𝒊𝒊 = 𝟐𝟐𝟔𝟔𝟔𝟔𝟏𝟏 × 𝟐𝟐.𝟔𝟔𝟔𝟔 × 𝟏𝟏𝟏𝟏−𝟓𝟓𝒎𝒎 = 𝟏𝟏.𝟐𝟐𝟐𝟐𝒎𝒎  (3-23) 
This length is reasonably long given the dimensional limitation of the chip.  Adding to its 
disadvantage, the unperturbed flow requires mixing length that grows linearly with velocity/Pe, 
rendering the re-usability of the pre-designed micro-channel at different flow conditions 
impossible. 
To circumvent this problem, we need to introduce a structure that mimics the effect of 
turbulence.  There are 3 options that have been 
intensely and thoroughly researched: squarewave,  
serpentine and herringbone.  Due to the simplicity 
of its fabrication, the herringbone configuration is 
generally deemed to be one of the most cost-
effective designs for mixing in micro-channels.  With PDMS as the raw material for chip 
fabrication, the mold for the herringbone grooves were made possible by a two-level photo-
lithography.  These grooves which were recessed into the floor of the flowing channel induce 
transverse components of flow that stretch and fold volumes of fluid.  These stirring flow 
Figure 3-15: Cross-sectional view of fluid flow 
pattern in the micro-channel (43) 
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patterns reduce the average distance over which diffusion must act in the transverse direction to 
homogenize unmixed volumes. (43)  As a result, mixing length is substantially reduced.  Before 
we continue, it is deemed necessary to briefly review the concept of mixing in micro-channels.  
The quality of mixing can be characterized by coefficient of variation (CV).  Mixing analysis 
generally assumes there are two steams flowing side by side; one contains the solutes dissolved 
uniformly in solvent and the other is pure solvent.  The CV quantifies the degree of 
concentration variation between the two streams.  Experimentally, the degree of mixing is 
evaluated after confocal microscopy is performed on the mixing streams.  The CV can be 
extrapolated from image analytical techniques.  Since the initial design of the herringbone mixer, 
analytical modeling of it becomes an intense area of research.  The most complex methods 
involve computational fluid dynamics (CFD) modeling, which considers the redistribution of 
streamlines and reduction of striation thickness.  Though these methods generally give a 
comprehensive picture of the mixer, the mathematical modeling can be prohibitively challenging, 
if not impossible.  
A simple analytical model accompanied 
the herringbone mixer adapted from (44) with 
minimum modification due to similarities in 
design specification is presented here to analyze 
the degree of mixing as a function of Pe and 
length by assuming uniform residence time 
distribution of SHM.  At molecular level, solute in 
each fluid element must diffuse to the other fluid for mixing to occur.  Diffusion from a point 
source follows a normal distribution, and the mean magnitude is denoted by 𝐿𝐿𝑑𝑑 = √2𝐴𝐴𝐷𝐷, where 
Figure 3-16: Exact solution of l01 vs. Pe in semi-log 
plot 
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D is diffusivity and t is the duration of the diffusion.  The probability that the solute has diffused 
the distance Ld with the boundary limit of Li is computed by (44)
   𝑨𝑨 (𝑳𝑳𝒅𝒅 < 𝑳𝑳𝒂𝒂) = 𝟏𝟏𝟐𝟐 𝒂𝒂𝒂𝒂𝒐𝒐 �𝟐𝟐√𝟐𝟐𝑳𝑳𝒂𝒂𝑳𝑳𝒅𝒅 � ≈ 𝟏𝟏.𝟔𝟔𝟏𝟏𝑳𝑳𝒂𝒂𝑳𝑳𝒅𝒅       (3-24) 
 as: 
The expression for Ld is substituted with the definition of Pe.  The following expression form 
(44) 
   𝑨𝑨 (𝑳𝑳𝒅𝒅 < 𝑳𝑳𝒂𝒂) = 𝟏𝟏.𝟔𝟔𝟏𝟏� 𝑨𝑨𝒂𝒂𝒘𝒘𝒊𝒊𝒅𝒅 𝑳𝑳𝒂𝒂       (3-25) 
is obtained: 
The empirical relation between l and Li is computed by MATLAB with COMSOL data by (44)
   𝑳𝑳𝒂𝒂 = 𝟏𝟏𝟐𝟐.𝟕𝟕𝐞𝐞𝐞𝐞𝐞𝐞(−𝟏𝟏.𝟓𝟓𝟓𝟓 𝒊𝒊)      𝑹𝑹𝟐𝟐 = 𝟏𝟏.𝟐𝟐𝟐𝟐𝟐𝟐     (3-26) 
: 
This is substituted into the previous equation and solved for 𝑙𝑙0.1  with an arbitrary cutoff 
probability of 0.1.  The exact solution is generated by Maple 11 and graphed (Figure 3-16). This 
is approximation of the solution 
   𝒊𝒊𝟏𝟏.𝟏𝟏 ≈ 𝟏𝟏.𝟕𝟕𝟐𝟐 𝐥𝐥𝐥𝐥𝐥𝐥(𝑨𝑨𝒂𝒂) − 𝟐𝟐.𝟏𝟏𝟔𝟔         (3-27) 
The exact value of 𝑙𝑙0.1is 4.58 cycles corresponding to Pe of 9680 from Figure 3-16.  This value 
computed by using the analytical model agrees to a reasonable extent with the experimental 
value (Figure 3-17).  It is important to note that 𝑙𝑙  is expressed in terms of cycle numbers; 
therefore the length per cycle multiplies the cycle number, 𝑙𝑙, to give the actual length of the 
mixer. 
   𝑳𝑳 = 𝒊𝒊𝟏𝟏.𝟏𝟏 × 𝒅𝒅 = 𝟐𝟐.𝟓𝟓𝟔𝟔𝒅𝒅       (3-28) 
where d is the length of one cycle, which is computed as the following: 
𝒅𝒅 = 𝒅𝒅𝒂𝒂𝒄𝒄𝒂𝒂𝒂𝒂𝒂𝒂𝒄𝒄𝒂𝒂 𝒃𝒃𝒂𝒂𝒂𝒂𝒘𝒘𝒂𝒂𝒂𝒂𝒂𝒂 𝒂𝒂𝒅𝒅𝒂𝒂𝒂𝒂𝒄𝒄𝒂𝒂𝒂𝒂𝒂𝒂 𝒂𝒂𝒂𝒂𝒂𝒂𝒂𝒂𝒗𝒗𝒂𝒂𝒄𝒄 𝒎𝒎𝒂𝒂𝒂𝒂𝒄𝒄𝒎𝒎𝒂𝒂𝒂𝒂𝒅𝒅 𝒐𝒐𝒂𝒂𝒂𝒂𝒎𝒎 𝒂𝒂𝒄𝒄𝒂𝒂 𝒄𝒄𝒂𝒂𝒂𝒂𝒂𝒂𝒂𝒂𝒂𝒂 × 𝒂𝒂𝒄𝒄𝒂𝒂 𝒂𝒂𝒎𝒎𝒎𝒎𝒂𝒂𝒂𝒂 𝒂𝒂𝒐𝒐 𝒂𝒂𝒂𝒂𝒂𝒂𝒂𝒂𝒗𝒗𝒂𝒂𝒄𝒄 𝒄𝒄𝒂𝒂𝒂𝒂 𝒄𝒄𝒚𝒚𝒄𝒄𝒊𝒊𝒂𝒂 =
𝟏𝟏𝟐𝟐𝟓𝟓𝒎𝒎𝒎𝒎 × 𝟏𝟏𝟔𝟔 = 𝟏𝟏.𝟐𝟐𝟐𝟐𝟐𝟐 𝒄𝒄𝒎𝒎          (3-29) 
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The length can then be computed to be 1.06 cm.  Most importantly, note that the mixing 
length, 𝑙𝑙  is proportional to log(Pe), implying 
more “resistance” to perturbations in flow rate.  
This elegant feature introduces stability and re-
usability in our chip design, as this configuration 
can be employed to give only slight changes in 
mixing length under different flow conditions.  In 
addition, the mixing length is reduced from 93 cm 
to about 1cm, a scale that is compatible with our 
chip dimension.  Although 1 cm is manageable in terms of size, additional manipulative design is 
required to efficiently maximum the space utilization. 
Due to the chip dimensional constraint (with a width of 4 cm and a length of 6 cm), the 
herringbone supplemented micro-channel mixer is still relatively long and should not be 
linearized; it must be in a compacted form to accommodate the rest of the components of the 
chip.  To achieve this purpose, the squarewave configuration is employed.  
3.3 MCCRA Device 
 The basic concept of the device is a box type structure into which the disposable chip can 
be inserted.  Once inserted, a vacuum will puncture through the PDMS into the waste reservoir in 
Figure 3-18  Flow chart showing the basic mechanisms of the device’s operation. 
B C A 
Figure 3-17: Comparison of analytical model and 
experimental data (44) 
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order to provide the negative pressure required to make the blood flow through the chip.  Also 
within the device will be a row of eight white light emitting diodes (LEDs) situated above where 
the collagen portion of the chip will sit.  Below the lights there will be a transmission detector.  
Readings from the detector will be transmitted to an electronic device that will be connected to a 
computer.  The device will convert the readings into the necessary format to be read by the 
computer program.  (This analysis and graphing software will be developed by a hired 
programmer).  The program will display a comparison of the transmission data to the IC50 curve 
for MRS 2395.  Accompanying the program will be a manual of standard ranges for healthy 
individuals and the clinical implications of variations from these ranges, based on data acquired 
through testing and clinical trials.  From this the doctor can interpret the results and determine 
the proper clopidogrel dosing amount.  The vacuum will run for a total of 5 minutes, and 
readings will be taken in 5 second intervals.  Once the data has been collected, the chip will be 
ejected from the device (See Figure 3-18).  
 Due to limited knowledge of electronics and electrical engineering, a consultant advised 
the outsourcing of the manufacturing of the device.  The consultant suggested a “black box” style 
device, into which the MCCRA’s specifications can be added and an already existing electronic 
“reader” on the box can be programmed to this product’s specific needs.  
3.3.1 Instruction for Device Usage 
Press “on” button to turn on device.  Remove MCCRA chip from refrigerator, and then 
remove from the sterile packaging.  Put patient’s blood sample onto designated location on the 
MCCRA chip.  Insert chip into device, and press “start” button.  When device has finished 
operation, the red “complete” light will turn on.  Remove chip from device and dispose in 
- 73 - 
 
hazardous/biological waste container.  Use computer readout and compare to MRS 2395 IC50 
curves to determine dosing amount. 
3.4 Data Analysis 
3.4.1 Prototype Findings 
The photomask was designed in LayoutEditor3.  In order to probe the feasibility of the 
design of our chip, a high-resolution (10,000 
dpi) transparency of the chip design was 
printed4  KMPR 1050 positive photoresist5 was 
spun on a silicon wafer6 on a CEE 1007 spinner 
for 30 seconds at 3000 rpm to achieve a 
thickness of 62μm8.  Following a soft bake at 
100C for 15 minutes, the wafer was aligned 
with the aforementioned mask using a Karl Suss 
MA4 9  mask aligner, then exposed to 365nm 
light at a constant intensity of 5mW/cm2 for 195 seconds to manufacturer’s recommendations of 
975mJ/cm2 exposure energy.  Following a post exposure bake at 100C for 3 minutes, the 
unreacted photoresist was removed with AZ 300 MIF10
                                                 
 
3 Jürgen Thies 
4 CAD/Art Services, Bandon, OR 
5 Microchem, Newton, MA 
6 100mm diameter, <100>, Virginia Semiconductor, Fredericksburg, VA 
7 Brewer Science Inc., Rolla MA 
8 measured post-fabrication using a Tencor Alpha Step (KLA-Tencor Corp, San Jose, CA) 
9 Karl suss, Garching, Germany 
10 Clariant Corp., Somerville, NJ 
 developer for 10 minutes under constant 
agitation.  After fabrication, the master was silaized for three hours with 1,1,2,2-
Figure 3-19  PDMS block consisting of our chip design. 
Presence of defined and correctly patterned features, such 
as channels, mixing regions and reservoirs, has instilled 
confidence in our product design.  Note:  the upper left 
section of the chip shows the vacuum being punctured into 
the waste well. 
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tetrahydrooctyle-1-trichlorosilane 11  to facilitate PDMS removal.  The master was used to 
fabricate the mold in a process similar to that of the manufacturing mold design. 80mL of PDMS 
pre-polymer was mixed at a 1:10 ratio with curing agent12
  For proof of concept purposes, a number of 
analogous yet simplified chip designs were included on 
the master in addition to the intended microfluidic 
device. The simplified analogue consisted of only one 
of the eight channels. The same vacuum setup that 
would have been used for the more complex 
microfluidic chip was used for the single channel. The 
prototype testing was therefore 
intended to prove three things: that the 
chip design was capable of being 
manufactured, that MRS 2395 inhibits 
aggregation of platelets, and that 
platelet aggregation would occur on 
the collagen. Positive evidence for 
these factors would indicate that hard 
  and degassed, then poured onto the 
master.  This device was placed in an 80°C oven for two hours, and then removed, cut from the 
mold, and ports punched. (45) 
                                                 
 
11 United Chemical Technologies, Bristol, PA 
12 Sylgard 184, Dow Corning, Midland, MI 
Figure 3-21  A Harvard PHD 2000 Syringe Pump 
was used as the driving force for flow in our 
prototype.  
The syringe pump was set at a speed that 
mimicked the sheer rate of blood found in vivo. 
Figure 3-20  Microscope setup used to record platelet aggregation by 
measuring changes in light transmittance.  
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to measure system characteristics, such as specific concentration gradients, were correctly 
calculated. 
 With the microfluidic chip fabricated, the design was now ready to be tested. However, 
lab equipment needed to be used as substitutes for functions the box would normally perform. A 
lab-scale syringe pump13 was substituted for the vacuum pump to apply a constant flow rate 
across the channel. Upon obtaining blood from a willing volunteer, it was allowed to mix off 
chip with ADP in a 1.5 mL tube. From this mixture, approximately 200 µL were applied to one 
end of the channel while the syringe pump was attached to the other end of the channel. Similar 
to the way our box will assay the chip, the prototype was mounted on an inverted microscope14
3.4.2 Image J 
 
and light transmittance through the collagen patch was measured as a function of time. Images 
were collected every five seconds over a five minute period. To get an accurate numerical image 
of the light transmittance, a 10X objective was used. After a few trials, the experiment clearly 
showed the aggregation of platelets on the surface of the collagen. To bridge the gap between 
prototype and desired product even further, the blood and ADP mixture was incubated with 
varying concentrations of MRS 2395 and platelet aggregation was further tested. 
 Although the MCCRA will utilize a sophisticated computer algorithm capable of 
advanced interpretation and manipulation of recorded data and error detection ability, the 
prototype findings were susceptible to analysis with the ImageJ Image Processing program. 
                                                 
 
13 PHD 2000, Harvard Apparatus, Holliston, MA 
14 Olympus IX81, Olympus America, Center Valley, PA 
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 As the blood was run through the chip, a CCD camera15
3.4.3 Results 
  captured a black and white 
image of the channel every 5 seconds over the experimental time period of five minutes.  These 
pictures were then uploaded to ImageJ, where a region of interest was selected around the 
collagen patch of the channel and another area was drawn around an upstream part of the channel 
devoid of collagen.  The average grayness of the boxes (dark boxes equals less surface height, 
lighter surface equals higher surface height) were determined from intensity profiles from those 
regions, and the difference between the average pixel intensity of the collagen-free area and 
collagen area was calculated.  This value was divided by the average intensity of the collagen-
free region and relative intensity value was determined.  These values were plotted versus time 
and the trends were observed. 
As found in Figure 3-22, blood plus ADP initially mixed with inhibitor at 5, 10 and 50 µM 
was flowed over a collagen patch. The y-axis plots the relative grayness of the patch, which is a 
measure of the topology of the surface. The graphs all individually show a transient regime 
where platelet aggregation begins and increases steadily. A steady state value for the signal is 
then attained, normally when the experimental time equaled about 250 seconds. Compared 
against each other, the experimental trials lead to the conclusion that a more concentrated MRS 
2395 solution leads to less platelet aggregation. In addition, the experiments using 10 µM and 50 
µM inhibitor show graphs that lead to a similar steady state platelet aggregation. These graphs 
imply that a boundary is reached at above 10 µM MRS 2395, and thus any additional inhibitor is 
without effect. 
                                                 
 
15 ORCA-ER, Hamamatsu, Bridgewater, NJ 
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3.4.4 Dose Response Curve  
The steady state values 
from the experiments were used to 
construct a very elementary dose-
response curve. Shown in Figure 
3-23, the graph demonstrates the 
effects of the increasing MRS 
2395 concentration on platelet 
aggregation. Does-response curves 
are normally characterized by a 
sigmoidal shape, where the steepest 
(slope) portion of the curve is located in the middle of the graph, while the lower and higher 
Figure 3-22  The platelet aggregation is recorded as a function of time. 
 Aggregation was determined from a measure of pixel grayness, which is an indication of the surface topology. A darker 
surface (lower pixel grayness value) translated to less surface structures, while a lighter surface (higher pixel grayness 
value) meant higher surface structures. 
Figure 3-23  The results of increasing inhibitor concentration on platelet 
aggregation. The points shown represent the upper portion of the sigmoidal 
dose-response curve. 
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points show little change. Expecting the results in Figure 3-23 to be similar, the data points 
collected must occur after the inflection point of the sigmoidal curve. Therefore, the 
concentration of inhibitor used in this study must have been above the concentration that gives 
half inhibition of receptors and gives us an idea of the IC50 for MRS 2395 against the P2Y12 
receptor. One study of rat platelet aggregation found an IC50 of 3.6 µM, corresponding well with 
the data found here. (46) 
The curve serves to successfully prove the contention that MRS 2395 functions to inhibit 
platelet aggregation. Since it behaves as intended, the inhibitor should be successful in allowing 
the MCCRA to ascertain the amount of P2Y12
3.5 Financial Analysis 
 receptors that have not been inhibited clopidogrel. 
Thus, all of the proof of concept points have been accurately answered and the prototype 
validated. 
3.5.1 Market Share and Sales Project 
It has been shown that pre-treatment with clopidogrel before primary percutaneous 
coronary intervention (PCI) lowers the risk of future complications based angiographic outcomes, 
thus significantly reducing the risk of cardiovascular death. (47) (48)
For our project development, one year (Year 2010) is allocated for product design and 
development from the prototype.  The Food and Drug Administration approval and regulation 
  The number of PCI cases 
performed annually is 1.1 million in the US as of 2008.  Since the benefit from pre-treatment 
with clopidogrel before PCI has been known for at least 2 years, 90% of the patients requiring 
PCI, or about 1million, are currently pre-treated with clopidogrel.  Presumably, all clopidogrel 
prescription requires dosage measurements.   
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processes are generally expected for startup biotech devices that are used in health care settings.  
This process is anticipated to take 2 years (Year 2011 and 2012), a relatively short period due to 
the non-invasive nature of our device.  The expected date for launching our product is the 
beginning of 2013 and it is expected to initially capture 10% of the market share (1 million) or 
100,000 patients.  It is anticipated this number will grow thereafter due to the increasing 
awareness of the benefits from clopidogrel and the competitive advantage of our product.  The 
market share is expected to follow a step increase from 10% initially to 30% for the second year 
of operation, and finally 50% until the end of operation. 
Previously it has been shown that the market for clopidogrel resistance detection is 
fiercely competitive (See Competitive Analysis 2.8).  Several devices employing different 
clotting quantification techniques (for example, florescence transmittance aggregometry, 
turbidity measurement, electro-conductivity measurement etc) are competing to be the gold 
standard.  Their prices per test range from $50 to $100, while their run times plus incubation 
vary from 13 minutes to hours.  If the time is considered an opportunity cost, the most cost-
effective price and run-time combination charges 650 min*dollar/test (VerifyNow).  As the 
world is looking for a cost-effective, high-throughput device that efficiently measures 
clopidogrel resistance with sophisticated error checking mechanisms, we introduce our POC 
high-throughput screening device that utilizes high performance microfluidic technology that 
enables us to charge only $100 per 4 tests per 10 minutes (250 min*dollar/test).  From the time 
and cost perspectives, our product is expected to be at least 2.5 times more efficient than any of 
its existing competitors.   
In the subsequent revenue estimation, monetary figures are expressed in real terms (in 
today’s money value).  Inflation is not incorporated into our financial models, because it is 
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impracticable to accurately predict inflation rate based on historical data.  Furthermore, it is 
important to note that cash flow discounting (CFD) using quantities in real terms with the real 
discount rate is theoretically equivalent to CFD using quantities in nominal terms with nominal 
discount rate.  It is clear that estimating inflation rate and adjusting discounted revenues and 
costs accordingly is superfluous.  The real discount rate is related to the nominal discount rate 
and inflation rate by the Fisher equation: 
  𝟏𝟏+𝑵𝑵𝒂𝒂𝒎𝒎𝒂𝒂𝒂𝒂𝒂𝒂𝒊𝒊 𝑫𝑫𝒂𝒂𝒄𝒄𝒄𝒄𝒂𝒂𝒎𝒎𝒂𝒂𝒂𝒂 𝑹𝑹𝒂𝒂𝒂𝒂𝒂𝒂
𝟏𝟏+𝑰𝑰𝒂𝒂𝒐𝒐𝒊𝒊𝒂𝒂𝒂𝒂𝒂𝒂𝒂𝒂𝒂𝒂 𝑹𝑹𝒂𝒂𝒂𝒂𝒂𝒂 − 𝟏𝟏 = 𝑹𝑹𝒂𝒂𝒂𝒂𝒊𝒊 𝑫𝑫𝒂𝒂𝒄𝒄𝒄𝒄𝒂𝒂𝒎𝒎𝒂𝒂𝒂𝒂 𝑹𝑹𝒂𝒂𝒂𝒂𝒂𝒂    (3-30) 
Cash Flow Discount (CFD) will be discussed in more detail in later sections.  Our plant 
operation is anticipated to last 7 years, after which the patent expires or our product loses its 
competitive edge to new technologies.  The annual revenue from MCCRA chip sales is 
summarized in the following table: 
Year 2013 2014 2015 2016-2019 
% Market 10% 30% 50% 50% 
Test/Yr                  100,000                   300,000                   500,000                   500,000  
Chip Price                        $100                         $100                        $100                         $100  
Revenue          $10,000,000           $30,000,000           $50,000,000           $50,000,000  
Table 3-4  Revenue Table 
3.5.2 Expenses 
Our design group has attempted to get in contact with sales representatives from various 
chemical suppliers.  A rough estimate of the costs of the raw materials for the chips, equipments, 
and general expenses were obtained.  Due diligence in the form of thorough research was 
performed to verify the quotes from these sales representatives.  It was recognized that these 
prices might represent an overestimation because quantities would be purchased in bulk, 
resulting in a discount.  Moreover, if the project was carried beyond the design stage, better deals 
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with the suppliers might be negotiated.  For the purpose of initial design, the prices found were 
satisfactory.  For subsequent cost analyses, the expense worksheet is dissected into the following 
3 categories: 1) total initial capital investment 2) variable costs, 3) fixed costs.  Each of these will 
be discussed in detail in the following subsections. 
3.5.2.1 Total Capital Investment 
Table 3-5 provides a summary of the items that are part of property, plant and equipment 
(PPE).  The focus of our project is product design, so all will be pre-fabricated upon purchase 
from suppliers.  However, before the purchase of some of these pieces of equipment (such as the 
oven, stirred tank, and cold room storage), equipment sizing has been performed (Appendix 7.7).  
With these sizing estimations, equipment with relevant capacities is chosen to avoid needless 
costs.  For example, the necessary storage space to accommodate a monthly inventory of 42,000 
chips is computed to be 70 cubic feet, while the refrigerator unit has a volume capacity of 78 
cubic feet.  The sizing-aided selections of other equipments are carried out in a similar fashion.   
As mentioned previously, the quotes for all equipments are obtained from sales 
representative and supplier websites.  For example, Silverson Laboratory Scale Batch Mixer 
costs about $1,500, taken from the Silverson website.  Bare modules factor for this item is 1.0 
because there is no extra installation fee associated with it; the mixer is pre-fabricated and pre-
configured upon purchase.  The bare module cost (𝐶𝐶𝐵𝐵𝐵𝐵) is the product of the bare module factor 
(𝐹𝐹𝐵𝐵𝐵𝐵) and the purchase cost (𝐶𝐶𝐴𝐴): 
    𝑪𝑪𝑨𝑨𝑩𝑩 = 𝑭𝑭𝑨𝑨𝑩𝑩 × 𝑪𝑪𝑨𝑨       (3-31) 
The bare module costs for all other process equipments, the storage, security system, and lab 
computers & software are computed in a similar fashion. 
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It should be noted that bare module factors associated with different equipments are not 
the same.  For example, the bare module factor of 1.5 for Biomek FX Robotic Arm reflects that 
the cost of installation is 50% of the purchase cost, while a bare module factor of 2 for 
Wisconsin Industrial Oven suggests that another 100% of the purchase cost is used in setting 
ventilation system associated with its installation.  All of the aforementioned items are purchased 
during the design stage in 2010.  The rest of the section is devoted to addressing the box and 
FDA approval expenses. 
The box manufacture will be out-sourced to an electronic supplier.  A list of functional 
specifications will be provided to the box manufacturer to customize the box.  Table 3-6 
summarizes the components in the box as well the cost of assembly (which is estimated to be 50% 
of the aggregate purchase costs of individual components).  It is essential to note that the box 
will not be processed by our chip manufacturing plant and one box is directly distributed to one 
hospital that hold contract with our service.  The box selling price is the same as the selling price 
required by the electronic supplier; in another words, we make no profit out of the sales of the 
box.  This should be deemed reasonable because we as the chip manufacturing side do not add 
extra value to the box.  Therefore, the box sales will not appear in our financial analysis, while 
box maintenance and technical support will be considered.  In Table 3-5, there is a “Box free 
trial” entry under “Other Equipments”.  One major reason is that most of the hospitals (we are 
targeting about 4000 large hospitals in the US) already purchased our competitors’ boxes; these 
expenses represent sunk costs to them, costs that they incurred in the past.  For this reason, they 
might not be willing to dispose these boxes and replace them with ours.  Hence, we will purchase 
50 boxes and offer them as free trial products to 50 selected hospitals in 2013 (1st year of 
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operation).  This business strategy will not only ensure us market share, but also support our 
marketing effort. 
The cost of FDA approval excluding overhead expenditure is assumed to be 10% of the 
annual sales at full capacity, or $5 MM, evenly distributed over the 2 year period (2011 and 
2012).  Overhead is defined as all costs but direct labor and materials on the income statement.  
This is treated as “other equipment” in the profitability worksheet.  It is important to recognize 
FDA approval is not a one-time cost.  Congress enacted the Medical Device Amendments of 
1976 to further FDA regulation on the safety and effectiveness of medical devices (49).  The 
medical device regulation generally can be divided into 2 stages: 1) pre-market evaluation and 
approval process and 2) post-market evaluation.  This implies overhead expenditures will be 
allocated to deal with federal regulation on an annual basis.  Therefore, for economic analysis at 
the design stage, it is convenient and reasonable to treat the $5 MM spent on FDA approval as 
depreciable capital investment, and overhead is computed as a percentage of this amount 
annually.  This will be discussed in detail in the section on (Fixed Costs 3.5.2.3). Some of the 
plant equipments and process facilities need modifications of the factory for installation.  For 
example, ventilation system might have to be set up before installing the oven.  We account for 
this type of expenses within Cost of Site Preparation in Table 3-5, which is taken as 5% of bare 
module costs. (50)  To maintain a well-managed, orderly factory, service facilities are 
indispensable and take about 5% of bare module costs. (50)  The sum of bare module costs, cost of 
site preparation and service facilities is denoted as the Direct Permanent Investment (DPI).  The 
cost of contingencies and contractor fees is about 18% of DPI.  The accumulated sum of DPI and 
cost of contingencies and contractor fees is known as Total Depreciable Capital (TDC).  The cost 
of land is not included in the section because the manufacturing facility will be rented.  The 
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annual rent payment is treated as fixed cost in annual basis in the section on Fixed Costs.  Finally, 
there are costs incurred for the plant start-up, which is usually 2% of TDC (50)
 
.  Working capital, 
which includes accounts receivable, cash reserves, accounts payable and inventory, is about 12% 
of annual sales at full capacity, or 1 month of sales revenue.  The sum of the aforementioned 
items is lumped together as the Total Capital Investment (TCI).  It should be noted that TCI is a 
one-time cost, in contrast with fixed costs and variable costs, which we incur on an annual basis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3-6  The box price is estimated by taking the sum of the costs of individual components and adding the installation cost 
and required profit from the out sourced company. 
 
 
 
3.5.2.2 Variable Cost 
The variable cost is defined as the cost per unit of merchandise produced.  It is 
partitioned into 3 major categories: raw materials, utilities, general expenses.  As mentioned 
previously, the quotes for the raw materials expressed in terms of either per volume basis or 
per mass basis are obtained from supplier sales representatives.  Material balance is carried 
out to compute the amount of each reagent needed to produce 1 chip (refer to section on 
chip manufacture).  With this, the cost of each reagent per chip can be calculated (Table 3-7).  
In the United States, energy consumption is reported ranging from $1.50 to $2.50 per 
square foot in a typical building (51)
𝑼𝑼𝒂𝒂𝒂𝒂𝒊𝒊𝒂𝒂𝒂𝒂𝒚𝒚 𝑪𝑪𝒂𝒂𝒄𝒄𝒂𝒂 = 𝟏𝟏.𝟐𝟐 × 𝑻𝑻𝒚𝒚𝒄𝒄𝒂𝒂𝒄𝒄𝒂𝒂𝒊𝒊 𝑪𝑪𝒂𝒂𝒄𝒄𝒂𝒂 𝒐𝒐𝒂𝒂𝒂𝒂 𝒂𝒂 𝒃𝒃𝒎𝒎𝒂𝒂𝒊𝒊𝒅𝒅𝒂𝒂𝒂𝒂𝒂𝒂 = 𝟏𝟏.𝟐𝟐 × 𝟔𝟔𝟐𝟐𝟓𝟓𝟏𝟏 = $𝟕𝟕𝟓𝟓𝟏𝟏𝟏𝟏 𝒂𝒂𝒂𝒂 $𝟏𝟏.𝟏𝟏𝟏𝟏𝟓𝟓/𝑪𝑪𝒄𝒄𝒂𝒂𝒄𝒄  (3-32) 
.  With area occupancy of 2500 square feet, our plant 
utility cost can reach up to $6250. 
This is considered the most basic cost in our manufacturing plant.  However, the 
most utility-consuming equipments that are used in chip production include a group 
comprised of the oven, robotic pin tools and the packaging machine.  The power of all these 
equipment can be found in their product descriptions and multiplied by operation time and 
cost per utility unit to give the costs of utilities expended by them.  The overall cost of utility 
is the sum of the cost for a typical building and the cost from utility heavy equipments.  
Nonetheless, for simplicity, we just multiple a factor of 1.2 to account for extra cost of 
utilities by these equipments here: 
The cost items listed above are the most obvious or direct expenses incurred in 
producing chips.  However, the less obvious or indirect costs are lumped together as General 
Expenses, which include transportation, direct research, allocated research, administrative 
expense and management incentives.  All these expense items are computed as percentages 
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of annual sales: 3% for product transfer, 4.8% for direct research, 0.5% for allocated 
research, 2% for administrative expense and 1.25% for management incentive compensation 
(or bonus).  These are normally considered variable costs instead of fixed costs because 
annual sales actually vary for the first 3 years of operation. 
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Type of Process Number of Operators per Process Section
Mixing of PDMS and curing reagents 1
Pouring PDMS onto molds 2
Curing in oven 1
Depositing ADP, MRS, and collagen 5
Sealing chip with glass slide 3
Packaging 3
Total 15
3.5.2.3 Fixed Cost 
The fixed cost includes the costs from annual operation, maintenance, operating 
overhead, property taxes and insurance, and space rental.  In the rest of the section, a 
comprehensive review of each cost is given.   
Operations include 1) direct wages and benefits (DWB), 2) direct salaries and 
benefits (DSB) and 3) operating supplies and services (OSS).  To compute DWB, it is 
deemed necessary to elucidate a few operating conditions.  Firstly, the operating hour is 
allotted 10 hr per day such that the manufacturing process can achieve the production of 
4000 chips daily.   Secondly, the number of operation days per year is assumed to be 250, or 
70% of 360 days/1 year.  The other 30% of the time is spent on maintenance and inspection; 
this is a typical assumption for a biomedical manufacturing plant. (50)  Thirdly, the number 
of operators per shift is estimated by considering the amount labor required for each process 
in the production chain (Table 3-8).  Lastly, the hourly rate of $42.5/hr is adopted from a 
similar project titled “High throughput screening of kinase inhibitors” in (50)
 
 direct wages 
and benefits are the following function of the aforementioned variables: 
 
 
 
 
 
 
Table 3-8  Estimation of the number of operators. 
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𝑫𝑫𝒂𝒂𝒂𝒂𝒂𝒂𝒄𝒄𝒂𝒂 𝑾𝑾𝒂𝒂𝒂𝒂𝒂𝒂𝒄𝒄&𝑨𝑨𝒂𝒂𝒂𝒂𝒂𝒂𝒐𝒐𝒂𝒂𝒂𝒂𝒄𝒄 = �𝟏𝟏𝟓𝟓𝑶𝑶𝒄𝒄𝒂𝒂𝒂𝒂𝒂𝒂𝒂𝒂𝒂𝒂𝒂𝒂𝒄𝒄
𝒄𝒄𝒄𝒄𝒂𝒂𝒐𝒐𝒂𝒂
� (𝟏𝟏 𝒄𝒄𝒄𝒄𝒂𝒂𝒐𝒐𝒂𝒂) �𝟐𝟐𝟓𝟓𝟏𝟏𝟏𝟏 𝒄𝒄𝒂𝒂
𝒚𝒚𝒂𝒂
− 𝒂𝒂𝒄𝒄𝒂𝒂𝒂𝒂𝒂𝒂𝒂𝒂𝒂𝒂𝒂𝒂𝒂𝒂� ($𝟐𝟐𝟐𝟐.𝟓𝟓
𝒄𝒄𝒂𝒂
)  (3-33) 
To continue our calculation of direct salaries and benefits (DSB), it is necessary to clarify 
the distinction between DSB and DWB.  Direct wages and benefits are paid to operators 
who are directly involved in production while direct salaries and benefits are compensated 
to supervisory and engineering personnel who oversees the operation.  Direct salaries and 
benefits is usually 15% of DWB and added to DWB to give the total labor cost of plant 
operation (50).  It is clear labor itself will not accomplish the entire operation.  Operating 
supplies and services are generally essential and usually taken as 6% of DWB (50)
 Similarly, maintenance cost include 1) Maintenance Wages and Benefits (MWB), 2) 
Maintenance Salaries and Benefits (MSB), 3) Materials and Services (analogous to 
operating supplies and services), and 4) Maintenance Overhead.  The distinction between 
MWB and MSB is analogous to the difference between DWB and DSB; generally salaries 
refer to supervisory personnel compensation in this report.   Since maintenance is done on 
the plant equipment (Total Depreciable Capital), MWB should be proportional to TDC; in 
fact, MWB is taken as 4.5% of TDC here.   It is common practice to take 25% of MWB as 
Maintenance Salaries and Benefits.  Materials and services take into account for spare parts 
and external technical support for repairs.  This is usually 100% of the Maintenance Wages 
and Benefits because machine parts and repair services are quite hefty.  Accounting fees, 
legal fees, utilities etc. that we incur during maintenance are classified as maintenance 
overhead, which is 5% of MWB, typical for a biomedical manufacturing plant. (50)
; these are 
the tools beside the plant equipments that the operators use to carry out their tasks. 
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In addition, there are overhead expenses that are associated with the operation as 
well.  This can be broken down to 1) general plant overhead, 2) mechanical department 
services, 3) employee relations department, and 4) business services.  These expense items 
are rather self-explanatory or previously addressed, and 7.1%, 2.4%, 5.9%, and 7.4% of the 
sum of DWB and MWB, respectively. 
Rental fee for factory and office space is computed based on cost per square feet and 
estimated size of our plant: 
  𝑨𝑨𝒂𝒂𝒂𝒂𝒎𝒎𝒂𝒂𝒊𝒊 𝑹𝑹𝒂𝒂𝒂𝒂𝒂𝒂𝒂𝒂𝒊𝒊 𝑭𝑭𝒂𝒂𝒂𝒂 = 𝑪𝑪𝒂𝒂𝒄𝒄𝒂𝒂
𝒐𝒐𝒂𝒂𝟐𝟐
× 𝒂𝒂𝒐𝒐𝒐𝒐𝒂𝒂𝒄𝒄𝒂𝒂 & 𝑒𝑒𝑓𝑓𝑓𝑓𝐷𝐷𝑓𝑓𝑟𝑟𝑓𝑓 𝑠𝑠𝑝𝑝𝑓𝑓𝑓𝑓𝑒𝑒  3-34) 
The fixed cost components are tabulated in Table 3-9. 
Figure 3-24  Chip Cost Composition 
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3.5.3 Valuation/Discounted Cash Flow 
The fundamental principle of the time valuation of money tells us that a dollar today 
is not the same as a dollar a year from today, simply because if we invest a dollar today in 
the market, we will get back a dollar plus interest.  Similarly, a dollar a year from today is 
worth actually less than a dollar today.  It is clear that the money values at different times 
are somehow related.  This seemingly intricate relationship is unexpectedly simple; all cash 
flows at different times can be jointly expressed, that is, in the form of the discount interest 
rate (52)
   𝑵𝑵𝑨𝑨𝑽𝑽 = 𝑪𝑪𝟏𝟏 + 𝑪𝑪𝟏𝟏(𝟏𝟏+𝒂𝒂) + 𝑪𝑪𝟐𝟐(𝟏𝟏+𝒂𝒂)𝟐𝟐 + ⋯+ 𝑪𝑪𝒂𝒂(𝟏𝟏+𝒂𝒂)𝒂𝒂    (3-35) 
where C subscript represents the cash flow at date 0 (or today), date 1, date 2 and so on.  
The net present value (NPV) is the sum of discounted cash flows; in another words, paying 
one all these cash amounts (C
: 
0, C1...Ct
    𝑹𝑹� = 𝑹𝑹𝑭𝑭 + 𝜷𝜷 × (𝑹𝑹�𝑩𝑩 − 𝑹𝑹𝑭𝑭)      (3-36) 
) at different times is equivalent to paying him/her a 
lumped sum of NPV today.  Therefore, once we know the discount rate, we can express our 
project sales and costs in terms of money today. 
Simple as it seems, estimation of the discount rate is one of the major challenges in 
financial analysis.  Often, the discount rate is misinterpreted as simply the interest rate in the 
bank, while in reality it is the expected return on the asset.  For this reason, we will expound 
on how we obtain the discount rate through the capital asset pricing model (CAPM): 
𝑅𝑅� is the expected return on our project (taken as the discount rate).  𝑅𝑅𝐹𝐹  represents the risk 
free expected rate of return or the current return on 10-year treasury bills, which is 2.7%. (53)  
𝑅𝑅�𝐵𝐵  is the expected return on the market and estimated to be 10.83% based on the Dow Jones 
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Industry Average from 1975 to 2006. (54)
    𝜷𝜷 = 𝑪𝑪𝒂𝒂𝒗𝒗(𝑹𝑹𝒂𝒂,𝑹𝑹𝑩𝑩)
𝝈𝝈𝟐𝟐(𝑹𝑹𝑩𝑩)   3-37) 
  The difference between 𝑅𝑅�𝐵𝐵 and 𝑅𝑅𝐹𝐹 , 8.13%, known 
as the market risk premium, is always positive because average return on the market is 
higher than riskless interest rates historically.  𝛽𝛽 is a measure of risk or volatility on return 
associated with our project.  The exact definition can be clarified by this equation: 
The numerator is the covariance between 
return on a similar project and average 
return on the market, while the 
denominator is the variance of the 
average return on the market.  We 
selected few biotech startup companies 
from the market and take the average of their 
beta values to give a crude estimate of the beta value for our project. (55) Given all the 
required inputs into Table 3-11, the discount rate is then calculated to be about 15%.  Now, 
we have all the information we need to construct the cash flow table; in summary, the 
required parameters are initial capital investment, variable cost/year, fixed cost/year and the 
discount rate.  The net present value (NPV) and investor rate of return (IRR) are also 
included in Table 3-11.  
 
Table 3-10: beta estimation from similar stocks 
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3.5.4 Sensitivity Analyses 
Although a price estimate of the 
cost of the fabrication of each chip has 
been done to the best of our ability, price 
fluctuation in the future is not something 
that is readily accounted for.  It is 
anticipated that some of the cost 
estimates based on the current state of 
the economy might not be consistent 
throughout the operating life of our plant.  
For example, some of the raw material prices might change; the chip price might need to be 
adjusted to respond to our competitors; gas price might go up due to short supply, increasing 
transportation cost.  Uncertainty clouds the future in every way, and it is generally common 
practice to observe how much each 
cost/revenue component causes the 
investor rate of return (IRR) to change.  
In another words, we want to see how 
“resistant” IRR is in response to 
“disturbances” in fixed cost, variable 
costs, product price and initial capital 
investment.  Amongst all of them, variable cost and product price are most likely subject to 
change.  Figure 3-25 shows the IRR at chip price ranging from $85 to $115.  The steepness 
Figure 3-25:  Sensitivity Analysis: Chip Price vs. IRR 
Figure 3-26  Sensitivity Analysis: Variable Cost vs. IRR. 
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of the slope gives us an idea how sensitive IRR is in response to potential changes; the 
closer to be horizontal implies the more stable IRR.  Similarly, IRR versus variable cost is 
graphed in Figure 3-26; the slope interpretation still holds.  IRR sensitivity analyses with 
changes in initial investment and fixed cost are not discussed here because it is anticipated 
that unexpected changes to these two parameters are unlikely.  However, a full IRR 
sensitivity analysis for all 4 parameters is included in the appendix for completion.   
3.5.5 Capital Structure 
Once the capital budgeting is complete, a decision on how to finance the project 
needs to be made.  There are generally two sources of financing: equity and debt.  If a 
combination of the two is used in our project, dividends are paid to stock holders while 
interest is also paid out annually to bond holders.  Because interest pay is tax deductable and 
dividend is not, there is an asymmetry in the tax code that enables us to increase the NPV of 
our company by borrowing money to finance our project.  It should be noted that so far we 
assume 100% ownership of the project.  However, there is also risk associated with debt, 
most notably the risk of bankruptcy.  For these reasons, there must be an optimum equity to 
debt ratio that maximizes the value of our company.  The follow equation helps explain this 
concept:  
𝑉𝑉𝐿𝐿 = 𝑉𝑉𝑈𝑈 + 𝐴𝐴𝑉𝑉𝑃𝑃𝑃𝑃 − 𝐴𝐴𝑉𝑉𝐶𝐶𝐹𝐹𝐴𝐴 
where 𝑉𝑉𝐿𝐿is the value of the company with leverage; PVTS represents the present value of 
tax reduction due to debt financing; and PVCFD is the present value of cost of financial 
distress (CFD). 
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Numerical calculations will not be performed in regard to capital structure.  The 
purpose of this section is to qualitatively describe the value increase potential of our project 
and the type of decisions we need to make beyond the preliminary design stage. 
3.5.6 Conclusions 
For 100% ownership of the project, the resulted net present value (NPV) of about 
$45 million looks promising.   The investor’s rate of return (IRR) of about 91% is extremely 
lucrative and seemingly unreasonable.  However, it should be noted that the initial 
investment for this project is relatively small compared to the cash inflow from sales. For 
example, the total capital investment associated with the chip manufacture is about 11 
million while the annual sales are $50 million. The IRR reflects the ratio of profit to the 
initial investment.  Generally, IRR is not used as the only guideline to accept or reject 
mutually exclusive projects because it neglects the magnitude of the investment.  On the 
other hand, a positive NPV suggests that the project not only satisfies the required return of 
15% (r=15%) but also gives an idea of how much extra value the project adds in addition to 
the required return.  Hence, we should accept this project with a positive NPV value of $45 
million.   
Although the NPV of the project indicates profitability in the long run, the initial 
capital investment and the FDA approval costs at the first 3 years represent a huge cash 
outflow at the beginning.  Table 3-11 (Cash Flow Table) suggests the payback period is 6 
years, after which the initial value put into the project is starts to be regained.  In reality, a 
project with this type of cash flow structure represents a risky investment.  Nonetheless, for 
a biomedical device development firm, this is rather typical and unavoidable.   
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Sensitivity analyses are carried out on IRR with two and single inputs variation from 
the expected value.  The resulted IRR ranges from 75% to 110% (Appendix 7.7.4), which 
looks favorable because of its implication that our project IRR is not susceptible to deviation 
from expected sales or costs of operation. 
The financial analysis in this report is performed by assuming 100% ownership.  In 
reality, this might not be actually feasible.  Presumably, the project is financed with equity 
and debt through venture capital.   The capital structure with debt reduces our tax liability, 
thus increases the value of our company. 
Limitations have certainly been encountered during calculations of the financials.  For 
instance, the quotes obtained from raw material and equipment suppliers might not be 
accurate because the sales representatives might not be aware of the magnitude of our 
intended purchase, the discount rate estimated by the capital asset price model might 
represent an underestimation of risk involved with our project, the expected market share 
might not be as optimistic as 50%; or there might be some competitors that we are not aware 
of.  If this project is carried out beyond the preliminary design stage, these are some areas 
that needed to be closely examined.  
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Part 4  Development, Manufacturing, and Product-Introduction 
Stages 
4.1 FDA approval 
 Since the MCCRA System is considered to be a medical device, it is necessary to 
obtain FDA approval before distribution to hospitals can begin.  One of the first steps is 
verify the class of our device.  Since the system has multiple components and is responsible 
for giving an accurate reading that will in turn be translated into a medication dosing amount, 
it will not fall into the category of Class I devices.  Class I encapsulates basic medical 
instruments, such as tongue depressors.  The proper functioning of these devices can mostly 
be determined by basic inspection, and their failure is either relatively impossible or 
presents no potential harm to the patient.  However, Class III devices are those which if they 
were to fail, could be harmful or even life-threatening, such as pacemakers.  The MCCRA 
System seems to fall in the category of a Class II device.  It has the potential for failure and 
its efficiency/safety must be demonstrated, but any malfunction of the device is not life-
threatening to the patient.  Determination of the class of the medical device is important in 
determining what paperwork needs to be filled out as well as what types of trials need to 
take place in order to gain FDA approval.  Product design specifications, manufacturing 
protocols, and product prototypes must be submitted to the FDA in order for verification of 
the MCCRA System as a Class II device.  Once this verification is obtained, the necessary 
paperwork can begin to be filled out and submitted and clinical trials can begin. (3) 
4.1.1 Clinical Trials (56) 
In order to gain FDA approval, it will need to be proved that the MCCRA System is 
both safe and effective.  One step is to try to prove Substantial Equivalence.  This means 
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that it will need to be shown that the basic mechanics of operation are the same as a product 
that is already on the market, and therefore can already be assumed to have a similar level of 
safeness and effectiveness.   
The safeness and effectiveness of the MCCRA System will also be tested through a 
series of clinical trials.  In each Phase of the trials, every test subject will first be tested 
without any additional medication, to serve as a control for that individual.  Then testing 
will be done with various amounts of clopidogrel dosing. 
4.1.1.1 Phase I 
In Phase I, approximately 75 test subjects will be used.  Each subject will tested at 
two different times.  The first test will be run without giving any amount of medication to 
the test subject.  About a week later, the subject will be given a standard pre-angioplasty 
dose of clopidogrel (300 mg (57)
4.1.1.2 Phase II 
) and his blood will be reanalyzed the next day.  This data 
will be compiled and analyzed.  The purpose of Phase I will primarily be to prove that the 
MCCRA System is in fact safe and does show a variance in detection data as a result of 
clopidogrel administration.  It is estimated that this phase will take approximately 1 month 
to run and analyze. 
In Phase II, the number of test subjects will be increase four-fold to approximately 
300.  In this series of testing, each subject will be tested 3 times.  The first test will be run 
without giving any amount of medication to the test subject.  About one week later, the 
subject will be administered one half of a standard dose of clopidogrel (150 mg) and his 
blood will be tested the following day.  Another two weeks later, the subject will be given a 
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full standard dose of clopidogrel (300 mg (57)
4.1.1.3 Phase III 
), and his blood will be tested the next day.  All 
of these results will be compiled and analyzed.  The primary intention of Phase II will be to 
start proving the effectiveness of the device by demonstrating the sensitivity of the testing 
(i.e. the variance of results due to variance of dosing amount) as well as to further prove the 
safety of the device and procedure.  It is estimated that this phase of trials and data analysis 
will take approximately 5 months to complete. 
Phase III the number of test subjects will increase ten-fold from Phase II, to 
approximately 3,000.  In this phase, each subject will be tested four separate times.  The 
subject will first be tested before the administering of any amount of medication.  One week 
later, the subject will be administered one-quarter of the standard clopidogrel dose (75 mg) 
and will be tested the next day.  This will be repeated two weeks later for a one-half 
standard dose (150 mg) and then two weeks after that for a full standard dose (300 mg).  
Once again the data will be compiled and analyzed.  The purpose of Phase III is to prove 
that the device is ready for distribution to hospitals.  The estimated duration of this phase is 
one year.   
4.1.1.4 Phase IV* 
(N.B. Phase IV* is going to be denoted with an asterisk because although it is 
technically a continuation of the clinical research, this phase actually takes place after FDA 
approval has been obtained.)  In Phase IV*, one MCCRA device and 25 disposable chips are 
distributed (at no cost) to each of 50 hospitals nation-wide (the hospitals that receive the free 
box and chips are the 50 hospitals with the highest number of angioplasties performed per 
year in the United States.)  By targeting the largest hospitals, our company has a better 
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chance of capturing a large amount of the market.  In addition, the hospitals that receive 
these boxes will do so under the obligation of providing our company with feedback.  By 
analyzing the data of a bigger and broader range of patients, any possible variances that may 
only occur in a small portion of the population may be discovered.  The purpose of Phase 
IV* is to investigate both this possibility, and also as a marketing tool to get the MCCRA 
System into hospitals. 
4.1.2 Manufacturing 
In order to perform the clinical trials, the manufacturing facility must be operating at 
partial capacity in order to produce the needed chips.  In order to determine this capacity, 
the number of MCCRA chips that will be required are tabulated in Table 4-1.   
 NUMBER 
OF 
SUBJECTS 
REQUIRED 
CHIPS 
REQUIRED 
FOR 
TESTING 
EXTRA 
CHIPS 
REQUIRED 
(25%) 
 
TOTAL 
CHIPS 
REQUIRED 
 
 
TIME 
FRAME 
PHASE I 75 150 50 200 1 month 
PHASE II 300 900 300 1,200 5 months 
PHASE III 3,000 12,000 4,000 16,000 12 months 
      
TOTALS 3,380 13,050 4,350 17,400 18 months 
Table 4-1 Number of test subjects and chips required for each phase of the clinical trials, as well as the approximated 
duration of each testing phase.  The chips required for testing are based on the number of chips that are to be used per 
test subject in each phase (Phase I = 2 chips per subject, Phase II = 3 chips per subject, Phase III = 4 chips per subject).  
The extra chips that are factored in are to account for Quality Assurance Testing (1 chip tested per 4 chips produced).   
The total number of chips required (with Quality Assurance Testing factored in) is 
17,400.  The rate of assumed chip failure must also be factored into this total (i.e. assume 
that 1 chip fails due to defect for every 4 chips that are produced, or a 25% failure rate).  
(See Equation 4-1) 
   
𝟏𝟏𝟕𝟕,𝟐𝟐𝟏𝟏𝟏𝟏 𝒂𝒂𝒂𝒂𝒂𝒂−𝒅𝒅𝒂𝒂𝒐𝒐𝒂𝒂𝒄𝒄𝒂𝒂 𝒄𝒄𝒄𝒄𝒂𝒂𝒄𝒄𝒄𝒄
𝟕𝟕𝟓𝟓% 𝒂𝒂𝒐𝒐 𝒄𝒄𝒄𝒄𝒂𝒂𝒄𝒄 𝒄𝒄𝒂𝒂𝒂𝒂𝒅𝒅𝒎𝒎𝒄𝒄𝒂𝒂𝒂𝒂𝒂𝒂𝒂𝒂 = 𝟐𝟐𝟐𝟐,𝟐𝟐𝟏𝟏𝟏𝟏 𝒂𝒂𝒂𝒂𝒂𝒂𝒂𝒂𝒊𝒊 𝒄𝒄𝒄𝒄𝒂𝒂𝒄𝒄𝒄𝒄𝟏𝟏𝟏𝟏𝟏𝟏% 𝒂𝒂𝒐𝒐 𝒄𝒄𝒄𝒄𝒂𝒂𝒄𝒄 𝒄𝒄𝒂𝒂𝒂𝒂𝒅𝒅𝒎𝒎𝒄𝒄𝒂𝒂𝒂𝒂𝒂𝒂𝒂𝒂  (4-1) 
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This means that at least 23,200 chips must be manufactured in order to accommodated those 
needed in the clinical trials.  Assuming that these are all produced in the first year of 
manufacturing (so that production of chips does not hold up the execution of the trials), the 
operation of the facility must be functioning at 4.2% of full operating capacity (See 
Equation 4-2). 
  
𝟐𝟐𝟐𝟐,𝟐𝟐𝟏𝟏𝟏𝟏 𝒄𝒄𝒄𝒄𝒂𝒂𝒄𝒄𝒄𝒄 𝒂𝒂𝒂𝒂𝒂𝒂𝒅𝒅𝒂𝒂𝒅𝒅 𝒄𝒄𝒂𝒂𝒂𝒂 𝒚𝒚𝒂𝒂𝒂𝒂𝒂𝒂
𝟓𝟓𝟓𝟓𝟏𝟏,𝟏𝟏𝟏𝟏𝟏𝟏 𝒄𝒄𝒄𝒄𝒂𝒂𝒄𝒄𝒄𝒄 𝒎𝒎𝒂𝒂𝒅𝒅𝒂𝒂 𝒄𝒄𝒂𝒂𝒂𝒂 𝒚𝒚𝒂𝒂𝒂𝒂𝒂𝒂 𝒂𝒂𝒂𝒂 𝒐𝒐𝒎𝒎𝒊𝒊𝒊𝒊 𝒂𝒂𝒄𝒄 = 𝟐𝟐.𝟐𝟐% 𝒂𝒂𝒐𝒐 𝒐𝒐𝒎𝒎𝒊𝒊𝒊𝒊 𝒂𝒂𝒄𝒄𝒂𝒂𝒂𝒂𝒂𝒂𝒂𝒂𝒂𝒂𝒂𝒂𝒂𝒂 (4-2) 
For ease of calculation, this is approximated at 5% of the manufacturing facility’s full 
operating capacity (or about 200 chips produced per day).  In the next year, during which 
the FDA approval process will still be underway, the facility will continue to operate at 5% 
of full capacity.  This will build up an inventory of MCCRA chips that will be stored and 
used for distribution in the following year, enabling the shipment of chips to the 50 hospitals 
that will receive free equipment right after FDA approval has been obtained, rather than 
needing to delay distribution until fabrication of the chips is completed.   
4.2 Recommendations for Future Studies 
By utilizing the microfluidics technology, we allow ourselves to study one of the most 
promising and intense areas of research.   As new applications of this concept is discovered, 
constant adaptation of our device is essential to keep pace with our competitors. 
One of the advantages of our device is its expandability to other areas of applications 
by simple modifications.  For example, MRS 2395 could simply be replaced with its aspirin 
counterpart (another anti-coagulant), so patients’ resistance to aspirin can also be measured.   
Of course, mixing behavior of aspirin is to be characterized and the dissolution of it should 
be studied; the box is being re-customized. 
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Clopidogrel’s usage has a potential to grow as its benefits are becoming known to the 
rest of the world.  Marketed in 110 countries, clopidogrel sales is currently ranked 2nd 
worldwide and exhibiting a growth rate of 20%, fueling for demand for clopidogrel 
resistance assay soon enough.  Although the US is our major target market at this stage, we 
should tailor a financial strategy to capture our share of the international market in a timely 
fashion.  
In this design report, the box manufacture is out sourced to an electronic supplier, 
who makes a 30% profit by the synergy from sales of our chips.  Rather than relying on an 
out source supplier, we can set up a box manufacturing division in our own site, which 
would facilitate the constant research and development aided improvements on our 
technology.  
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Part 7  Appendix 
7.1 MSDS Reports 
7.1.1 PDMS 
Material Safety Data Sheet 
Poly(dimethylsiloxane) 
ACC# 95130  
Section 1 - Chemical Product and Company Identification 
MSDS Name: Poly(dimethylsiloxane)  
Catalog Numbers: AC178440000, AC178442500, AC178445000  
Synonyms: Simethicone; Dimethicone.  
Company Identification: 
              Acros Organics N.V. 
              One Reagent Lane 
              Fair Lawn, NJ 07410 
For information in North America, call: 800-ACROS-01 
For emergencies in the US, call CHEMTREC: 800-424-9300 
Section 2 - Composition, Information on Ingredients  
 
CAS# Chemical Name Percent EINECS/ELINCS 
9016-00-6 Poly(dimethylsiloxane) 100  unlisted  
 
Section 3 - Hazards Identification  
 
EMERGENCY OVERVIEW 
Appearance: clear liquid. 
Caution! May cause eye, skin, and respiratory tract irritation. The toxicological properties 
of this material have not been fully investigated.  
Target Organs: None known.  
 
 
Potential Health Effects  
Eye: May cause eye irritation.  
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Skin: May cause skin irritation. May be harmful if absorbed through the skin.  
Ingestion: May cause irritation of the digestive tract. May be harmful if swallowed.  
Inhalation: May cause respiratory tract irritation. May be harmful if inhaled.  
Chronic: Adverse reproductive effects have been reported in animals. Animal studies have 
reported the development of tumors.  
Section 4 - First Aid Measures  
 
 
Eyes: Immediately flush eyes with plenty of water for at least 15 minutes, occasionally 
lifting the upper and lower eyelids. If irritation develo ps, get medical aid.  
Skin: Immediately flush skin with plenty of water for at least 15 minutes while removing 
contaminated clothing and shoes. Get medical aid if irritation develops or persists.  
Ingestion: Do not induce vomiting. Get medical aid if irritation or symptoms occur.  
Inhalation: Remove from exposure and move to fresh air immediately. If not breathing, 
give artificial respiration. If breathing is difficult, give oxygen. Get medical aid if cough or 
other symptoms appear.  
Notes to Physician: Treat symptomatically and supportively.  
Section 5 - Fire Fighting Measures  
 
 
General Information: As in any fire, wear a self-contained breathing apparatus in 
pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.  
Extinguishing Media: Use water spray, dry chemical, carbon dioxide, or appropriate foam.  
Flash Point: > 100 deg C (> 212.00 deg F)  
Autoignition Temperature: Not applicable.  
Explosion Limits, Lower:Not available.  
Upper: Not available.  
NFPA Rating: (estimated) Health: 1; Flammability: 1; Instability: 0  
Section 6 - Accidental Release Measures  
 
 
General Information: Use proper personal protective equipment as indicated in Section 8.  
Spills/Leaks: Absorb spill with inert material (e.g. vermiculite, sand or earth), then place 
in suitable container. Provide ventilation. Do not let this chemical enter the environment.  
Section 7 - Handling and Storage  
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Handling: Use with adequate ventilation. Avoid contact with eyes, skin, and clothing. Avoid 
ingestion and inhalation.  
Storage: Store in a cool, dry place. Store in a tightly closed container.  
Section 8 - Exposure Controls, Personal Protection  
 
 
Engineering Controls: Facilities storing or utilizing this material should be equipped with 
an eyewash facility and a safety shower. Use adequate ventilation to keep airborne 
concentrations low.  
Exposure Limits  
Chemical Name ACGIH NIOSH OSHA - Final PELs 
Poly(dimethylsiloxane)  none listed  none listed  none listed  
 
OSHA Vacated PELs: Poly(dimethylsiloxane): No OSHA Vacated PELs are listed for this 
chemical.  
Personal Protective Equipment  
Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by 
OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard 
EN166.  
Skin: Wear appropriate protective gloves to prevent skin exposure.  
Clothing: Wear appropriate protective clothing to prevent skin exposure.  
Respirators: A respiratory protection program that meets OSHA's 29 CFR 1910.134 and 
ANSI Z88.2 requirements or European Standard EN 149 must be followed whenever 
workplace conditions warrant respirator use.  
Section 9 - Physical and Chemical Properties  
 
 
Physical State: Liquid  
Appearance: clear  
Odor: odorless  
pH: Not available.  
Vapor Pressure: Not available.  
Vapor Density: Not available.  
Evaporation Rate:Not available.  
Viscosity: 100 cSt @ 25 deg C  
Boiling Point: > 65 deg C @ 760 mmHg  
Freezing/Melting Point:Not available.  
Decomposition Temperature:Not available.  
Solubility: Insoluble.  
Specific Gravity/Density:0.965  
Molecular Formula:Not available.  
Molecular Weight:Not available.  
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Section 10 - Stability and Reactivity  
 
 
Chemical Stability: Stable under normal temperatures and pressures.  
Conditions to Avoid: Incompatible materials, excess heat.  
Incompatibilities with Other Materials: Strong oxidizing agents, strong acids, strong 
bases.  
Hazardous Decomposition Products: Carbon monoxide, carbon dioxide, silicon dioxide.  
Hazardous Polymerization: Will not occur.  
Section 11 - Toxicological Information  
 
 
RTECS#:       
CAS# 9016-00-6: TQ2690000  
LD50/LC50: 
Not available. 
 
Carcinogenicity: 
CAS# 9016-00-6: Not listed by ACGIH, IARC, NTP, or CA Prop 65. 
 
Epidemiology: Tumorigenic effects have been reported in experimental animals.  
Teratogenicity: No information found  
Reproductive Effects: Adverse reproductive effects have occurred in experimental animals.  
Mutagenicity: No information found  
Neurotoxicity: No information found  
Other Studies:  
Section 12 - Ecological Information  
 
 
Ecotoxicity: Fish: Rainbow trout: LC50 > 10000 mg/L; 96 Hr; UnspecifiedFish: 
Bluegill/Sunfish: LC50 > 10000 mg/L; 96 Hr; Static bioassay Based on the Koc values, this 
substance will be immobile in soil and is expected to adsorb to particulates and organic 
matter in the water column. Rapid and extensive degradation is expected on dry surface 
soils. Some microbial degradation of small compounds is likely. High molecular weight 
poly(dimethylsiloxane) may bioconcentrate in aquatic organisms.  
Environmental: Poly(dimethylsiloxane) with lower molecular weights exist in the 
atmosphere in the vapor and particulate phases. Those with higher molecular weights exist 
solely in the particulate phase. Particulate phase poly(dimethylsiloxane) will be removed 
from the atmosphere by dry deposition while vapor phase poly(dimethylsiloxane) will be 
degraded by the reaction with photochemically-produced hydroxyl radicals with a half-life of 
32 hours.  
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Physical: No information available.  
Other: Do not empty into drains.  
Section 13 - Disposal Considerations  
 
Chemical waste generators must determine whether a discarded chemical is classified as a 
hazardous waste. US EPA guidelines for the classification determination are listed in 40 CFR 
Parts 261.3. Additionally, waste generators must consult state and local hazardous waste 
regulations to ensure complete and accurate classification.  
RCRA P-Series: None listed.  
RCRA U-Series: None listed.  
Section 14 - Transport Information  
 
 US DOT Canada TDG 
Shipping Name: Not regulated. Not regulated. 
Hazard Class:   
UN Number:   
Packing Group:   
 
Section 15 - Regulatory Information  
 
US FEDERAL 
 
TSCA  
     CAS# 9016-00-6 is not listed on the TSCA inventory. It is for research and development 
use only.  
Health & Safety Reporting List 
     None of the chemicals are on the Health & Safety Reporting List.  
Chemical Test Rules 
     None of the chemicals in this product are under a Chemical Test Rule.  
Section 12b 
     None of the chemicals are listed under TSCA Section 12b.  
TSCA Significant New Use Rule 
     None of the chemicals in this material have a SNUR under TSCA.  
CERCLA Hazardous Substances and corresponding RQs 
     None of the chemicals in this material have an RQ.  
SARA Section 302 Extremely Hazardous Substances 
     None of the chemicals in this product have a TPQ.  
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Section 313      No chemicals are reportable under Section 313.  
Clean Air Act: 
     This material does not contain any hazardous air pollutants.  
     This material does not contain any Class 1 Ozone depletors.  
     This material does not contain any Class 2 Ozone depletors.  
Clean Water Act: 
     None of the chemicals in this product are listed as Hazardous Substances under the CWA.  
     None of the chemicals in this product are listed as Priority Pollutants under the CWA.  
     None of the chemicals in this product are listed as Toxic Pollutants under the CWA.  
OSHA: 
     None of the chemicals in this product are considered highly hazardous by OSHA.  
STATE 
     CAS# 9016-00-6 is not present on state lists from CA, PA, MN, MA, FL, or NJ.  
 
California Prop 65 
 
California No Significant Risk Level: None of the chemicals in this product are listed.  
 
European/International Regulations 
European Labeling in Accordance with EC Directives 
Hazard Symbols: 
      Not available.  
Risk Phrases: 
 
Safety Phrases: 
     S 24/25 Avoid contact with skin and eyes.  
 
WGK (Water Danger/Protection) 
     CAS# 9016-00-6: No information available.  
Canada - DSL/NDSL 
     CAS# 9016-00-6 is listed on Canada's DSL List.  
Canada - WHMIS 
     This product has a WHMIS classification of D2B.  
This product has been classified in accordance with the hazard criteria of the Controlled 
Products Regulations and the MSDS contains all of the information required by those 
regulations.  
Canadian Ingredient Disclosure List 
Section 16 - Additional Information  
 
MSDS Creation Date: 5/14/1999  
Revision #4 Date: 1/11/2008  
 
The information above is believed to be accurate and represents the best information currently available to us. However, 
we make no warranty of merchantability or any other warranty, express or implied, with respect to such information, and 
we assume no liability resulting from its use. Users should make their own investigations to determine the suitability of the 
information for their particular purposes. In no event shall Fisher be liable for any claims, losses, or damages of any third 
party or for lost profits or any special, indirect, incidental, consequential or exemplary damages, howsoever arising, even if 
Fisher has been advised of the possibility of such damages. 
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7.1.2 MRS 2395 
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7.1.3 Collagen 
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7.1.4 ADP 
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7.1.5 Isopropanol 
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7.1.6 Acetone 
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7.2 Reagent Volume 
Although we have calculated the surface concentrations of MRS 2395 required to reach the 
targeted concentrations in the 4 streams (table x), the process of reagent deposition in liquid form 
and drying creates uncertainties in how much reagents are actually left in anhydrous form on the 
micro-channel.  Before we conduct experimentation to study this process, the amount of MRS 
2395 deposition is estimated to be 10 times the required amount in the flowing streams in this 
report.   The computation is performed on 1X IC50 of MRS 2395 as an example.   The results are 
tabulated in table x. 
Known: 
Targeted MRS concentration:  IC50=3.6uM 
Total Volume of Blood:  360 uL 
Molecular Weight of MRS 2395: 440 g/mol 
Find:  
10 times the mass (mg) in this blood volume with the specified concentration. 
Answer: 
𝐵𝐵𝑓𝑓𝑠𝑠𝑠𝑠 𝑓𝑓𝑒𝑒 𝐵𝐵𝑅𝑅𝑃𝑃1×𝐼𝐼𝐶𝐶50 = 10 × 3.6𝑢𝑢𝐵𝐵 × 360𝑢𝑢𝐿𝐿 × 440𝑔𝑔/𝑚𝑚𝑓𝑓𝑙𝑙 = 0.0057𝑚𝑚𝑔𝑔 
Target concentration Amount deposited (mg) 
0XIC50, or 0 um 0 
0.1XIC50, or 0.36 uM 0.00057 
1XIC50, or 3.6 uM 0.0057 
10XIC50, or 36 uM 0.057 
The total mass of MRS 2395 deposition is the sum of MRS 2395 in 8 streams: 
𝑃𝑃𝑓𝑓𝐷𝐷𝑓𝑓𝑙𝑙 𝐵𝐵𝑓𝑓𝑠𝑠𝑠𝑠𝐵𝐵𝑅𝑅𝑃𝑃2395 = 0.00057 × 2 + 0.0057 × 2 + 0.057 × 2 = 0.127mg 
The diffusivity of ADP in water can be reasonably approximated as that of MRS 2395.  Since 
both ADP and MRS 2395 target P2Y12, ADP EC50 concentration can be inferred as in the same 
order of magnitude as MRS 2395 IC50.  The same amount of 1XIC50 ADP is deposited on the 
channel, so the total mass of ADP is: 0.0057𝑚𝑚𝑔𝑔 × 8 = 0.0456𝑚𝑚𝑔𝑔 
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7.3 Channel Bifurcation Calculations 
The desired width of the final eight channels is 250 µm.  The height for all of the channels is 60 
µm.  With this desired width in mind, the effective diameter (𝑑𝑑𝑒𝑒𝑒𝑒𝑒𝑒 ) of the channel was calculated 
width the equation below: 
𝑑𝑑𝑒𝑒𝑒𝑒𝑒𝑒 = 2 ∗ �𝑤𝑤∗ℎ𝜋𝜋      (1) 
  with w = width of the channel and h = height of the channel. 
Once the effective diameter is known, the length of the channel can be calculated using Equation 
2: 
𝑙𝑙 = 5 ∗ 𝑑𝑑𝑒𝑒𝑒𝑒𝑒𝑒        (2) 
Working backwards using Murray’s Law, the effective diameter of the parent channel is 
calculated from the effective diameter of the daughter channel. 
𝑟𝑟𝑝𝑝
3 = 𝑟𝑟𝑑𝑑13 + 𝑟𝑟𝑑𝑑23 + ⋯+ 𝑟𝑟𝑑𝑑𝑛𝑛3 = 2 ∗ 𝑟𝑟𝑑𝑑3  (3) 
Since both daughter channels have the same width, the equation can be simplified to: 
𝑟𝑟𝑝𝑝 = 1.26 ∗ 𝑟𝑟𝑑𝑑      (4) 
After the effective diameter for the channel is calculated, the following equation is used to 
calculate the width of the parent channel. 
𝑤𝑤 = 𝜋𝜋 ∗ �𝑑𝑑𝑒𝑒𝑒𝑒𝑒𝑒2 �2
ℎ
     (5) 
After these calculations have been performed, this parent channel now becomes the daughter 
channel for the next set of calculations and the previous steps are repeated until the first single 
channel is reached.  The calculations were performed in Microsoft Excel and the table below 
shows the results, 
 
Channel Width (µm)
Height 
(µm)
Effective 
Diameter (µm)
Entry Length 
(µm)
Entry Length 
(mm)
Final 8 Channels 250 60 138 691 => 0.691
4 Channels After 2nd Split 397 60 174 871 => 0.871
2 Channels After 1st Split 630 60 219 1097 => 1.097
1st Channel 1000 60 276 1382 => 1.382
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7.4 Dissolution of ADP and MRS 2395 
 
 
 
 
 
. 
 
 
𝑉𝑉 = 0.01 𝑚𝑚 × 60 × 10−6𝑚𝑚 × 250 × 10−6𝑚𝑚 = 1.5 × 10−10𝑚𝑚3/𝑠𝑠 
Substituting all the physical constants: 
𝑪𝑪𝑨𝑨𝑫𝑫𝑨𝑨,𝒄𝒄 =
⎝
⎜
⎛ 𝟏𝟏.𝟓𝟓𝟏𝟏𝟔𝟔?̇?𝑽
�𝒎𝒎𝒎𝒎𝒗𝒗 �
𝝁𝝁
𝝆𝝆𝑫𝑫𝑨𝑨𝑨𝑨
�
𝟏𝟏
𝟐𝟐 𝑫𝑫𝑨𝑨𝑨𝑨𝑾𝑾
⎠
⎟
⎞
𝑪𝑪𝑨𝑨𝑫𝑫𝑨𝑨 = 𝟐𝟐𝟐𝟐𝟔𝟔 𝒎𝒎𝑩𝑩 
All other 2 surface concentrations of ADP associated with the 2 specified ADP in-stream 
concentrations are computed by substituting CADP
Physical Constant 
 with 0.36 uM and 36 uM. 
  
Value @ 37 o
𝛍𝛍 
C 
7*10-4
𝛒𝛒 
 Pa s 
992.2 kg/m
D
3 
~10AB -9 m2
C
/s  
3.6 uM ADP, required 
x (patch length) 150 um 
u (velocity) 1 cm/s 
W (width chan.) 250 um 
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7.5 Runtime Calculations for Whole Blood Volume 
Based on the widths and shear rates of the channels which model the flow of whole blood in the 
body, the flow rate calculated was 1 cm/s.  Using this flow rate, the volumetric flow rate is 
calculated below for one channel. 
�1 𝑓𝑓𝑚𝑚
𝑠𝑠
� (. 025 𝑓𝑓𝑚𝑚)(. 006 𝑓𝑓𝑚𝑚) = .00015 𝑓𝑓𝑚𝑚3
𝑠𝑠
= �1.5 ∗ 10−10  𝑚𝑚3
𝑠𝑠
� �
1,000,000,000 𝜇𝜇𝐿𝐿
𝑚𝑚3 �=  .15 𝜇𝜇𝐿𝐿
𝑠𝑠
 
  where velocity = 1 𝑓𝑓𝑚𝑚
𝑠𝑠
, width = .025 cm, and height = .006 cm. 
The total volumetric flow rate for eight channels is then 
�. 15 𝜇𝜇𝐿𝐿
𝑠𝑠
� (8 𝑓𝑓ℎ𝑓𝑓𝑛𝑛𝑛𝑛𝑒𝑒𝑙𝑙𝑠𝑠) = 1.2 𝜇𝜇𝐿𝐿
𝑠𝑠
  
The amount of whole blood needed for all eight channels to flow for one minute is calculated 
below. 
�1.2 𝜇𝜇𝐿𝐿
𝑠𝑠
� �
60 𝑠𝑠
𝑚𝑚𝑚𝑚𝑛𝑛
�  = 72 𝜇𝜇𝐿𝐿
𝑚𝑚𝑚𝑚𝑛𝑛
 
If the channels run for 5 minutes, 
�72 𝜇𝜇𝐿𝐿
𝑚𝑚𝑚𝑚𝑛𝑛
� (5 𝑚𝑚𝑚𝑚𝑛𝑛) = 360 𝜇𝜇𝐿𝐿  
Extra blood is needed to verify that the collagen strip is kept covered with blood so the results 
are free of experimental error.  It is assumed that an extra 20 seconds of blood per channel would 
be sufficient. (20 𝑠𝑠) �1.2 𝜇𝜇𝐿𝐿
𝑠𝑠
� (8 𝑓𝑓ℎ𝑓𝑓𝑛𝑛𝑛𝑛𝑒𝑒𝑙𝑙𝑠𝑠) = (192 𝜇𝜇𝐿𝐿)  
Therefore the total amount of blood being used is 192 𝜇𝜇𝐿𝐿 + 360 𝜇𝜇𝐿𝐿 = 552 𝜇𝜇𝐿𝐿 
The waste reservoir volume has ample amount of room for this volume of blood.  The volume of 
the waste reservoir is calculated below. (. 25 𝑓𝑓𝑚𝑚)(3 𝑓𝑓𝑚𝑚)(2 𝑓𝑓𝑚𝑚) = (1.5 𝑓𝑓𝑚𝑚3) �1,000 𝜇𝜇𝐿𝐿
𝑓𝑓𝑚𝑚3 � = 1,500 𝜇𝜇𝐿𝐿 
where height = .25 cm, width = 3cm, and length = 2 cm. 
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7.6 Image J Analysis 
7.6.1 5µM MRS 2395 
 
 High Low B High Low Clot C-B (C-B)/B 
Time 
(sec) 
0001 1345 1330 1337.5 1586 1566 1576 238.5 0.178318 5 
0002 1346 1328 1337 1562 1541 1551.5 214.5 0.160434 10 
0003 1353 1338 1345.5 1623 1604 1613.5 268 0.199182 15 
0004 1344 1331 1337.5 1589 1571 1580 242.5 0.181308 20 
0005 1351 1314 1332.5 1613 1560 1586.5 254 0.190619 25 
0006 1343 1308 1325.5 1599 1546 1572.5 247 0.186345 30 
0007 1340 1305 1322.5 1576 1521 1548.5 226 0.170888 35 
0008 1349 1248 1298.5 1580 1468 1524 225.5 0.173662 40 
0009 1348 1292 1320 1634 1528 1581 261 0.197727 45 
0010 1350 1260 1305 1623 1543 1583 278 0.213027 50 
0011 1343 1270 1306.5 1636 1523 1579.5 273 0.208955 55 
0012 1359 1247 1303 1601 1525 1563 260 0.19954 60 
0013 1348 1280 1314 1622 1518 1570 256 0.194825 65 
0014 1348 1289 1318.5 1622 1512 1567 248.5 0.188472 70 
0015 1350 1268 1309 1617 1498 1557.5 248.5 0.18984 75 
0016 1350 1258 1304 1641 1506 1573.5 269.5 0.206672 80 
0017 1348 1253 1300.5 1654 1540 1597 296.5 0.227989 85 
0018 1344 1227 1285.5 1620 1486 1553 267.5 0.20809 90 
0019 1350 1217 1283.5 1645 1527 1586 302.5 0.235684 95 
0020 1344 1223 1283.5 1629 1486 1557.5 274 0.213479 100 
0021 1341 1200 1270.5 1622 1469 1545.5 275 0.21645 105 
0022 1341 1251 1296 1598 1500 1549 253 0.195216 110 
0023 1309 1216 1262.5 1571 1430 1500.5 238 0.188515 115 
0024 1299 1205 1252 1590 1440 1515 263 0.210064 120 
0025 1284 1207 1245.5 1589 1467 1528 282.5 0.226817 125 
0026 1325 1230 1277.5 1620 1502 1561 283.5 0.221918 130 
0027 2269 2249 2259 2755 2684 2719.5 460.5 0.203851 135 
0028 2221 2142 2181.5 2663 2598 2630.5 449 0.205822 140 
0029 Contaminated             
 0030 1339 1317 1328 1671 1533 1602 274 0.206325 150 
0031 1359 1327 1343 1674 1582 1628 285 0.212211 155 
0032 1356 1330 1343 1657 1581 1619 276 0.20551 160 
0033 1370 1348 1359 1704 1598 1651 292 0.214864 165 
0034 1361 1328 1344.5 1664 1540 1602 257.5 0.191521 170 
0035 1357 1321 1339 1671 1574 1622.5 283.5 0.211725 175 
0036 1359 1323 1341 1678 1584 1631 290 0.216257 180 
0037 1346 1310 1328 1702 1615 1658.5 330.5 0.24887 185 
0038 1323 1286 1304.5 1670 1591 1630.5 326 0.249904 190 
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0039 1338 1301 1319.5 1710 1604 1657 337.5 0.255779 195 
0040 1345 1301 1323 1705 1609 1657 334 0.252457 200 
0041 1347 1318 1332.5 1703 1620 1661.5 329 0.246904 205 
0042 1347 1310 1328.5 1708 1636 1672 343.5 0.258562 210 
0043 1355 1297 1326 1730 1650 1690 364 0.27451 215 
0044 1355 1317 1336 1707 1588 1647.5 311.5 0.233159 220 
0045 1333 1287 1310 1729 1592 1647.5 337.5 0.257634 225 
0046 1334 1297 1315.5 1673 1608 1640.5 325 0.247054 230 
0047 1333 1295 1314 1689 1609 1649 335 0.254947 235 
0048 1329 1292 1310.5 1698 1607 1652.5 342 0.260969 240 
0049 1322 1287 1304.5 1655 1597 1626 321.5 0.246455 245 
0050 1332 1301 1316.5 1737 1655 1696 379.5 0.288264 250 
0051 1329 1293 1311 1675 1637 1656 345 0.263158 255 
0052 1331 1298 1314.5 1666 1588 1627 312.5 0.237733 260 
0053 1318 1275 1296.5 1685 1609 1647 350.5 0.270343 265 
0054 1312 1275 1293.5 1678 1605 1641.5 348 0.269037 270 
0055 1316 1269 1292.5 1687 1603 1645 352.5 0.272727 275 
0056 1290 1263 1276.5 1669 1597 1633 356.5 0.279279 280 
0057 1304 1271 1287.5 1668 1609 1638.5 351 0.272621 285 
0058 1287 1259 1273 1646 1573 1609.5 336.5 0.264336 290 
0059 1292 1248 1270 1649 1584 1616.5 346.5 0.272835 295 
0060 1276 1254 1265 1657 1542 1599.5 334.5 0.264427 300 
 
7.6.2 10 µM MRS 2395 
 
High Low B High Low Clot C-B (C-B)/B 
Time 
(sec) 
0001 1756 1707 1731.5 1856 1796 1826 94.5 0.054577 5 
0002 1754 1710 1732 1839 1783 1811 79 0.045612 10 
0003 1753 1716 1734.5 1832 1796 1814 79.5 0.0458345 15 
0004 1760 1709 1734.5 1853 1769 1811 76.5 0.0441049 20 
0005 1749 1710 1729.5 1828 1778 1803 73.5 0.0424978 25 
0006 1749 1700 1724.5 1829 1776 1802.5 78 0.0452305 30 
0007 1721 1647 1684 1821 1743 1782 98 0.0581948 35 
0008 1718 1676 1697 1797 1759 1778 81 0.0477313 40 
0009 1716 1669 1692.5 1810 1750 1780 87.5 0.0516987 45 
0010 1705 1650 1677.5 1801 1742 1771.5 94 0.0560358 50 
0011 1719 1636 1677.5 1807 1718 1762.5 85 0.0506706 55 
0012 1704 1638 1671 1793 1719 1756 85 0.0508677 60 
0013 1727 1633 1680 1807 1724 1765.5 85.5 0.0508929 65 
0014 1722 1632 1677 1821 1723 1772 95 0.0566488 70 
0015 1720 1666 1693 1818 1730 1774 81 0.0478441 75 
0016 1745 1670 1707.5 1834 1780 1807 99.5 0.0582723 80 
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0017 1727 1678 1702.5 1853 1779 1816 113.5 0.0666667 85 
0018 1731 1684 1707.5 1840 1776 1808 100.5 0.058858 90 
0019 1731 1666 1698.5 1862 1764 1813 114.5 0.0674124 95 
0020 1764 1708 1736 1914 1829 1871.5 135.5 0.078053 100 
0021 1790 1743 1766.5 1934 1841 1887.5 121 0.068497 105 
0022 1788 1728 1758 1933 1842 1887.5 129.5 0.0736633 110 
0023 1795 1672 1733.5 1954 1827 1890.5 157 0.0905682 115 
0024 1788 1733 1760.5 1959 1853 1906 145.5 0.082647 120 
0025 1797 1716 1756.5 1972 1872 1922 165.5 0.0942215 125 
0026 1794 1755 1774.5 1961 1851 1906 131.5 0.0741054 130 
0027 1805 1759 1782 1984 1903 1943.5 161.5 0.0906285 135 
0028 1794 1715 1754.5 1973 1882 1927.5 173 0.0986036 140 
0029 1796 1753 1774.5 1961 1889 1925 150.5 0.0848126 145 
0030 1809 1753 1781 1988 1891 1939.5 158.5 0.0889949 150 
0031 1808 1739 1773.5 1976 1876 1926 152.5 0.0859882 155 
0032 1783 1753 1768 1966 1908 1937 169 0.0955882 160 
0033 1798 1735 1766.5 1966 1903 1934.5 168 0.0951033 165 
0034 1791 1690 1740.5 1987 1872 1929.5 189 0.1085895 170 
0035 1787 1732 1759.5 1966 1877 1921.5 162 0.0920716 175 
0036 1798 1751 1774.5 1968 1905 1936.5 162 0.0912933 180 
0037 1782 1715 1748.5 1964 1817 1890.5 142 0.0812125 185 
0038 1789 1740 1764.5 1976 1869 1922.5 158 0.0895438 190 
0039 1800 1699 1749.5 1964 1907 1935.5 186 0.1063161 195 
0040 1791 1703 1747 1976 1848 1912 165 0.0944476 200 
0041 1791 1743 1767 1970 1905 1937.5 170.5 0.0964912 205 
0042 1791 1753 1772 1958 1898 1928 156 0.0880361 210 
0043 1775 1689 1732 1950 1888 1919 187 0.1079677 215 
0044 1797 1742 1769.5 1966 1862 1914 144.5 0.0816615 220 
0045 1788 1711 1749.5 1954 1887 1920.5 171 0.0977422 225 
0046 1778 1655 1716.5 1953 1878 1873 156.5 0.0911739 230 
0047 1784 1660 1722 1960 1882 1921 199 0.1155633 235 
0048 1774 1657 1715.5 1948 1853 1900.5 185 0.1078403 240 
0049 1777 1728 1752.5 1964 1882 1923 170.5 0.0972896 245 
0050 1774 1711 1742.5 1952 1821 1886.5 144 0.0826399 250 
0051 1764 1707 1735.5 1946 1879 1912.5 177 0.1019879 255 
0052 1766 1712 1739 1943 1859 1901 162 0.093157 260 
0053 1779 1664 1721.5 1960 1787 1873.5 152 0.0882951 265 
0054 1760 1592 1676 1952 1848 1900 224 0.1336516 270 
0055 1767 1667 1717 1952 1869 1910.5 193.5 0.1126966 275 
0056 1767 1652 1709.5 1955 1892 1923.5 214 0.1251828 280 
0057 1748 1697 1722.5 1946 1869 1907.5 185 0.107402 285 
0058 1778 1651 1714.5 1962 1904 1933 218.5 0.1274424 290 
0059 1756 1678 1717 1959 1892 1925.5 208.5 0.1214327 295 
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0060 1769 1704 1736.5 1962 1870 1916 179.5 0.1033688 300 
 
7.6.3 50 µM MRS 2395 
 
High Low B High Low Clot C-B (C-B)/B 
Time 
(sec) 
0001 1824 1768 1796 1936 1842 1889 93 0.051782 5 
0002 1821 1772 1796.5 1932 1875 1903.5 107 0.05956 10 
0003 1816 1789 1802.5 1909 1888 1898.5 96 0.053259 15 
0004 1759 1737 1748 1883 1846 1864.5 116.5 0.066648 20 
0005 1772 1731 1751.5 1914 1796 1852 100.5 0.057379 25 
0006 1779 1740 1759.5 1901 1831 1866 106.5 0.060529 30 
0007 1788 1757 1772.5 1897 1808 1852.5 80 0.045134 35 
0008 1807 1766 1786.5 1906 1851 1878.5 92 0.051497 40 
0009 1810 1753 1781.5 1914 1819 1866.5 85 0.047713 45 
0010 1796 1770 1783 1918 1816 1867 84 0.047112 50 
0011 1814 1768 1791 1917 1820 1868.5 77.5 0.043272 55 
0012 1807 1766 1786.5 1911 1842 1876.5 90 0.050378 60 
0013 1799 1767 1783 1910 1869 1889.5 106.5 0.059731 65 
0014 1789 1752 1770.5 1899 1857 1878 107.5 0.060717 70 
0015 1786 1741 1763.5 1895 1854 1874.5 111 0.062943 75 
0016 1775 1730 1752.5 1889 1852 1870.5 118 0.067332 80 
0017 1786 1730 1758 1879 1823 1851 93 0.052901 85 
0018 1782 1725 1753.5 1878 1840 1859 105.5 0.060165 90 
0019 1760 1720 1740 1873 1840 1856.5 116.5 0.066954 95 
0020 1765 1716 1740.5 1872 1750 1811 70.5 0.040506 100 
0021 1747 1705 1726 1863 1762 1812.5 86.5 0.050116 105 
0022 1752 1710 1731 1856 1809 1832.5 101.5 0.058637 110 
0023 1753 1696 1724.5 1846 1808 1827 102.5 0.059438 115 
0024 1774 1742 1758 1851 1797 1824 66 0.037543 120 
0025 1749 1688 1718.5 1871 1802 1836.5 118 0.068665 125 
0026 1762 1691 1726.5 1859 1709 1784 57.5 0.033304 130 
0027 1763 1628 1695.5 1828 1717 1772.5 77 0.045414 135 
0028 1775 1697 1736 1849 1785 1817 81 0.046659 140 
0029 1748 1694 1721 1876 1714 1795 74 0.042998 145 
0030 1746 1689 1717.5 1860 1799 1829.5 112 0.065211 150 
0031 1781 1686 1733.5 1878 1815 1846.5 113 0.065186 155 
0032 1759 1681 1720 1840 1749 1794.5 74.5 0.043314 160 
0033 1767 1712 1739.5 1845 1767 1806 66.5 0.038229 165 
0034 1762 1689 1725.5 1873 1801 1837 111.5 0.064619 170 
0035 1729 1674 1701.5 1842 1800 1821 119.5 0.070232 175 
0036 1757 1691 1724 1862 1801 1831.5 107.5 0.062355 180 
0037 1762 1685 1723.5 1841 1806 1823.5 100 0.058021 185 
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0038 1764 1675 1719.5 1874 1802 1838 118.5 0.068915 190 
0039 1747 1650 1698.5 1871 1812 1841.5 143 0.084192 195 
0040 1751 1678 1714.5 1892 1791 1841.5 127 0.074074 200 
0041 1756 1656 1706 1873 1780 1826.5 120.5 0.070633 205 
0042 1736 1668 1702 1855 1780 1817.5 115.5 0.067861 210 
0043 1738 1638 1688 1872 1769 1820.5 132.5 0.078495 215 
0044 1744 1667 1705.5 1875 1735 1805 99.5 0.058341 220 
0045 1741 1699 1720 1875 1840 1857.5 137.5 0.079942 225 
0046 1746 1646 1696 1881 1825 1853 157 0.092571 230 
0047 1764 1723 1743.5 1885 1837 1861 117.5 0.067393 235 
0048 1734 1700 1717 1871 1830 1850.5 133.5 0.077752 240 
0049 1745 1692 1718.5 1888 1806 1847 128.5 0.074775 245 
0050 1755 1708 1731.5 1898 1842 1870 138.5 0.079988 250 
0051 1725 1674 1699.5 1898 1828 1863 163.5 0.096205 255 
0052 1729 1680 1704.5 1894 1821 1857.5 153 0.089762 260 
0053 1724 1685 1704.5 1898 1832 1865 160.5 0.094163 265 
0054 1734 1656 1695 1903 1827 1865 170 0.100295 270 
0055 1732 1653 1692.5 1936 1801 1868.5 176 0.103988 275 
0056 1727 1668 1697.5 1929 1835 1882 184.5 0.108689 280 
0057 1735 1668 1701.5 1954 1830 1892 190.5 0.11196 285 
0058 1727 1669 1698 1952 1827 1889.5 191.5 0.11278 290 
0059 1729 1686 1707.5 1962 1839 1900.5 193 0.113031 295 
0060 1727 1682 1704.5 1971 1850 1910.5 206 0.120857 300 
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7.7 Equipment Sizing 
7.7.1 Oven 
Daily Chip Output (DCO) at 100% production capacity: 
𝐴𝐴𝐶𝐶𝐷𝐷 = 500,000 𝐶𝐶ℎ𝑚𝑚𝑝𝑝𝑠𝑠250 𝑑𝑑𝑓𝑓𝑓𝑓𝑠𝑠 𝑓𝑓𝑒𝑒 𝑓𝑓𝑝𝑝𝑒𝑒𝑟𝑟𝑓𝑓𝐷𝐷𝑚𝑚𝑓𝑓𝑛𝑛 = 2000 𝐶𝐶ℎ𝑚𝑚𝑝𝑝𝑠𝑠𝑑𝑑𝑓𝑓𝑓𝑓  
There are 2 shifts, morning shift and afternoon shift, per day.  
𝐶𝐶ℎ𝑚𝑚𝑝𝑝 𝑝𝑝𝑒𝑒𝑟𝑟 𝑠𝑠ℎ𝑚𝑚𝑒𝑒𝐷𝐷 = 2000 𝐶𝐶ℎ𝑚𝑚𝑝𝑝𝑠𝑠2 𝑠𝑠ℎ𝑚𝑚𝑒𝑒𝐷𝐷𝑠𝑠 = 1000 𝐶𝐶ℎ𝑚𝑚𝑝𝑝𝑠𝑠 
With the chip surface dimension of 4 cm by 6 cm, the theoretical minimum space is: 
𝐴𝐴𝑚𝑚𝑚𝑚𝑛𝑛 = 1000 × 4 𝑓𝑓𝑚𝑚 × 6𝑓𝑓𝑚𝑚 = 2.4 𝑚𝑚2 
Considering the fact that there are gaps between individual chips on manifold, we multiple a 
factor of 1.5 to obtain the actual space required from an oven. 
𝐴𝐴𝑓𝑓𝑓𝑓𝐷𝐷 = 2.4 𝑚𝑚2 × 1.5 = 3.6 𝑚𝑚2 ≈ 6.2 𝑒𝑒𝐷𝐷 × 6.2 𝑒𝑒𝐷𝐷 
As shown above, this is equivalent to 6.2 ft by 6.2 capacity oven.  If two manifolds were to be 
stacked upon one another before being inserted into the oven, the space required is halved.   
7.7.2 Stirred Tank 
The volume of PDMS per batch is about 10 L and a factor of 1.5 is multiplied to leave extra 
space to buffer again overflow: 
𝑉𝑉 = 10 𝐿𝐿 × 1.5 = 15 𝐿𝐿 
7.7.3 Storage 
Monthly Chip Output (MCO) is computed as: 
𝐵𝐵𝐶𝐶𝐷𝐷 = 500,000 𝐶𝐶ℎ𝑚𝑚𝑝𝑝𝑠𝑠12 𝐵𝐵𝑓𝑓𝑛𝑛𝐷𝐷ℎ𝑠𝑠 = 42,000 𝐶𝐶ℎ𝑚𝑚𝑝𝑝𝑠𝑠𝐵𝐵𝑓𝑓𝑛𝑛𝐷𝐷ℎ 
One of the operating assumptions is that our inventory is shipped to clients every month, so the 
storage unit should be able to accommodate the volume of MCO, which is computed as: 
𝑉𝑉𝑚𝑚𝑚𝑚𝑛𝑛 ,𝐵𝐵𝐶𝐶𝐷𝐷 = 42,000 𝐶𝐶ℎ𝑚𝑚𝑝𝑝𝑠𝑠𝐵𝐵𝑓𝑓𝑛𝑛𝐷𝐷ℎ × 6 𝑓𝑓𝑚𝑚 × 4 𝑓𝑓𝑚𝑚 × 1 𝑓𝑓𝑚𝑚 = 35 𝑒𝑒𝐷𝐷3 
A factor of 2.0 is multiplied with 𝑉𝑉𝑚𝑚𝑚𝑚𝑛𝑛 ,𝐵𝐵𝐶𝐶𝐷𝐷  to consider voided volume in the storage unit: 
𝑉𝑉𝑓𝑓𝑓𝑓𝐷𝐷 ,𝐵𝐵𝐶𝐶𝐷𝐷 = 35 𝑒𝑒𝐷𝐷3 × 2.0 = 70 𝑒𝑒𝐷𝐷3  
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7.7.4 Profitability Input Summary 
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7.7.5 Two Variable Sensitivity Analysis 
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7.8 Prior Microfluidic Chip Designs 
 
- 54 - 
 
 
- 55 - 
 
7.9 Consulting with Thomas Kohli 
7.9.1 Recurring Costs for Box Manufacture 
 
 
Recurring Costs based on a Quantity of 1
PC
Hardware $2,000
Software $2,000
assumes full version of LabVIEW; much 
cheaper alternative availabe but I am 
too tired to check now.  DAD
Component & Instrumentation Selection
Power Supply $50
Vacuum $100
LED $25 x8
Detector $25
Interlock Switch $25
Box $100
Wire $200
Mechanical Parts
assume all mechanical parts are 
machined parts.  Usually a setup charge 
is required.
Box Mods $250 $125 setup & remainder is cost of item.
Chip Hoder Brackets $200
Chip Vacuum Cover $250
LED Bracket $200
Detector Bracket $200
Box Lid with Interlock $250
Silk Screens/Labeling $250 silk screen $125 per screen
Chip ????
Assembly Labor 40 hours
System Integration and Verification 40 hours
User Manual Desciption & Maintenance 40 hours
Certification
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7.10 E-mail Regarding Plavix Test System Diagrams 
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7.11 Velocity Profile within a Rectangular Microchannel (58) 
 
The shear rate at the wall can be found by taking the derivatives of the above expression with 
respect to y and z, evaluated at y=0, and z=0. 
A pre-programmed excel spreadsheet made possible by Sean Maloney computed the linear 
velocity (u) corresponding to a average wall shear rate of 1000 s-1 to be 1 cm in a 250um by 60 
um microchannel. 
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7.12 Manufacturing Equipment List 
 
Wisconsin Oven Corporation Ltd. 
SWN Series Normal Duty Walk-In Oven 
Model 610-6 
CFM X 
100 
Specifications: 
Horsepower Kilowatts-
Electric 
BTU’s 
X 
1,000-
Gas 
Cubic 
Feet of 
Chamber 
Chamber 
Width 
Chamber 
Width 
Chamber 
Height 
34 3 72 400 360 6’ 10’ 6’ 
 
Outside Width Outside 
Length 
Outside 
Height 
Approximate 
Weight 
8’ 11’ 9’9” 4,474 lbs. 
 
 
Electro-Technic Products 
High-Frequency Corona Surface Treater 
Model BD-80 
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7.13 Communication with David Burke of Wisconsin Oven Corporation 
----- Forwarded message from dj_burke@comcast.net ----- 
   Date: Thu, 2 Apr 2009 14:51:22 -0400 
   From: David Burke <dj_burke@comcast.net> 
 Subject: Your inquiry to Wisc Oven Corp 
     To: paoba@seas.upenn.edu 
     Cc: "Hank Hubbell (WOC)" <hhubbell@wisoven.com> 
 
Hello Paul, 
 
Per your inquiry to Wisconsin Oven Corporation I've attempted to reach you a couple of times via phone and in 
order to assist you, will need to find out more about your application.  Per your request, attached is a brochure of our 
SWN Series of batch ovens.  If you refer to line 43 you will find the model SWN-610-6 you inquired 
about.  However we don't know if you want it heated by electricity or gas and there are a lot of other questions we 
will need answered in order to best assist you. 
 
The price range for this oven without any options would be in the area of $22,000.00 without any options for an 
electrically heated oven and around $24,000.00 for a gas fired unit.  All our ovens are shipped FOB: E Troy WI, 
freight collect 
 
If you would please contact me at your convenience to discuss your application and installation area in greater detail, 
I will be able to determine what will be required and provide you with more firm pricing. 
 
Thank you for your interest in our thermal process related equipment, we look forward to working with you. 
 
Regards, 
 
David J. Burke 
WOC District Sales Rep 
Torrid Enterprises Inc. 
978-779-0317 
dj_burke@comcast.net 
www.torridenterprises.com 
 
----- End forwarded message ----- 
 
Paul A. O'Brien 
University of Pennsylvania 
School of Engineering and Applied Science '09 
paoba@seas.upenn.edu 
(845) 527-0886 
 
 
